https://theses.gla.ac.uk/

Theses Digitisation:
https://www.gla.ac.uk/mygla/thesis/enlighten/theses/digitisation/

This is a digitised version of the original print thesis.

Copyright and moral rights for this work are retained by the author
A copy can be downloaded for personal non-commercial research or study, without prior permission or charge
This work cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author
The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author
When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given
ANALYSIS OF NEUROVIRULENCE IN THE MOUSE MODEL SYSTEM USING DELETION VARIANTS OF HERPES SIMPLEX VIRUS TYPE 2 (HSV-2)

by

MAHMOUD Y. M. TAHA

A Thesis Presented for the Degree of Doctor of Philosophy in

The Faculty of Science at the University of Glasgow

Institute of Virology,
Church Street,
Glasgow G11 5JR

February 1990
I would like to acknowledge the following people for their help and encouragement throughout the course of the study:

Professor John H. Subak-Sharpe for giving me the opportunity to work in the Institute of Virology, his interest in and overall supervision of my project and critical reading of papers arising from this thesis.

My supervisors, Drs. S. Moira Brown and Geoffrey B. Clements, for their excellent guidance, encouragement, friendship and critical reading of this thesis.

Professor David I. Graham for the invaluable help and advice in the neuropathological studies. The latter studies have been carried out in collaboration with Professor David I. Graham in the Department of Neuropathology, Southern General Hospital, Glasgow.

Dr. Duncan J. McGeoch for his help, advice in the DNA sequencing analysis and critical reading of the discussion.

Dr. Philip Taylor for all the help I needed on the computer.

All the people in labs 202, 209 and 210 for their advice and friendship.

All the people who allowed me to quote their unpublished work in this thesis: Drs. Duncan J. McGeoch, Geoffrey B. Clements, Fazil Junjjo, Alasdair MacLean, Mr. Jim Mullaney and Miss. June Harland.

Mrs. Fiona Jamieson, Miss. June Harland, Miss. Iris McDougall and Mr. Aidan Dolan for giving me the benefit of their technical knowledge in molecular biology and DNA sequencing.
The help of Mr. David Miller in the animal experiments and Mr. Jim Aitken in the particle counts is much appreciated.

All the staff of the washroom, media, cytology, office and administrative departments who ensured that the course of this study was as trouble-free as possible.

Miss. Lesley Kattenhorn for printing out the top copy of this thesis.

Most of all, my wife Salwa and my children Zayed and Sura for their endless support and the sweet smiles I received when I go back home. In addition my family for their moral and financial support to whom I can never adequately express my thanks.

And finally the Iraqi Government, Ministry of Higher education and Scientific Research, for giving me the opportunity to continue my postgraduate studies.

Unless otherwise stated, all the results were obtained by the author's own efforts.
The aim of the work described in this thesis was to identify gene(s) involved in determining the neurovirulence of HSV-2 strain HG52 in the mouse model system using deletion variants. The availability of variants with deletions in specific regions of the genome afforded the unique opportunity to determine the possible role of specific sequences in virulence. The phenotype of the parental wild type virus has also been determined by examining the neurovirulence of individual plaque stocks to identify the baseline from which to evaluate the deletion variants.

Twenty well separated plaques were picked from the elite stock of HG52 and passaged twice at 37°C. Restriction endonuclease analysis of the DNA from each of the twenty plaque stocks showed no differences in the size of fragments and distribution of the sites. To determine their neurovirulence, ten of the individual plaque stocks were selected randomly for mice inoculation. Following intracranial inoculation of 3 week old BALB/c mice, the plaque stocks segregated into three classes of neurovirulence on the basis of their LD_{50} values; high (<10^3 pfu/mouse), intermediate (10^3-10^4 pfu/mouse) and low virulence (>10^5 pfu/mouse). The particle : pfu ratios of the plaque stocks were within the acceptable range for HSV-2. Restriction endonuclease analysis of viruses reisolated from the brains of infected mice showed no apparent difference in their DNA profiles compared to the initial infecting viruses.

Two plaque stocks of high, one of intermediate and one
of low virulence were selected on the basis of their LD$_{50}$ values and particle : pfu ratios. These stocks retained their original LD$_{50}$ values compared to the non-plaque purified elite stock of HG52 ($<10^2$ pfu/mouse) when retested in mice. Following intraperitoneal inoculation, the selected plaque stocks showed differences in their LD$_{50}$ values comparable to the differences seen following intracranial inoculation.

The selected plaque stocks grew as well as the parental HG52 in one step growth experiments in BHK-21 C13 cells. However, they showed differences in the growth kinetics in vivo in mouse brain where the high virulence stocks showed comparable growth to HG52, while the intermediate and low virulence stocks grew less well.

The selected plaque stocks were passaged five times in BHK-21 C13 cells and ten plaques from each were picked and stocks grown. Restriction endonuclease analysis of their DNA showed no differences compared to the wild type HG52. Following intracranial inoculation of the virus stock derived from the fifth passage, those derived from intermediate or low virulence virus remained stably of intermediate or low virulence, while those derived from high virulence virus showed in some cases a shift to intermediate levels of virulence.

These results clearly demonstrate virulence heterogeneity within the elite stock of HSV-2 strain HG52. The LD$_{50}$ value of high virulence virus was chosen as a baseline from which to evaluate the virulence of deletion variants.

A number of deletion variants of HSV-2 strain HG52 with deletions ranging in size from 1.5 to 9 kb have been tested.
for virulence following intracranial inoculation of 3 week old BALB/c mice. The variants were segregated into three categories of virulence on the basis of their LD$_{50}$ values; avirulent ($>10^7$ pfu/mouse), reduced ($10^5-10^6$ pfu/mouse) and attenuated ($10^4$ pfu/mouse) compared to $<10^2$ pfu/mouse for the elite stock of HG52.

Analysis of the variants with deletions in U$_S$/TR$_S$ indicated that the US4, US10, US11 and US12 genes have a role in neurovirulence. Deletion of one copy of ori$_S$ and one copy of the IE3 gene has a minor effect on neurovirulence.

Analysis of the variants with deletions in IR$_L$/TR$_L$ regions of the genome implies that deletion of one copy of the IE1 gene and part of LAT transcripts in IR$_L$ has a minor effect on neurovirulence. The analysis demonstrated that none of the deleted genes appear to be a unique determinant of neurovirulence with the exception of the DNA sequences between 0-0.02 and 0.81-0.83 m.u.

The variant JH2604 whose genome is deleted by 1.5 kb in both copies of the BamHI v fragment between 0-0.02 and 0.81-0.83 m.u. in TR$_L$ and IR$_L$ respectively was avirulent for mice following intracranial and footpad inoculation with LD$_{50}$ values of $>10^7$ and $>10^8$ pfu/mouse respectively compared to $<10^2$ pfu/mouse for the elite stock of HG52. Therefore, the variant JH2604 is at least 6 logs less neurovirulent than the wild type virus. The variant JH2604 grew as well as the wild type virus in vitro in BHK-21 C13 and 3T6 cells, but it failed to grow in mouse brain in vivo demonstrating that the lack of neurovirulence was due to inefficient replication in mouse brain. The variant JH2604 synthesises TK as efficiently as the wild type virus and its infected
cell polypeptide profile shows no detectable differences.

The lack of growth in mouse brain in vivo of JH2604 has been confirmed by neuropathological studies which showed that JH2604 did not cause necrotising encephalitis but there was infiltration of lymphocytes and perivascular cuffing around the blood vessels localised to the site of inoculation. The wild type HG52 infected brains showed necrotising encephalitis throughout. Using polyclonal anti-HSV antibodies in immunohistochemical studies, viral antigens were seen along the needle track in JH2604 infected brains, while they were widely distributed in HG52 infected brains.

Correction of the deletion in JH2604 by cotransfection in vitro using large wild type XbaI fragments resulted in the isolation of recombinants which gave LD<sub>50</sub> values comparable to those of individual plaque stocks of the parental HG52. Correction of the deletion by the small wild type BamHI g fragment using in vivo selection in mouse brain resulted in recombinant viruses which displayed wild type LD<sub>50</sub> values.

Introduction of the deletion into the wild type genome by in vitro cotransfection resulted in recombinants which on intracranial inoculation of mice were avirulent. These results imply that the sequences within BamHI g most probably within both copies of the BamHI v fragment between 0-0.02 and 0.81-0.83 m.u. in TR<sub>l</sub> and IR<sub>L</sub> are required for maximum demonstration of virulence in HSV-2 strain HG52.

Cloning of the deleted fragment of JH2604 in pAT153 and restriction enzyme and Southern blot analysis of the positive clones confirmed that the deletion was approximately 1.5 kb in both copies of the BamHI v fragment
with apparently identical end points. Sequencing analysis revealed that the deletion in each copy of the BamHI v fragment was 1488 bp and was contained within the XhoI-HincII fragment within BamHI v. It includes a complete 17 bp DR1 element, four copies of a 19 bp reiterated sequence and terminates 522 bp upstream of the IE1 gene. These results clearly demonstrate that the deleted sequence has a function in vivo which may suggest that the region is protein coding.
ABBREVIATIONS

A          adenosine
ABC        avidin biotinylated horseradish peroxidase complex
ACV        acyclovir
AIDS       acquired immunodeficiency syndrome
APS        ammonium persulphate
ATP        adenosine triphosphate
BCIG       5-chloro-4-bromo-3 indolyl-β-D-galactoside
BHK        baby hamster kidney cells
BMV        bovine mammilitis virus
bp         base pairs
CAM        chorioallantoic membrane
CCV        channel catfish virus
Ci         curies
CIP        calf intestinal phosphatase
cm         centimetre
cpe        cytopathic effect
CSF        cerebrospinal fluid
dATP       deoxyadenosine triphosphate
DBP        DNA binding protein
dCTP       deoxycytidine triphosphate
ddNTP      dideoxynucleoside triphosphate
dGTP       deoxyguanosine triphosphate
DMEM10     Dulbecco's Modified Eagle's medium containing 10% calf serum
DMSO       dimethyl sulphoxide
DNA        deoxyribonucleic acid
DNase      deoxyribonuclease
dNTP       deoxynucleoside triphosphate
DR         direct repeat
dTTP  deoxythymidine triphosphate
dUMP  deoxyuridine monophosphate
dUTPase deoxyuridine triphosphatase
E  early
EBV  Epstein-Barr virus
E.coli  Escherichia coli
EDTA  sodium ethylene diamine tetra-acetic acid
EHu5  Eagle’s medium containing 5% human serum
EHV  equine herpes virus
EMC5  Eagle’s medium containing 1.5% methyl cellulose
Emet/5C2  Eagle’s medium containing 20% the normal concentration of methionine plus 2% calf serum
ETC10  Eagle’s medium containing 10% calf serum
Fc  fragment crystalisable
G  guanosine
g  gram
h  hour
H & E  haematoxylin and eosin
HCMV  human cytomegalovirus
HHV  human herpesvirus
HSV  herpes simplex virus
HVS  herpesvirus saimiri
ICP  infected cell polypeptide
IE  immediate early
IFN  interferons
IgG  immunoglobulin G
IPTG  isopropyl-D-thiogalactoside
IR_L  inverted long repeat
IR_S  inverted short repeat
K  kilodalton
kb  kilobase
L  late
l  litre
LAT  latency associated transcripts
LD₅₀  50% lethal dose
M  molar
mar  monoclonal antibody resistant
mCi  millicuries
MCMV  murine cytomegalovirus
MCP  major capsid protein
MDV  Mareks disease virus
mg  milligram
min  minute
ml  millilitre
mM  millimolar
mm  millimetre
moi  multiplicity of infection
Mr  molecular weight
mRNA  messenger ribonucleic acid
m.u.  map units
ng  nanogram
NP40  Nonidet P40
OD  optical density
ORF  open reading frame
ori  origin of viral DNA replication
oz  ounce
PAGE  polyacrylamide gel electrophoresis
PBS  phosphate buffered saline
PEG  polyethylene glycol
pfu  plaque forming units
PIC  phosphate free Eagle’s medium containing 1% calf serum
PRV pseudorabies virus
RF replicative form
RNA ribonucleic acid
RNase ribonuclease
rpm revolution per minute
RR ribonucleotide reductase
RT room temperature
SDS sodium dodecyl sulphate
SSC trisodium citrate and sodium chloride
\textit{syn}+ non-syncytial
T thymidine
TBE Tris, boric acid and EDTA
TE Tris-EDTA
TEMED \textit{N,N',N'-tetramethylethylenediamine}
TIF trans-inducing factor
TK thymidine kinase
TK- thymidine kinase negative
TK+ thymidine kinase positive
ts temperature sensitive
TR\textsubscript{L} terminal long repeat
TR\textsubscript{S} terminal short repeat
3T3 mouse embryo fibroblast cells clone 3
3T6 mouse embryo fibroblast cells clone 6
UL long unique
US short unique
UV ultraviolet
V voltage
V\textsubscript{mm} molecular weight of viral-induced polypeptide
v/v volume per volume
VZV varicella zoster virus
W watt
w/v weight per volume
w/w weight per weight
X times
°C degree centigrade
uCi microcuries
ug microgram
ul microlitre
uM micromolar
% percentage
< less than
> higher than
TABLE OF CONTENTS

ACKNOWLEDGEMENTS

SUMMARY

ABBREVIATIONS

CHAPTER 1

INTRODUCTION

1.1 HERPESVIRIDAE FAMILY AND ITS CLASSIFICATION
1.1.1 Classification on the basis of biological properties 2
1.1.2 Classification on the basis of genomic structure 3

1.2 HUMAN HERPESVIRUSES 4

1.3 GENOMIC STRUCTURE OF HSV
1.3.1 General properties of the HSV genome 5
1.3.2 Organisation of HSV genes 7
1.3.3 Relationship between HSV-1 and HSV-2 genomes 9

1.4 THE HSV 'a' SEQUENCE
1.4.1 General properties of the 'a' sequence 10
1.4.2 Functions of the 'a' sequence 11

1.5 HSV TRANSCRIPTION
1.5.1 HSV temporal regulation 14
1.5.2 Immediate early (IE) gene expression 15
1.5.3 Early (E) gene expression 17
1.5.4 Late (L) gene expression 18

1.6 THE HSV REPLICATIVE CYCLE 19
1.6.1 Attachment, penetration and uncoating 19
1.6.2 Suppression of cellular macromolecular synthesis 20
1.6.3 DNA replication 21
1.6.4 Assembly and maturation 24

1.7 HSV-INDUCED POLYPEPTIDES 25
1.7.1 HSV-induced enzymes 26
1.7.2 HSV DNA binding proteins 28

1.8 VIRULENCE OF HSV 29
1.8.1 Introduction 29
1.8.2 Neurovirulence and neuroinvasiveness 30
1.8.3 Extrinsic factors influencing the virulence of HSV 30
1.8.4 Viral genes determining virulence of HSV 33
1.8.4.a Viral enzymes 33
1.8.4.b Vmw65 trans-inducing factor (TIF) 36
1.8.4.c Temperature-sensitive (ts) mutants 36
1.8.4.d Glycoproteins 36
1.8.4.e Other loci 41

1.9 LATENCY OF HSV 46

1.10 HSV INFECTIONS OF THE NERVOUS SYSTEM 50
1.10.1 HSV-1 encephalitis 51
1.10.2 HSV-2 encephalitis and meningitis 52
CHAPTER 2
MATERIALS

Cells
Viruses
Tissue culture media
Agar and bacterial growth media
Plasmids
Sera
Experimental animals
Stains
Enzymes
Radiochemicals
Solutions and buffers
Chemicals

METHODS

2.1 Growth of cells
2.2 Cell storage
2.3 Growth of virus stocks
2.4 Sterility checks on virus and cell stocks
2.5 Titration of virus stocks
2.6 Preparation of virion DNA (HSV)
2.7 Virus particle counts
2.8 Purification of single plaque isolates
2.9 Virus growth properties in vitro
2.10 Virus growth properties in vivo
2.11 Animal inoculation
2.12 Preparation and isolation of $^{32}$P-labelled virus DNA
2.13 Thymidine kinase assay
2.14 Preparation and analysis of HSV infected cell polypeptides
2.15 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
2.16 Agarose gel electrophoresis
2.17 Restriction enzyme digestion
2.18 Elution of DNA fragments from agarose gels
2.19 Transfection of viral DNA by calcium phosphate precipitation
2.20 Transfection and in vivo selection
2.21 Glycerol stocks of bacteria
2.22 Construction of recombinant plasmids
2.23 Transformation of bacterial cells with plasmid DNA
2.24 Small scale isolation of plasmid DNA
2.25 Large scale isolation of plasmid DNA
2.26 Transfer of DNA fragments to nitrocellulose
2.27 Hybridisation procedure
2.28 In vitro $^{32}$P-labelling of DNA by nick translation
2.29 Construction of recombinant M13
2.30 Transfection of bacterial cells with M13
2.31 Growth and extraction of recombinant M13 clones
2.32 Sequence analysis of recombinant M13 clones
2.33 Electrophoresis and autoradiography of sequencing gels
2.34 Accumulation and handling of the sequence
CHAPTER 3
RESULTS

3.1 VIRULENCE VARIATION WITHIN THE ELITE LABORATORY STOCK OF HSV-2 STRAIN HG52

3.1.1 Introduction

3.1.2 Isolation of single plaque stocks

3.1.3 Neurovirulence of single plaque stocks

3.1.4 Virulence analysis using the intraperitoneal route of inoculation

3.1.5 Replication efficiency \textit{in vitro} and \textit{in vivo}

3.1.6 Effect of passage on neurovirulence of individual stocks

3.2 VIRULENCE OF DELETION VARIANTS OF HSV-2 STRAIN HG52

3.2.1 Introduction

3.2.2 Neurovirulence of the deletion variants

3.3 ANALYSIS OF THE DELETION VARIANT JH2604

3.3.1 Neurovirulence of JH2604

3.3.2 Growth of JH2604 \textit{in vivo}

3.3.3 Growth of JH2604 \textit{in vitro}

3.3.4 Infected cell polypeptide synthesis by JH2604

3.3.5 Thymidine kinase synthesis by JH2604

3.3.6 Correction of the deletion in JH2604

3.3.7 Neurovirulence of Rl7(192) recombinants

3.3.8 Introduction of the JH2604 deletion into the
3.3.9 Neurovirulence of R192(17) recombinants
3.3.10 In vivo selection

3.4 SEQUENCE ANALYSIS OF THE FRAGMENT CONTAINING
THE DELETION IN THE VARIANT JH2604
3.4.1 Size variability of the BamH Ig (v+u) joint
fragment of the variant JH2604
3.4.2 Subcloning of BamH Ig of the variant JH2604
into M13 bacteriophage and nucleotide
sequencing

3.5 NEUROPATHOLOGY
3.5.1 Macroscopic examination of brains infected
with JH2604 and HG52
3.5.2 Microscopic examination of paraffin sections
of brains infected with JH2604 and HG52
3.5.3 Immunohistochemistry of paraffin sections of
brains infected with JH2604 and HG52

CHAPTER 4
DISCUSSION AND FUTURE PROSPECTS

REFERENCES
CHAPTER 1
The subject of this thesis is the identification of genes involved in neurovirulence of herpes simplex virus type 2 (HSV-2) using HSV-2 deletion variants. The introduction provides background information on the general biology and molecular biology of HSV with particular reference to advances in the understanding of virulence and pathogenesis.

1.1 Herpesviridae family and its classification

At least 80 viruses which comprise the family, herpesviridae, have been isolated from a wide variety of animal species and man. The members of the herpesviridae can be identified by the presence of double stranded DNA in the core of the virion, an icosahedral capsid containing 162 capsomeres which is assembled in the nucleus and an envelope derived from the nuclear membrane (Roizman and Batterson, 1986).

The herpesvirion consists of four structural elements (Figure 1.1) (i) an electron-opaque core containing DNA (ii) an icosahedral capsid containing 162 capsomeres (iii) an electron-dense amorphous proteinaceous layer (the tegument) distributed around the capsid and (iv) an outer membrane, or envelope, which surrounds the capsid and tegument (Wildy et al., 1960; Roizman and Furlong, 1974). Herpesviruses can not be differentiated from each other by electron microscopic examination but are differentiated with respect to virion antigenic properties, biological properties and composition, size and arrangement of their genomes (Roizman, 1982).
Schematic diagram of a HSV virion. The virion consists of four structural elements; the core, capsid, tegument and envelope. The viral DNA is within the core and is spooled around a cylindrical protein mass. The virion envelope contains a number of glycoproteins, visible on electron microscopy as spikes protruding from the envelope. The capsid contains the capsomeres.
1.1.1 Classification on the basis of biological properties

Using biological properties, the members of the family herpesviridae have been classified into three subfamilies, alphaherpesvirinae, betaherpesvirinae and gammaherpesvirinae. The biological properties include host range, cytopathogenicity, duration of the replicative cycle and characteristics of the latent infection (Matthews, 1982).

Members of alphaherpesvirinae have a short replicative cycle and grow rapidly in tissue culture resulting in mass destruction of infected cells. They have also the capacity to establish latent infections. This subfamily contains herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), bovine mammilitis virus (BMV), pseudorabies virus (PRV), varicella zoster virus (VZV) and equine herpes virus-1 (EHV-1).

Betaherpesvirinae have restricted host range, long replicative cycles and grow slowly in tissue culture resulting in enlargement of infected cells. The virus can be maintained in a latent form in secretory glands, lymphoreticular cells, kidney and other tissue. This subfamily contains human cytomegalovirus (HCMV) and murine cytomegalovirus (MCMV).

Gammaherpesvirinae have limited host range, replicate in lymphoid cells and some cause lytic infections in some types of epitheliod and fibroblastic cells. Latent infections can be established in lymphoid tissue. This subfamily contains herpes virus saimiri (HVS), Epstein-Barr virus (EBV), Mareks disease virus (MDV) and herpes virus ateles.
1.1.2 Classification on the basis of genomic structure

There are three characteristic features of herpesvirus genomes; base composition, size of the genome and arrangement of the reiterated sequences. Molecular weights (Mr) range from 80 to $150 \times 10^6$, base composition from 32 to 75% G+C and the different sequence arrangements are illustrated in Figure 1.2. On the basis of genomic structure, the viral genomes fall into five groups (Roizman, 1982).

Group A

This group is represented by channel catfish virus (CCV) and their genomes contain a single set of reiterated sequences in the same orientation at the termini (Chousterman et al., 1979).

Group B

The genomes of the members of this group contain multiple reiterations of the same set of sequences at both termini in the same orientation and is represented by HVS (Bornkamm et al., 1976).

Group C

Group C genomes contain multiple reiterations of one set of sequences at both termini in the same orientation and variable numbers of internal tandem reiterations of different sequences. This group is represented by EBV (Raab-Traub et al., 1980).

Group D
Schematic diagram of the genomic arrangement of channel catfish virus (CCV), herpesvirus saimiri (HVS), Epstein-Barr virus (EBV), pseudorabies virus (PRV) and herpes simplex virus (HSV) representing subgroups A, B, C, D and E respectively of the family Herpesviridae. Lines represent unique sequences (long and short). Repeat sequences larger than 1kb are shown in open boxes and those of small reiterated sequences are shown in shaded boxes. Arrowheads above boxes indicate the orientation of the repeat sequences. Letters $a_n$ and $b_n$ signify multiple tandem repeat sequences. The small terminal direct and internal inverted repeats of HSV ('a' sequence) are indicated. The type of genomes and number of isomers are also indicated.
Genome type isomer
This group is represented by PRV (Ben-Porat et al., 1979) and their genomes contain a single set of reiterated sequences from one terminus inverted internally plus a subset of reiterated sequences at the other terminus in the same orientation.

**Group E**

Genomes of group E viruses contain a single set of sequences from both termini reiterated internally in inverted form as well as a subset of terminal sequences reiterated at both termini in the same orientation. This group is represented by HSV.

1.2 Human herpesviruses

There are six known human herpesviruses which are HSV-1, HSV-2, VZV, EBV, HCMV (Roizman, 1982) and human herpesvirus 6 (HHV-6) (Salahuddin et al., 1986).

Infection with HSV is commonly associated with lesions of mucous membranes where HSV-1 causes mouth and lip lesions (cold sores), while HSV-2 classically is encountered in genital tract infections. Other diseases caused by HSV include eye infection, encephalitis and meningitis (see section 1.10). A characteristic feature of HSV following primary infection at the peripheral site is the establishment of latency in neurons of the peripheral nervous system and reactivation upon stimulation (see section 1.9).

VZV infection causes chicken pox during primary infection whereas in adults the disease shingles is more severe and is a consequence of reactivation from latency (Gleb, 1985).
Infection with HCMV is usually subclinical, but it causes severe problems in immunocompromised patients especially those on transplant therapy and with acquired immunodeficiency syndrome (AIDS) (Hamilton, 1982).

EBV infects B-lymphocytes, is implicated in causing infectious mononucleosis and is strongly associated with Burkitts lymphoma and nasopharyngeal carcinoma (Epstein et al., 1964).

HHV-6 was first described in 1986 and was then termed human B-lymphotropic virus (Salahuddin et al., 1986). It is associated with exanthem subitum, a transient childhood illness (Yamanishi et al., 1988).

1.3 Genomic structure of HSV

1.3.1 General properties of the HSV genome

The HSV genome is a linear double stranded DNA molecule. The genome of HSV-1 strain 17 has been sequenced and contains 152260 base pairs (McGeoch et al., 1985; 1986; 1988; Perry and McGeoch, 1988). The DNA consists of two covalently joined segments, designated as the long (L) and short (S) regions (Figure 1.3.A) (Roizman, 1979). The L region consists of a long unique sequence (UL) flanked by a pair of oppositely oriented repeated elements termed long repeat (RL) with the terminal and internal copies designated (TRL) and (IRL) respectively. Similarly the S region consists of a short unique (US), a short terminal repeat (TRS) and a short internal repeat (IRS) region. The TRL/IRL sequences flanking the UL segment are designated ab and b'a' while IRS/TRS flanking US are designated a'c' and ca respectively. The sequences of RL and RS are distinct, except for the 'a' sequence, at least one further copy of
A. The structure of the HSV-1 genome. The long region (L) is composed of unique long (UL) bounded by a terminal sequence (TRL) which is repeated internally in an inverted orientation (IRL). Similarly, the short region (S) is composed of a unique region (US) bounded by a terminal sequence (TRS) which is repeated internally in an inverted orientation (IRS). The 'a' sequence at the termini of the L and S regions and in inverted orientation at the L/S junction (a') is also shown. The remaining sequences within TR_L/IR_L and TR_S/IR_S are designated b/b' and c/c' respectively.

B. The four genome isomers

P = prototype.

IL = inversion of the long region (L).

IS = inversion of the short region (S).

ISL = inversion of both short and long regions.
which is found at the L/S joint in the orientation opposite to the terminal copies (Roizman, 1979; Davison and Wilkie, 1981). Each terminus possesses an overhanging residue with its 3'‐hydroxyl (OH) group free and lacking a complementary residue on the opposite strand (Mocarski and Roizman, 1982).

Preparations of HSV DNA contain equimolar amounts of four sequence‐oriented isomers, in which $U_L$ and $U_S$ are independently in one of two possible orientations with respect to the joint between L and S (Roizman, 1979). The isomers are shown in Figure 1.3.B and are designated as prototype (P), inversion of the S region ($I_S$), inversion of the L region ($I_L$) and inversion of both S and L regions ($I_{SL}$).

HSV-1 DNA has an overall base composition of 68.3% G+C (McGeoch et al., 1988) which is not uniform throughout the genome e.g the 6.6 kb $R_S$ elements have a G+C value of 79.5% (McGeoch et al., 1986). In the HSV genome there are families of short, directly repeated sequences ranging in size from 10 to 100 bp (McGeoch, 1989). The copy number of these repeats differs between virus stocks (Rixon et al., 1984). Three of these repeats are located within the coding region of the US7 gene and in the intergenic region of the US9 and US10 genes (McGeoch et al., 1985). The other repeats present in the S region are (i) in the introns of IE mRNA4 and 5 (Murchie and McGeoch, 1982) and (ii) downstream of the IE mRNA3 (Rixon et al., 1984). There are also other repeats in the 'a' sequence (Davison and Wilkie, 1981; Mocarski and Roizman, 1981) and downstream of the IE mRNA1 (Perry et al., 1986). The only repeat family in the $U_L$ region is present within the coding region of the UL36 gene (McGeoch et al., 1988).
1.3.2 Organisation of HSV genes

The open reading frames (ORF) corresponding to the proposed HSV-1 genes in Glasgow strain 17 are shown in Figure 1.4. It has been shown that UL contains 56 genes termed UL1 to UL56 (McGeoch et al., 1988), while US contains 12 genes designated US1 to US12 (McGeoch et al., 1985). There is also one gene in each copy of RL and RS, giving a total of 72 genes encoding for 70 distinct proteins. Chou and Roizman (1986) and Ackermann et al. (1986) have postulated another gene upstream of the IE1 gene and in the same orientation, but their interpretation has been questioned (Perry and McGeoch, 1988). In addition, there is a 3500 bp region in RL downstream of IE1, whose functional potential is obscure. The latency associated transcripts (LAT), which are the major virus-specific transcripts in latently infected neurons lie in RL downstream of the IE1 gene (Stevens et al., 1987; Wagner et al., 1988; see section 1.9).

The genes in HSV-1 are classified into three categories; those with control functions; those involved in DNA replication and associated functions and those encoding structural and assembly proteins. During HSV infection, the IE genes are first expressed. Five IE genes have been identified, IE1, IE2 (UL54), IE3, IE4 (US1) and IE5 (US12) encoding for VmwIE110, VmwIE63, VmwIE175, VmwIE68 and VmwIE12 respectively (see section 1.5.2). The functions of the products of the first three IE genes are transcription and regulation, controlling the expression of later classes of genes and autoregulation of the IE genes (Everett, 1987; see section 1.5.2). The functions of the products of the
Organization of the genes of HSV-1, represented on four successive lines of 40 kbp each. Locations of the reading frames are shown by arrows and the splicing within the coding regions is indicated. Genes UL1-UL56 are shown on the top three lines as 1-56 and genes US1-US12 are shown in the bottom line as 1-12. Locations of origins of DNA replication are indicated by vertical arrows. This Figure is taken from McGeoch (1989).
IE4 and IE5 genes remain unknown.

The Vmw65 trans-inducing factor (Vmw65 TIF) encoded by the UL48 gene (Campbell et al., 1984), has a clear regulatory role. It acts in combination with one or more cellular proteins to activate IE gene expression through the upstream sequences of these genes (O'Hare and Goding, 1988; Preston et al., 1988). Another regulatory protein, is the product of UL41, which acts by shutting off host cell macromolecular synthesis by degradation of mRNA (Kwong et al., 1988). Two other genes, US3 and UL13, which have recently been identified and proposed to encode protein kinases may have a role in control and modulation of HSV infection.

The second class of genes include those whose products are involved in nucleotide or nucleoside metabolism, DNA replication and DNA metabolism and repair. Of those involved in nucleotide and nucleoside metabolism, thymidine kinase (TK) has been extensively studied (see section 1.8.4.a). More recently ribonucleotide reductase (see section 1.8.4.a) encoded by the UL39 and UL40 genes (Preston et al., 1984; Frame et al., 1985) and deoxyuridine triphosphatase (dUTPase) encoded by the UL50 gene (Preston and Fisher, 1984) have been identified and analysed. Seven genes were found to be necessary for DNA replication; UL5, UL8, UL9, UL29, UL30, UL42 and UL52 (see section 1.6.3). The deoxyribonuclease encoded by the UL12 gene has an unknown role in replication. Finally the gene UL2 encodes the DNA repair enzyme, uracil-DNA glycosylase (Worrad and Caradonna, 1988; Mullaney et al., 1989).

Other elements of the HSV genome which have specific roles in DNA replication are (1) the origins of DNA
replication; ori<sub>_L_</sub>, located between genes UL29 and UL30 and two copies of ori<sub>_S_</sub> in RS between genes IE3 and IE4 in RS and IE3 and IE5 in TR<sub>_S_</sub> (see section 1.6.3) and (2) the 'a' sequence which contains elements involved in cleavage of concatameric DNA as part of the process of packaging of DNA into nascent virions (see section 1.4.2).

The third class of genes consists of those encoding structural proteins and proteins involved in assembly of virions. Herpes virus particles are complex assemblies containing at least 30 different species of protein (Dargan, 1986). Twenty two genes have been identified as specifying structural or assembly proteins. The major capsid protein (MCP) is encoded by gene UL19 (Costa et al., 1984; Davison and Scott, 1986), although the capsid contains at least seven other proteins whose genes have not been identified (McGeoch, 1989). The major tegument protein is encoded by the UL48 gene (Campbell et al., 1984) and other tegument proteins are encoded by the UL36, US9 and US10 genes (Batterson et al., 1983; Frame et al., 1986a; Rixon and McGeoch, 1984).

Seven viral glycoproteins have been identified (see section 1.8.4.d) and these are gH (encoded by gene UL22), gB (UL27), gC (UL44), gG (US4), gD (US6), gI (US7) and gE encoded by the US8 gene (McGeoch, 1989).

1.3.3 Relationship between HSV-1 and HSV-2 genomes

HSV-1 and HSV-2 are closely related viruses and show many serological cross reactions. DNA hybridisation studies have shown that most of the genome sequences are highly related (Davison and Wilkie, 1983). It is likely that the genetic organisation of HSV-2 is indistinguishable from that
of HSV-1. Around 33 kb of the HSV-2 genome has been sequenced. This includes the 'a' sequence, ori_L, ori_S, the equivalents of the HSV-1 genes, UL2, UL11, UL12, UL23, UL27, UL39, UL40, UL44, UL45, US2, US7, US12 and parts of the UL30, UL54, US1, US8, US10 and IE3 genes (McGeoch, 1989).

Direct comparison of the coding sequences of corresponding genes has shown 70-80% identities (McGeoch et al., 1987). The greatest differences were shown in the non-coding sequences which are highly divergent especially in parts of the major repeats (Davison and Wilkie, 1981; Whitton and Clements, 1984). A difference was found between the two genomes in their US4 genes, encoding gG (McGeoch et al., 1987). HSV-1 has a deletion of 1460 bp in its US4 coding sequence relative to HSV-2, therefore gG of HSV-1 is of smaller Mr than that of HSV-2.

1.4 The HSV 'a' sequence
1.4.1 General properties of the 'a' sequence

The HSV genome contains a 200-500 bp sequence called the 'a' sequence, situated at the junction between the L and S components and repeated in an inverted orientation at the termini of the genome (Wadsworth et al., 1975). Multiple copies of the 'a' sequence can be present at the L terminus and the L-S junction, but only one copy is present at the S terminus (Wagner and Summers, 1978; Locker and Frenkel, 1979; Davison and Wilkie, 1981; Mocarski and Roizman, 1981). The size variation of the 'a' sequence between different strains has been shown by DNA sequencing of the 'a' sequence (Davison and Wilkie, 1981; Mocarski and Roizman, 1981, 1982; Mocarski et al., 1985; Varmuza and Smiley, 1985).

The 'a' sequence of HSV-1 strain F is shown in Figure
1.5 (Mocarski and Roizman, 1982). It is arranged as a head-to-tail dimer which has one copy of the direct repeat (DR1) at the point of fusion. The 'a' sequence consists of (1) a 20 bp terminal repeat designated DR1 (2) a 64 bp unique sequence designated Ub (3) 22 repeats of a 12 bp sequence designated DR2 (4) three repeats of a 37 bp sequence designated DR4 and containing 11 of the 12 nucleotides of DR2 (5) a unique 58 bp sequence designated Uc and (6) a second copy of DR1. Variability of the copy number of DR elements accounts for most of the observed 'a' sequence polymorphism in different strains. For example, HSV-2 strain HG52 has only one copy of DR2 (Davison and Wilkie, 1981) while HSV-1 strain F has 22 copies (Mocarski and Roizman, 1982). Similarly HSV-1 strain 17 and HSV-2 strain HG52 contain one copy of DR4 homology, which is a part of Uc (Davison and Wilkie, 1981). Some strains of HSV-1 like Justin contain an extra direct repeat called DR3 which is present in two copies (Mocarski and Roizman, 1981, 1982; Mocarski et al., 1985). Although there is variation in the copy number of the DR2 and DR4 elements, some regions of the 'a' sequence are highly conserved in different strains. These are within Ub and Uc and are represented by a short well conserved sequence about 20 bp in length located approximately 40 bp and 35 bp respectively from the ends of the 'a' sequence (Davison and Wilkie, 1981; Deiss et al., 1986).

1.4.2 Functions of the 'a' sequence

The 'a' sequence has a number of functions associated with genome organisation and viral DNA replication. These functions are described in the following section.
The structure of the HSV-1 strain F 'a' sequence (Mocarski and Roizman, 1982). The top line shows the prototype virus genome. An expansion of the 'a' sequence in the orientation found at the L/S junction is shown below the top line.

**DR1 =** 20 bp elements present as a direct repeat at the ends of the 'a' sequence.

**Ub =** a unique sequence of 64 bp located towards the b' sequence.

**DR2 =** a 12 bp repeat element present in 22 copies.

**DR4 =** a 37 bp repeat element present in 3 copies.

**Uc =** a unique sequence of 58 bp located towards the c' sequence.
(1) Circularisation of the genome

Circularisation of the HSV genome soon after infection is believed to be controlled by the 'a' sequence (Davison and Wilkie, 1983; Poffenberger et al., 1983). Circularisation of the genome occurs by ligation of the two termini which possess a single base overhang on the opposite strands (Mocarski and Roizman, 1982).

(2) Isomerisation of the genome

HSV DNA contains equimolar amount of four isomers differing in the orientation of $U_L$ and $U_S$ (see section 1.3.1). Inversion of the genome at the L-S junction occurs by site specific recombination mediated by the 'a' sequence (Mocarski et al., 1980; Mocarski and Roizman, 1981; Smiley et al., 1981). The role of the 'a' sequence in inversion and isomerisation of the genome has been demonstrated by Chou and Roizman (1985) who carried out detailed deletion analysis of the 'a' sequence. They found that deletion of the DR4 sequence results in impairment of genomic inversion, while deletion of DR2 and DR4 sequences abolished inversion. This demonstrates the presence of a cis-acting signal for site specific recombination and inversion in the DR2 and DR4 elements. The authors however did not exclude the role of DR1 in inversion, since deletion of both DR1 elements resulted in an extremely low frequency of inversion (Varmuza and Smiley, 1985).

(3) Cleavage and packaging of the genome

Linear viral DNA molecules circularise soon after infection and newly replicated viral DNA molecules consist
of large head-to-tail concatamers (Ben-Porat et al., 1976; Jacob et al., 1979) which are subsequently cleaved and packaged into capsids (Vlazney et al., 1982). The HSV 'a' sequence has been shown to contain cis-acting signals for cleavage/packaging of viral genomes and plasmid constructs containing an HSV DNA origin of replication can replicate but are only packaged if they contain an 'a' sequence (Stow et al., 1983; Deiss and Frenkel, 1986). Two separate signals designated Pad and Pac2, located in the Ub and Uc regions respectively of the 'a' sequence, were essential for cleavage/packaging of viral genomes (Varmuza and Smiley, 1985; Deiss et al., 1986). Recently Nasseri and Mocarski (1988), using a transient cleavage assay, have shown that a 179 bp fragment (containing Uc - DR1 - Ub) from the junction of two tandem 'a' sequence carries all the sequence elements necessary for cleavage recognition and encapsidation.

(4) Promoter activity

It has been reported that the Ub region of the 'a' sequence of HSV-1 strain F contains the promoter of a gene encoding a polypeptide ICP34.5 whose coding region is in the long repeat in the same orientation as the IEl gene (Ackermann et al., 1986; Chou and Roizman, 1986). The gene encoding ICP34.5 lacks TATA consensus and instead there is TATA homology (TTTAAA). The 5' terminus of the transcript maps to DR1. The function of this gene is not clear and its sensitivity to phosphonoacetate suggests that it belongs to the late category genes. DNA sequence analysis of the corresponding region of HSV-1 strain 17 has not identified a similar ORF (Perry and McGeoch, 1988).
(5) Protein binding

The HSV 'a' sequence encodes several cis-acting sites involved in circularisation, inversion, cleavage and packaging of DNA and expression of mRNA. It would be expected that specific viral or host proteins or both interact with the DNA at the specific cis sites to mediate such functions. Wu et al. (1979) using the electron microscope, have shown that a small polypeptide binds to both termini and to L-S junctions of DNA extracted from virions. Similarly Dalziel and Marsden (1984) have shown that the late polypeptides (21K and 22K) encoded by gene US11 (Rixon and McGeoch, 1984) interact with the 'a' sequence of HSV-1 in vitro. These polypeptides were shown to be strong binding proteins (MacLean et al., 1987). The function of the interaction with the 'a' sequence is still not clear, since viruses lacking the US11 gene are viable in tissue culture (Longnecker and Roizman, 1986; Umene, 1986; Brown and Harland, 1987).

Recently Chou and Roizman (1989) have reported that, the virus-specific DNAase as well as two proteins with Mr of >250K and 140K, form complexes with both Pac1 and DRI regions of the 'a' sequence.

1.5 HSV transcription

Transcription of viral DNA takes place in the nucleus by the host cell polymerase II (Costanzo et al., 1977). Viral RNAs are capped at their 5' ends, methylated at A residues and polyadenylated although non-polyadenylated RNA can be isolated (Bachenheimer and Roizman, 1972; Bartoski and Roizman, 1976; Moss et al., 1977; Stringer et al., 1977). A relatively small proportion of HSV mRNAs are spliced; these
include mRNAs of IE1, IE4, IE5 (Rixon and Clements, 1982; Watson et al., 1981; Perry et al., 1986), UL15 (McGeoch et al., 1988) and the mRNA of gC (Frink et al., 1983). The abundance and the stability of the various HSV-1 mRNAs vary and generally mRNAs of IE genes appear more stable than those of late genes (Wolf and Roizman, 1978). Following transcription, HSV mRNAs are transported to the cytoplasm, bind to ribosomes and are translated into proteins (Wagner and Roizman, 1969).

1.5.1 HSV temporal regulation

HSV encodes 70 predicted genes (McGeoch et al., 1988) which are expressed as three temporally regulated classes of proteins, immediate early (IE or alpha), early (E or beta) and late (L or gamma) according to their order of synthesis (Honess and Roizman, 1974; Clements et al., 1977; Jones and Roizman, 1979). Synthesis of these proteins is sequentially ordered in a cascade fashion. IE proteins induce E proteins and the latter shut off the expression of IE proteins and induce the expression of L proteins. The L proteins in turn shut off the expression of E proteins, and immediately after the next round of infection, induce the expression of IE proteins. Regulation of viral gene expression would appear to be predominantly at the level of transcription.

1.5.2 Immediate early (IE) gene expression

IE genes are the first to be expressed during viral infection and are first detected very early (1 h post infection), reach peak rates at approximately 2 to 4 h following infection and then decrease. Their corresponding RNAs are produced in the absence of viral protein synthesis.
There are five IE genes in HSV-1, their transcript locations and orientations on the viral genome are shown in Figure 1.6. These are IE1, IE2, IE3, IE4 and IE5 coding for polypeptide products VmwIE110 (ICP0), VmwIE63 (ICP27), VmwIE175 (ICP4), VmwIE68 (ICP22) and VmwIE12 (ICP47) respectively (Clements et al., 1979; Preston, 1979a; Easton and Clements, 1980; Wagner, 1985; Everett, 1987).

Three of the five IE transcripts are spliced. The IE4 and IE5 transcripts are derived from identical promoters located in the repeated sequences of the S region of the viral genome. The splice sites of their RNAs are also in the repeated sequences while their coding regions are different (Watson et al., 1981; Rixon and Clements, 1982). The transcript of the IE1 gene is also spliced and lies totally within the repeated sequences of the L region and is therefore diploid (Perry et al., 1986). The transcript of the IE3 gene is unspliced, diploid and transcribed entirely within TR_S (Rixon et al., 1982). The only IE gene that is not associated with the repeated sequences is IE2 whose unspliced RNA lies in U_L (Whitton et al., 1983).

Most of the IE polypeptides are phosphorylated and found predominantly in the nucleus of infected cells. The exceptional IE polypeptide is VmwIE12 which is not phosphorylated and is found in the cytoplasm (Preston, 1979a; Hay and Hay, 1980; Marsden et al., 1982; Ackermann et al., 1984). The IE1 and IE3 gene products have been shown to be potent transactivators of early and late gene promoters in transient expression assays (Everett, 1984, 1987; O'Hare and Goding, 1988). The IE2 gene product (VmwIE63) has also been implicated in the regulation of
The genome structure of HSV-1 (prototype) showing the map locations and orientations of the immediate early (IE) mRNAs (numbered 1 to 5). The spliced mRNAs are indicated.
viral promoters (Everett, 1986; Rice and Knipe, 1988; Sekulovich et al., 1988).

Analysis of ts mutants demonstrated that the gene products of both IE2 (VmwIE63) and IE3 (VmwIE175) are essential for productive infection and that VmwIE175 is required for early and late gene expression while VmwIE63 appears to be required after the onset of early gene expression and DNA replication (Preston, 1979b; Dixon and Schaffer, 1980; Watson and Clements, 1980; Sacks et al., 1985). Viable mutants with deletions in IE1 show growth restriction in certain cell types at low multiplicity of infection (moi) and normal growth at high moi (Stow and Stow, 1986; Sacks and Schaffer, 1987). Deletion mutants in IE4 confer a host range phenotype to the virus (Post and Roizman, 1981; Searset al., 1985). The IE5 gene has been shown to be non essential for the growth of HSV in tissue culture (Longnecker and Roizman, 1986; Umene, 1986; Brown and Harland, 1987).

All the IE genes contain a characteristic cis-acting element, TAATGARAT, which interacts with the major tegument protein (Vmw65 TIF) resulting in stimulation of IE gene expression (Mackem and Roizman, 1982; Batterson and Roizman, 1983; Cordingley et al., 1983; Campbell et al., 1984; Preston et al., 1984). Mutations within the gene coding for Vmw65 TIF abolish its ability to stimulate IE gene expression (Ace et al., 1989).

1.5.3 Early (E) gene expression

The early or beta genes are distributed in both the L and S regions of the HSV genome. Their transcription begins following the synthesis of functional IE polypeptides.
The synthesis of the E gene products starts at 3 h post infection, reaches peak rates of synthesis about 5 to 7 h post infection after which it declines with time (Honess and Roizman, 1974).

The E genes have been subdivided into beta 1 and beta 2 on the basis of their requirement of IE polypeptides (Pereira et al., 1977; Roizman and Batterson, 1985). The functions of several E polypeptides appear to be related to the synthesis of viral DNA. The beta 1 polypeptides are exemplified by the major DNA binding protein (DBP) and the large subunit of ribonucleotide reductase (RR1).

The beta 2 polypeptides include the viral TK and the DNA polymerase. Some early polypeptides require DNA synthesis for maximal expression and gD is an example of such a protein (Gibson and Spear, 1983; Johnson et al., 1986).

1.5.4 Late (L) gene expression

The late or gamma gene products can be detected by 2 to 3 h post infection and reach their maximum peaks by 10 to 16 h post infection parallel to DNA synthesis which starts about 2 h post infection and reaches its maximum peak by 8 h post infection (Wilkie, 1973; Roizman, 1979).

The late genes can be subdivided into two classes, the gamma 1 (leaky late) and gamma 2 (true late), depending on their DNA replication requirement (Roizman and Batterson, 1985; Wagner, 1985). In the absence of DNA synthesis, the expression of gamma 1 genes is reduced but still detectable, while those of gamma 2 is reduced to barely detectable levels (Powell et al., 1975; Johnson et al., 1986; Godowski
and Knipe, 1985). Examples of the leaky late genes are UL19, UL27 encoding the MCP and gB respectively, while UL44 and US11 encoding gC and 21K/22K proteins are examples of true late genes.

The regulation of late gene expression is not fully understood. Some have been shown to require IE products for maximum trans-activation of their promoters (Everett, 1987).

1.6 The HSV replicative cycle

The replicative cycle of HSV starts with the initiation of infection in which the virus envelope attaches to cell receptors resulting in fusion with plasma membranes and release of the capsid which is then transported to the nuclear pore where DNA is released into the nucleus. Transcription, DNA replication and assembly of capsids takes place in the nucleus. The steps of the replicative cycle are discussed below.

1.6.1 Attachment, penetration and uncoating

Attachment of the virus to the host cell surface takes place through specific receptors on the cell surface (Vahlne et al., 1978). The nature of these receptors has not been identified. It appears that HSV-1 and HSV-2 have different receptors. Infection of cells with one virus strain causes interference with the attachment of a second virus strain of homologous but not heterologous serotype (Vahlne et al., 1979). Following attachment, the virus enters the cells either by endocytosis (Hummeler et al., 1969) or by fusion of the viral envelope and plasma membrane (Morgan et al., 1969). The latter is more likely to be the case since it has been demonstrated that the viral envelope fragment
crystalisable (Fc) receptors can be detected on the cell surface following penetration (Para et al., 1980). The identification of virus-encoded gB (Manservigi et al., 1977) which is involved in membrane fusion supports the fusion mode of entry of HSV into cells. Temperature-sensitive mutants (ts) which are defective in the gB gene can attach but are unable to penetrate the cells (Sarmiento et al., 1979).

Following penetration, the naked viral particle is transported via the cytoplasm (Batterson and Roizman, 1983) to the nuclear membrane where the capsid is degraded and the viral DNA released. The DNA enters the nucleus through the nuclear pores (Hummeler et al., 1969) where transcription occurs using the cellular polymerase II (see section 1.5).

1.6.2 Suppression of cellular macromolecular synthesis

Infection with HSV results in a decrease in the host cell DNA, RNA and protein synthesis. An immediate consequence of infection is the disaggregation of polyribosomes which is mediated by a component of the infecting virion. This process results in inhibition of host protein synthesis (Sydiskis and Roizman, 1966; Fenwick and Walker, 1978; Nishioka and Silverstein, 1978). The virion component is also involved in inhibition of host mRNA. These events called early shut off of protein synthesis, are more rapid in HSV-2 infected cells than in HSV-1 infected cells (Fenwick and Clark, 1982; Fenwick and McMenamin, 1984). Delayed inhibition of host protein synthesis depends on virus gene expression which results in the degradation of host transcripts (Nishioka and Silverstein, 1978; Hill et al., 1983). The virion function
involved in shut off of host protein synthesis has been mapped to the region between 0.52-0.59 map units (m.u.) on the HSV-2 strain HG52 genome (Morse et al., 1978; Fenwick et al., 1979) and to 0.604-0.606 m.u. on the HSV-1 strain KOS genome (Kwong et al., 1988). In addition, transfer of the UL41 equivalent gene from HSV-2 strain G (strong shut off) into the HSV-1 strain 17 genome (naturally weak shut off) results in enhancement of the shut off function of strain 17 (R.D. Everett, personal communication). The mechanism by which HSV decreases the rate of host cell DNA synthesis remains unclear.

1.6.3 DNA replication

Replication of HSV is a complex process which is not fully understood. Soon after infection, viral DNA circularises by ligation of the termini in the nucleus (Davison and Wilkie, 1983). DNA synthesis starts at 3 h post infection, reaches a maximum between 9-11 h and is completed by 16 h post infection (Rixon, 1977).

Electron microscope analysis of viral DNA molecules before the onset and during the first round of DNA replication showed the presence of single stranded ends and circular molecules (Jean and Ben-Porat, 1976; Jacob and Roizman, 1977). At later times in infection, DNA molecules with internal eyes and forks, circular molecules with linear tails and large tangles of DNA are seen (Ben-Porat et al., 1976; Hirsch et al., 1977; Jacob and Roizman, 1977; Jean et al., 1977; Ben-Porat and Rixon, 1979). It has been shown that the number of terminal fragments detectable in replicating viral DNA was reduced compared to virion DNA (Jongeneel and Bachenheimer, 1981). This data suggested
that circular DNA molecules replicate by a rolling circle mechanism yielding head-to-tail concatameric DNA (Jacob et al., 1979).

Two approaches have indicated that the products of seven genes (UL5, UL8, UL9, UL29, UL30, UL42 and UL52) are involved in viral DNA replication. The first approach, using genetic analysis of HSV-1 mutants, has shown that seven complementation groups containing mutants with defects in DNA synthesis map to these genes (Chartrand et al., 1979; Conley et al., 1981; Purifoy and Powell, 1981; Matz et al., 1983; Weller et al., 1983, 1987; Carmichael et al., 1988; Goldstein and Weller, 1988; Marchetti et al., 1988). The second approach, using a plasmid amplification assay for HSV-1 origin-dependent DNA replication, has demonstrated that the products of these seven genes are both necessary and sufficient for DNA synthesis (Challberg, 1986; McGeoch et al., 1988; Wu et al., 1988). Three of these seven DNA replication genes are UL29 which encodes for the major single strand DNA binding protein (Conley et al., 1981; Quinn and McGeoch, 1985), UL30 which encodes the viral DNA polymerase (Gibbs et al., 1985; Quinn and McGeoch, 1985) and UL42 which encodes a 65K double stranded DNA binding protein, DBP, (Marsden et al., 1987; Parris et al., 1988). Recently Weir et al. (1989), using a gel retardation assay, showed that the UL9 gene product binds specifically to a viral origin of replication. These results are consistent with the findings of Olivo et al. (1988) who showed that the UL9 gene specifies an origin binding protein. The UL5 gene product is a part of the DNA helicase in infected cells (Zhu and Weller, 1988). The DNA helicase has been shown to consist of three polypeptides with Mr of 120,000, 97,000 and
70,000 which are the products of genes UL52, UL5 and UL8 required for replication of a plasmid containing HSV-1 oriS (Crute et al., 1989). Furthermore, the DNA primase (Holmes et al., 1988) has been found to be tightly associated with the DNA helicase forming a helicase-primase complex (Crute et al., 1989). The relationship between the two enzymes remains unclear.

The cis-acting elements needed for replication (viral origins of DNA replication) are specified by two distinct but related sequences. One (oriL) lies close to the centre of the U region while the other (oriS) is present within the short repeats, TRS and IRS (Vlazney and Frenkel, 1981; Spaete and Frenkel, 1982; Stow, 1982; Weller et al., 1985). It has been shown that a DNA fragment of 90 bp specifies a functional oriS (Stow and McMonagle, 1983; Deb and Doelberg, 1988; Lockshon and Galloway, 1988) and includes a 45 bp near perfect palindrome with a central A+T rich region. Elias and Lehman (1988) have demonstrated the presence of two specific binding sites within oriS.

The oriL is located in UL between 0.360 and 0.419 m.u. However, when fragments spanning these sequences were cloned into plasmid vectors, between 100-650 bp were deleted. The deleted fragments have no origin activity (Spaete and Frenkel, 1982). Successful cloning of oriL in an undeleted form was achieved in yeast plasmid vectors (Weller et al., 1985). Sequence analysis of oriL from HSV-1 KOS (Weller et al., 1985), HSV-1 ANG (Gray and Kaerner, 1984) and HSV-1 strain 17 (Quinn and McGeoch, 1985) has shown that oriL contains a large palindrome (144 bp) which is responsible for the deletion and cloning instability. The palindrome constitutes the minimum requirement of oriL (McGeoch, 1987).
with a high degree of homology to ori_\text{S}. Sequence analysis of HSV-2 ori_L showed a strong degree of homology to the HSV-1 sequence especially its palindrome (Lockshon and Galloway, 1986). The significance of why the HSV genome has three origins of replication and their contribution to DNA replication is unknown. Mutant viruses lacking either one copy of ori_\text{S} (Longnecker and Roizman, 1986; Brown and Harland, 1987) or ori_L (Polvino-Bodnar et al., 1987), grow normally \textit{in vitro}.

1.6.4 Assembly and maturation

Replicating viral DNA forms a pool of concatameric molecules which are cleaved into unit lengths and packaged into empty capsids in the nucleus (see section 1.4.2). The nuclear capsid containing the DNA attaches to the inner nuclear membrane and acquires an envelope by budding into the perinuclear space (Dargan, 1986; Roizman and Batterson, 1986). It has been reported that herpesviruses can acquire their envelopes by budding into the cytoplasmic vacuoles or Golgi membranes (Nii, 1971; Haguenau and Michelson-Fiske, 1975). Virus particles maturing from different sites may exhibit morphological differences in their envelopes. It has been noted that HSV particles derived from nuclear membranes are circular and electron-dense, while those derived from cytoplasmic membranes have projections or globular structures on the surface (Nii, 1971).

Viruses egress from infected cells by a reverse phagocytosis process which is thought to happen when virus particles acquire envelopes from the cytoplasmic membrane. These particles bud into cytoplasmic vacuoles and are transported via the cytoplasm to the plasma membrane.
Fusion of the vacuolar membrane with the plasma membrane extrude the enveloped viruses into the extracellular space (Nii, 1971; Katsumoto et al., 1981). Those virus particles that acquire envelopes from the inner nuclear membrane move along the reticulo-endothelial system and then either pass directly into the extracellular space or extrude by vacuole formation and reverse phagocytosis (Nii, 1971; Fong et al., 1973).

1.7 HSV-induced polypeptides

Following HSV infection, approximately 50 HSV-induced polypeptides have been identified on SDS-PAGE (Powell and Courtney, 1975; Marsden et al., 1976). Over 230 distinct polypeptides have been recognised using two dimensional PAGE (Haarr and Marsden, 1981). This greater number may be due in part to the resolution of families of peptide species related through post translational modification. The occurrence of post translational modification is reflected by the failure of some in vitro synthesised viral polypeptides to comigrate with their in vivo synthesised counterparts on SDS-PAGE (Preston, 1977). Four main post translational events occur comprising glycosylation (Haarr and Marsden, 1981; Palfreyman et al., 1983; Hope and Marsden, 1983), phosphorylation (Marsden et al., 1978; Wilcox et al., 1980), sulphation (Hope et al., 1982; Hope and Marsden, 1983) and cleavage (Eisenberg et al., 1984; Balachandran and Hutt-Fletcher, 1985). However, other forms of HSV polypeptide modification have been reported e.g fatty acylation which includes palmitylation of several surface glycoproteins (Schmidt, 1982) and myristylation of the HSV-1 UL11 gene product (MacLean et al., 1989).
1.7.1 HSV-induced enzymes

During the course of infection, many viral enzymes are expressed by HSV. Most of them are involved in nucleic acid metabolism and some of them are associated with virus particles. These enzymes are briefly described below.

The HSV-induced DNA polymerase, which is distinguishable from the host cell polymerase (Keir and Gold, 1963; Keir et al., 1966), has a Mr of 136.272 in HSV-1 strain 17 as deduced from DNA sequence data (Quinn and McGeoch, 1985). It has been mapped to the UL30 gene between 0.40-0.42 m.u. of the genome and been shown to be essential for virus DNA replication (Hay and Subak-Sharpe, 1976; Chartrand et al., 1979, 1980). The HSV DNA polymerase has an associated 3' to 5' exonuclease activity (Knopf, 1979).

The thymidine kinase (TK) encoded by HSV has been mapped to the UL23 gene between 0.300-0.309 m.u. and sequenced (McKnight, 1980, Wagner et al., 1981). This enzyme phosphorylates thymidine and deoxycytidine (Jamieson and Subak-Sharpe, 1974). TK-negative viruses have been shown to have reduced pathogenicity (see section 1.8.4.a).

The alkaline exonuclease induced by HSV has been mapped to 0.145-0.185 m.u. (Moss et al., 1979; Preston and Cordingley, 1982) and shown to be essential for DNA synthesis (Francke et al., 1978; Moss et al., 1979). This enzyme possesses an associated endonuclease activity (Hoffmann and Cheng, 1979).

DNA topoisomerases have been described in HSV virions (Muller et al., 1985). These enzymes catalyse the breakage and rejoining of phosphodiester bonds in DNA and may be involved in DNA replication, transcription and recombination.
Uracil-DNA glycosylase, a class of enzyme involved in DNA repair (Lindahl, 1979), is responsible for removing uracil residues in the DNA. The pathways which result in the presence of uracil in DNA are the incorporation of dUMP into it during replication (Bessman et al., 1958) and deamination of cytosine (Shapiro et al., 1973). The induction of viral DNA-uracil glycosylase activity has been reported in cells infected with HSV-1 and HSV-2 (Caradonna and Cheng, 1981). Isolation of an HSV-2 cDNA which encodes this enzyme has been described (Caradonna et al., 1987). The latter authors concluded that uracil-DNA glycosylase acts in removing uracil residues by deamination of cytosine rather than by misincorporation of dUMP residues. Recently the HSV-1 UL2 gene, has been shown to encode uracil-DNA glycosylase and is dispensible for virus growth in tissue culture (Mullaney et al., 1989). Moreover, viruses with double insertion mutations in deoxyuridine triphosphatase (dUTPase) and uracil-DNA glycosylase grow normally in vitro (J. Mullaney, personal communication).

The HSV-induced ribonucleotide reductase (see section 1.8.4.a) has been described in both HSV-1 (Cohen, 1972) and HSV-2 (Cohen et al., 1974). This enzyme has been mapped to genes UL39 and UL40 between 0.580-0.585 m.u. (Preston et al., 1984) and consists of two subunits, large (RR1) and small (RR2) which form a complex that is essential for its activity (Frame et al., 1985; Bacchetti et al., 1986). Synthetic oligopeptides corresponding to the carboxy terminus of RR2 inhibit ribonucleotide reductase activity in vitro (Frame et al., 1985). This lack of enzyme activity is believed to be due to inhibition of the complex formation.
between RRL and RR2 (Cohen et al., 1986; Dutia et al., 1986).

Deoxuryridine triphosphatase (dUTPase) catalyses the conversion of dUTP to dUMP and pyrophosphate and has been mapped to gene UL50 between 0.69-0.70 m.u. (Wohlrab et al., 1982; Preston and Fisher, 1984). Virus mutants lacking dUTPase activity have been shown to grow normally in vitro (Fisher and Preston, 1986).

HSV-1 and HSV-2 have been shown to encode protein kinases by US3 genes (McGeoch, 1987) which are homologous with the members of the protein kinase family of eukaryotes (McGeoch and Davison, 1986). The role of protein kinase in HSV infection has not been determined although it is not essential for virus growth in tissue culture (Longnecker and Roizman, 1987).

### 1.7.2 HSV DNA binding proteins

Approximately 16 HSV-1 induced polypeptides and 12 HSV-2 induced polypeptides have DNA binding properties (Bayliss et al., 1975; Powell and Purifoy, 1976). Some of these like the major DBP (Powell et al., 1981) and the 65K DBP (Vaughan et al., 1985) bind to DNA directly. VmwIE175 has been shown to be a DNA binding protein (Hay and Hay, 1980; Faber and Wilcox, 1986). In contrast, Freeman and Powell (1982) showed that VmwIE175 binds to DNA indirectly by association with the host cell DNA binding protein.

Several HSV-1 DNA binding proteins have enzymatic activities including DNA polymerase and alkaline exonuclease (see section 1.7.1) and have been shown to interact directly with DNA (Powell and Purifoy, 1977; Banks et al., 1983). The 21K protein has been shown to bind to the 'a' sequence
The functions of the other DNA binding proteins are not yet known.

1.8 Virulence of Herpes simplex virus

1.8.1 Introduction

Herpes simplex virus (HSV) is a neurotropic human herpesvirus responsible for a variety of clinical conditions ranging from mild cutaneous lesions (cold sores) to the very rare fatal encephalitis. In many cases shedding may be asymptomatic. After acute infection, the virus travels via the axons of sensory neurons and establishes a latent infection in the dorsal root ganglia of the peripheral nervous system (Stevens and Cook, 1971). There is also evidence for latency in the central nervous system (Knotts et al., 1973). Following reactivation and travel down the axons infectious virus is produced at the periphery which in some cases may result in disease that can range in severity from benign cutaneous lesions to acute fatal encephalitis (Baringer and Swoveland, 1973; Johnson, 1982). A variety of animal models e.g rabbits, mice, guinea pigs and tree shrews have been used to study HSV pathogenesis. Laboratory strains and clinical isolates with differing virulence for animal hosts exist (Dix et al., 1983) and strain specific differences within a given virus type may in part account for the variability of the resulting disease patterns (Wander et al., 1980).

Two types of HSV have been identified and classified on the basis of neutralisation (Nahmias and Dowdle, 1968) and restriction endonuclease patterns (Lonsdale et al., 1979; Buchman et al., 1981). In addition to these differences, functional difference such as variation in tissue culture
cytopathic effect (cpe) has been demonstrated (Ejercito et al., 1968).

1.8.2 Neurovirulence and neuroinvasiveness

Although neurovirulence and neuroinvasiveness are in part related, they can be distinguished. The molecular events that determine the neurovirulence and neuroinvasiveness of HSV are largely unknown. Neurovirulence of a virus can be defined as the capacity to replicate following direct inoculation and to cause disease in the nervous system. Neuroinvasiveness relates to the capacity of virus to enter and move through the nervous system following inoculation at the peripheral site. All neuroinvasive viruses are also neurovirulent; the converse, however, is not true (Stevens, 1987).

Virulence is determined by calculating the 50% lethal dose (LD_{50}) for example using the formula of Reed and Muench (1938), following inoculation of experimental animals. The LD_{50} value for a given virus in a particular inbred strain of animal is also dependent on the age of the animal (Kohl and Loo, 1980; Zawatsky et al., 1982; Ben-Hur et al., 1983) and the route of inoculation (Caspary et al., 1980; Dix et al., 1983).

1.8.3 Extrinsic factors influencing the virulence of HSV

The interaction between HSV and the host is complex and heavily influenced by the genotype of both virus and host. The outcome of HSV infection, which ranges from subclinical to fatal, depends on many factors acting in concert. The factors determining the outcome of HSV infection are not fully understood and the relationship between them is
unclear. These factors are listed in Table 1.1.

The in vivo roles of specific immunological processes (humoral and cell-mediated) in modulating the course of primary and recurrent HSV infection have not been fully elucidated. It is apparent that both processes are effective defence mechanisms which may act together to clear acute HSV infection at peripheral sites. HSV infection stimulates the production of antibodies which participate in virus neutralisation, antibody-dependent complement mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity (Norrild, 1985). Humoral immunity has been reported to play a role in restriction and spread of virus from peripheral sites to sites within the nervous system (McKendall et al., 1979). Knowledge regarding cell-mediated immunity has been derived from murine models of experimental herpesvirus infection. During HSV infection of mice a number of cell-mediated immune responses are stimulated which result in virus clearance from tissue. These include macrophages, natural killer cells (Lopez, 1985) and a variety of T-lymphocyte subpopulations which mediate cytotoxicity, delayed type hypersensitivity and helper or suppressor functions (Nash and Wildy, 1983; Nash et al., 1985).

Interferons (IFN) a group of proteins with a wide range of biological activities (Lengyel, 1982) play a central role in determining resistance to HSV infection (Lopez, 1985). There is increasing evidence that the antiviral activity of IFN is based on a number of different antiviral mechanisms which may operate independently of each other and may affect different stages of the virus growth cycle (Friedman, 1977; Jacobsen, 1986). Recent work on HSV infection in IFN
Table 1.1 Factors involved in determining the outcome of HSV infection

<table>
<thead>
<tr>
<th>I. Host factors</th>
<th>II. Viral factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Immunological</td>
<td>1. Interference</td>
</tr>
<tr>
<td>1. Antigen specific</td>
<td>2. Strain of virus</td>
</tr>
<tr>
<td>a. T-lymphocytes</td>
<td></td>
</tr>
<tr>
<td>b. Antibodies</td>
<td></td>
</tr>
<tr>
<td>2. Antigen non-specific</td>
<td></td>
</tr>
<tr>
<td>a. Interferon</td>
<td></td>
</tr>
<tr>
<td>b. Macrophages</td>
<td></td>
</tr>
<tr>
<td>c. Natural killer cells</td>
<td></td>
</tr>
<tr>
<td>B. Non-immunological</td>
<td></td>
</tr>
<tr>
<td>1. Barrier (skin, mucous membrane)</td>
<td></td>
</tr>
<tr>
<td>2. Age of the host</td>
<td></td>
</tr>
<tr>
<td>3. Route of inoculation</td>
<td></td>
</tr>
</tbody>
</table>
treated cells shows that IFN inhibits the onset of HSV IE transcription (Mittnacht et al., 1988).

Non-immunological host factors such as the integrity of the skin and mucous membranes are also involved in resistance to HSV infection. Recent work on Langerhan's cells, which are present in the epidermis of the skin, suggests that in mice these cells play an important role in defence against HSV infection and an increase in their density in the skin was correlated with increased resistance to infection with HSV (Sprecher and Becker, 1986, 1987). Langerhan's cells have also been shown to be highly efficient as antigen presenting cells (Braathen et al., 1980) and to be able to interact with T-lymphocytes in local lymph nodes (Silverberg et al., 1976).

Many studies have demonstrated that virus strain, route of inoculation, age of host, all have effects on virulence of HSV (Lopez, 1975; Caspary et al., 1980; Kohl and Loo, 1980; Zawatsky et al., 1982; Ben-Hur et al., 1983; Dix et al., 1983; Sprecher and Becker, 1987). It has also been reported that serial passage of virus in vivo (Kaerner et al., 1983), in vitro (Goodman and Stevens, 1986) and at body temperature i.e 37.5°C (Thompson and Stevens, 1983a) could increase the virulence of HSV.

Viral interference is a very important determinant of viral infection and is defined as a phenomenon in which the presence of an initial or primary virus infection prevents the infection or replication by a secondary (superinfecting or challenge) virus. The mechanism by which this occurs is not well understood. Stow (1985) suggested that the block may result from either the presence of defective viral particles or competition for host proteins necessary for
viral DNA replication.

1.8.4 Viral genes determining virulence of HSV

HSV may rarely induce a life threatening encephalitis in humans (Rawls, 1985) and there is a continuing interest in understanding the properties of the virus relating to this syndrome. To define various aspects of the disease, experimental animals such as mice, rabbits, guinea pigs and rats have been used as models. Genetic analysis designed to identify specific neurovirulence and neuroinvasiveness associated genes is limited by the availability of suitable mutant viruses. Many laboratories are studying HSV genes and gene products associated with virulence using deletion mutants, monoclonal antibody resistance (mar) mutants, temperature sensitive (ts) mutants, drug resistance mutants and intertypic recombinants. Genes and loci modifying virulence of HSV are shown in Figure 1.7.A and B and described in the following sections.

1.8.4.a Viral enzymes

HSV encodes a thymidine kinase (TK) which is distinct from mammalian TK (Kit, 1979) and facilitates HSV replication in non-dividing cells (Jamieson et al., 1974). Virus mutants (TK⁻) deficient in the production of this enzyme replicate well in actively growing cell cultures and poorly in serum starved cells (Jamieson et al., 1974; Field and Wildy, 1978). This led to the speculation that such mutants might be less virulent in vivo and it has been reported that TK⁻ mutants of HSV-2 are less virulent than wild type (TK⁺) HSV-2 (Marcialis et al., 1975; Field and Wildy, 1978; Stanberry et al., 1985). Similarly TK⁻ mutants
Figure 1.7

A. Genes and loci in $U_L$, $TR_L$ and $IR_L$ involved in virulence of HSV. The top line shows the fraction map units (m.u.) of the genome from 0 to 0.83. The locations of different genes and loci are indicated on the viral genome.

B. Genes in $IR_S$, $U_S$ and $TR_S$ involved in virulence of HSV. The top line shows the fraction m.u. of the viral genome from 0.83 to 1.0. The locations and orientations of the genes are indicated on the viral genome.
of HSV-1 have been shown to have reduced pathogenicity in animal models of herpes encephalitis (Field and Wildy, 1978), herpes keratitis (Marcialis et al., 1975; Price and Khan, 1981) and herpes labialis (Klein et al., 1981). Therefore viral TK would appear to influence HSV virulence, although the possibility that there are additional defects in these virus stocks arising from unrecognised mutations can not be excluded. The mechanism by which virus coded TK influences the pathogenicity of HSV may relate to reduced virus replication in neural tissue (Field and Wildy, 1978; Tenser et al., 1979; Klein et al., 1981; Price and Khan, 1981; McDermott et al., 1984). During maturation, nerve cells stop expressing cellular TK and it is likely that TK⁺ viruses are able to replicate in such cells since these viruses are able to produce enough of their own TK to multiply in the central nervous system (Gordon et al., 1983).

The TK enzyme is required for DNA synthesis through phosphorylation of thymidine to thymidine monophosphate. This function makes a good target for antiviral drugs. The common anti-HSV drug used for prophylaxis and therapy of HSV infections is acyclovir (ACV). It was initially feared that ACV resistant HSV strains might become a serious problem, analogous to penicillin resistant bacteria. ACV behaves as a nucleoside analogue which is selectively phosphorylated by HSV specific TK. The monophosphate form of ACV is then converted to the diphosphate and subsequently by cellular kinases to the triphosphate which is a potent inhibitor of HSV DNA polymerase. Three mechanisms of resistance to ACV have been described (i) loss of TK activity, (ii) alteration in TK substrate specificity and (iii) alteration of DNA
polymerase (Coen and Schaffer, 1980; Crumpacker et al., 1980; Schippers and Crumpacker, 1980; Darby et al., 1981; Field et al., 1982; Larder et al., 1983; Schinazi et al., 1986; Ellis et al., 1987; Kit et al., 1987). Mutants with an altered TK which are resistant to ACV may have reduced virulence (Darby et al., 1981; Klein et al., 1981; Sibrack et al., 1982). In one case, an ACV resistant mutant with an alteration in TK was shown to be highly virulent for mice (Sakuma et al., 1988). Mutants containing a drug resistance mutation in the viral DNA polymerase gene were attenuated for pathogenicity after intracranial inoculation and cataracts were reported as a common sequel (Field and Coen, 1986). Modulation of pathogenicity was also seen using flank and ear inoculation (Larder et al., 1986).

Ribonucleotide reductase (RR) catalyses the reduction of ribonucleotides to deoxyribonucleotides (Thelander and Reichard, 1979). The HSV enzyme consists of two subunits named large (RR1) and small (RR2) (Cohen, 1972; Dutia, 1983; Preston et al., 1984; Cohen et al., 1985; Frame et al., 1985). It has been shown that RR is essential for virus growth in tissue culture (Preston et al., 1984). Recent findings by Goldstein and Weller (1988) utilising viral RR mutants have substantiated the theory that the HSV enzyme is non-essential for virus growth in vitro. It has been shown that the HSV-1 ts mutants in RR, ts 1207 and ts 1222 (Preston et al., 1988) have reduced pathogenicity for mice following intracranial and intraperitoneal inoculation (Cameron et al., 1988). Jacobson et al. (1989) showed that a mutant containing a deletion in the RR1 gene is severely impaired in growth during acute infection of the eye and trigeminal ganglia in mice. In contrast, Turk et al. (1989)
showed that two mutants containing a deletion in HSV-1 RRI produce lesions in guinea pigs as severe as those of wild type strains following intradermal inoculation.

1.8.4.b Vmw65 trans-inducing factor (TIF)

A distinguishing feature of the IE genes is the presence of the cis-acting element, TAATGARAT, in their 5' regulatory regions. This element responds to the HSV-1 virion polypeptide Vmw65 TIF resulting in stimulation of transcription from the IE promoters (Mackem and Roizman, 1982; Batterson and Roizman, 1983; Cordingley et al., 1983; Campell et al., 1984; Kristie and Roizman, 1984; Gaffney et al., 1985; Pellett et al., 1985; O'Hare and Hayward, 1987). Recent work by Ace et al. (1989) has shown that a HSV-1 mutant unable to transinduce IE gene expression has reduced virulence for mice following intracranial and intraperitoneal inoculation.

1.8.4.c Temperature sensitive (ts) mutants

Most of the ts mutants of HSV have been generated using a variety of mutagens (Schaffer et al., 1970, 1974; Timbury, 1971; Brown et al., 1973; Esparza et al., 1974; Manservigi, 1974). It has been shown that some ts mutants of HSV have reduced virulence for guinea pigs (Anderson et al., 1980) and for mice (Lofgren et al., 1977). Temperature-sensitive mutants have been valuable in understanding the molecular events of the virus replication cycle in vitro.

1.8.4.d Glycoproteins

The genome of HSV-1 encodes at least seven antigenically distinct glycoproteins; gB, gC, gD (Spear, 1976), gE (Baucke
and Spear, 1976), gG (Marsden et al., 1984; Roizman et al., 1984), gH (Buckmaster et al., 1984) and gI (Longnecker et al., 1987). HSV-2 counterparts for gB, gC, gD, gE and gG have also been described based on biochemical or immunological criteria or analysis of DNA sequence data (Pereira et al., 1981; Balachandram et al., 1982; Eisenberg et al., 1982; Hope et al., 1982; Para et al., 1982; Zezulak and Spear, 1983; Zweig et al., 1983; Dowbenko and Lasky, 1984; Swain et al., 1985; McGeoch et al., 1987). No HSV-2 counterpart of gH has yet been identified. Virus-specific glycoproteins are structural components of the virion envelope and are expressed on the surface of infected cells where they may serve as targets for immune surveillance (Norrild, 1985; Dix, 1987). The known HSV-1 glycoproteins and their biological and immunological functions are summarised in Table 1.2 and their map locations is indicated in Figure 1.8.

Studies with ts and deletion mutants in various glycoproteins indicated that gC, gE, gG and gI are dispensable for growth of virus in tissue culture (Hoggan and Roizman, 1959; Heine et al., 1974; Cassai et al., 1975; Holland et al., 1984; Zezulak and Spear, 1984; Longnecker and Roizman, 1986, 1987; Longnecker et al., 1987; Weber et al., 1987; Harland and Brown, 1988; Schranz et al., 1989) whereas gB and gH have been shown to be essential (Manservigi et al., 1977; Little et al., 1981; Gompels and Minson, 1986). Studies involving HSV-1 ts mutants in gB have suggested a role for gB in the entry of virus into cells (Sarmiento et al., 1979; Little et al., 1981) and cell-cell fusion (Manservigi et al., 1977; Haffey and Spear, 1980). Furthermore evidence supporting the role of gB and
<table>
<thead>
<tr>
<th>Immununological properties</th>
<th>1a</th>
<th>1b</th>
<th>1c</th>
<th>1d</th>
<th>1e</th>
<th>1f</th>
<th>1g</th>
<th>1h</th>
<th>1i</th>
</tr>
</thead>
<tbody>
<tr>
<td>Induces neutralizing antibody</td>
<td>not determined</td>
<td>involved in cell fusion and entry</td>
<td>involved in cell fusion and entry</td>
<td>required for infectivity and involvement</td>
<td>required for infectivity and involvement</td>
<td>required for infectivity and involvement</td>
<td>required for infectivity and involvement</td>
<td>required for infectivity and involvement</td>
<td>required for infectivity and involvement</td>
</tr>
<tr>
<td>Induces neutralizing antibody and delayed type hypersensitivity</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
</tr>
<tr>
<td>Induces neutralizing antibody and delayed type hypersensitivity</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
</tr>
<tr>
<td>Cytotoxic T-lymphocytes and neutralizing antibody</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
</tr>
<tr>
<td>Cytotoxic T-lymphocytes and neutralizing antibody and delayed type hypersensitivity</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
<td>not determined</td>
</tr>
</tbody>
</table>

Table 1.2 Known biological and immunological properties of HSV-1 glycoproteins
Figure 1.8

Locations of the genes encoding HSV-1 glycoproteins.
The HSV-1 genome is represented in the prototype orientation with fractional genomic length (m.u.) above the genome. The approximate map locations of the glycoproteins are indicated by shaded boxes.
(Adapted from Marsden, 1987).
to a lesser extent gD in virus attachment to the cell and cell-cell fusion has come from experiments with reconstituted viral glycoproteins (Johnson et al., 1984) and monoclonal antibodies (Nobel et al., 1983; Fuller and Spear, 1985). Similar experiments have implicated gH in cell fusion (Gompels and Minson, 1986). Two antigenic sites in gB have been identified and shown to be linked with the ability of gB to contribute to virus infectivity (Highlander et al., 1989).

The role of gH in egress of virus from infected cells has been shown using a monoclonal antibody against gH which inhibits plaque formation suggesting the involvement of gH in cell-cell spread of infectious virus (Buckmaster et al., 1984). It has been reported recently that monoclonal antibodies specific to gH of HSV block viral penetration without inhibiting adsorption of virus to cells (Fuller et al., 1989).

HSV-1 gE (Bauke and Spear, 1979; Para et al., 1982) and gI (Johnson and Feenstra, 1987) have been associated with virus specific binding activity for the Fc component of immunoglobulin G (IgG). Evidence that binding of non-immune IgG to infected cell membranes can protect the cells from immune cytolysis (Adler et al., 1978) suggests that such binding may modify immune recognition of virus infected cells in vivo.

Glycoprotein C plays a role in the induction of humoral and cell-mediated immune responses during infection (Oakes et al., 1980; Glorioso et al., 1985; Kumel et al., 1985; Marlin et al., 1985; Nash et al., 1985; Rosenthal et al., 1987) and has the unique property of functioning as a receptor for the C3b component of complement (Friedman et
This activity has been shown to interfere with activation of the alternative complement pathway (Fries et al., 1986).

Glycoproteins have been identified as virulence factors in studies of other viruses such as rabies (Dietzschold et al., 1983) and murine corona virus (Fleming et al., 1986). Among herpesviruses gI and gIII, pseudorabies virus structural components have been reported to influence viral neurovirulence (Mettenleiter et al., 1987, 1988). Although HSV encodes at least seven glycoproteins, their roles in neurovirulence remain largely unexplored.

The ability of gC to interfere with activation of the complement pathway suggested that gC may act as an important virulence determinant by protecting the virus from complement-mediated antiviral host defence mechanisms. Intravaginal inoculation of mice with a gC-2 negative (gC⁻²) mutant produced local inflammation followed by lethal spread of virus infection into the nervous system in an identical manner to that produced by the parental HSV-2 strain 333 (Johnson et al., 1986). Similarly direct inoculation of a gC⁻² mutant into the central nervous system produced lethal neurological disease. These results support the impression that gC-2 is not involved in virulence. On the other hand, HSV-2 marC mutants were found to be reduced in pathogenicity for the nervous system (Kumel et al., 1985). HSV-1 strain MP which is gC⁻¹ (Hoggan and Roizman, 1959; Holland et al., 1984) was found to be highly virulent for mice following intracranial or footpad inoculation (Dix et al., 1983). Recently Sunstrum et al. (1988) have tested eight additional gC⁻¹ mutants derived from HSV-1 strain KOS 321 and shown that these mutants differ widely in their ability to induce
lethal encephalitis in mice following intracranial inoculation. It was concluded that gC-1 is not a virulence determinant in the mouse model of HSV-1 induced encephalitis. It has been suggested that it is unlikely that either gC-1 or gC-2 play an essential role in the entry of virus into epithelial or neural cells, either in mice or humans (Johnson et al., 1986).

MarB or marD mutants with single epitope changes have no effect on pathogenicity, while multi-marB mutants show significantly reduced pathogenicity. This difference may be due to an unrecognised mutation other than the ts phenotype of multi-marB mutants which alters pathogenicity (Kumel et al., 1985).

The involvement of gE and gG in virulence has been shown using genetically engineered deletion mutants of HSV-1 strain F (Meignier et al., 1988). The LD_{50} of a gG- was 10^4 fold higher than the wild type, while that of a gE- mutant was <100 fold higher following intracranial inoculation of mice. These results indicated that gG and to a lesser extent gE have important roles in virulence. In addition Weber et al. (1987) have shown that a HSV-1 mutant carrying a chain terminating Tn5 insertion in the gene encoding gG has reduced neurovirulence in mice. It has been shown recently that mutants of HSV-2 strain HG52 in the US4 gene encoding gG were reduced in virulence for mice following intracranial inoculation (see section 3.2.2).

The role of gB in pathogenicity was demonstrated by transfer of the gB gene from HSV-1 strain KOS, which has been shown to be apathogenic for mice following intraperitoneal inoculation (Schroder et al., 1983), to HSV-1 strain ANG path, which is pathogenic for mice when
inoculated by the same route (Kaerner et al., 1983), resulting in recombinant virus which was apathogenic for mice (Weise et al., 1987).

1.8.4.e Other loci

Many groups have identified regions in the HSV genome involved in virulence using different animal model systems. Thompson and Stevens (1983b) used the HSV-1 intertypic recombinant RE6 which was generated by marker rescue of *ts E syn* with wild type HG52 fragments (Marsden et al., 1978). They showed that RE6 was completely avirulent for mice following intracranial inoculation and concluded that RE6 was at least 10 million fold less neurovirulent than the parental wild type viruses. In an other study, Thompson et al. (1983) confirmed the avirulent phenotype of RE6 and localised the HSV-1 region which restored neurovirulence to between 0.71-0.83 m.u. Cleavage of the wild type HindIII c fragment (0.64-0.87 m.u.) with EcoRI eliminated its capacity to rescue RE6 and neurovirulence was restored by the addition of the HSV-1 BamHI 1 fragment (0.71-0.74 m.u.) that spans an EcoRI site at 0.72 m.u. (Thompson et al., 1985). Similarly Ben-Hur et al. (1987) following intracranial inoculation of mice concluded that a neurovirulence function resided in the BamHI 1 fragment (0.7-0.738 m.u.) of HSV-1 strain F and that the function was closely linked to the viral gene for cell fusion. The latter correlated with the report by Yamada et al. (1986), who examined several HSV-1 variants (all derived from the Miyama strain) and concluded that viral pathogenicity correlated with a higher cell fusion index and large plaque size.

Another intertypic recombinant RS6, which was generated
by cotransfection of unit length $ts$ S of 17 $syn^+$ DNA and Xbal generated DNA fragments derived from HG52 (Stow and Wilkie, 1978), was also studied in pathogenicity experiments. Javier et al. (1987) have shown that the HSV-1 intertypic recombinant RS6 was approximately $10^5$ times less neurovirulent for mice following intracranial inoculation than either of its wild type parental viruses. The avirulent phenotype of RS6 was due to failure to replicate in mouse brain. Cotransfection experiments of RS6 DNA with EcoRI e + k fragments (0.72-0.87 m.u.) of 17 $syn^+$ generated recombinant viruses with variable degrees of neurovirulence. The relevant region between 0.72-0.87 m.u. was tentatively delimited to 0.79-0.83 m.u. DNA analysis of the recombinant viruses showed that the highly neurovirulent recombinants had type 2 DNA replaced with type 1 DNA in the two regions between 0.11-0.14 m.u. and 0.79-0.83 m.u. One exceptional recombinant designated R13-1 was avirulent and had type 2 DNA replaced by type 1 DNA in the region between 0.79-0.83 m.u. These results suggested that there was at least another region (0.11-0.14 m.u.) involved in HSV neurovirulence. The same group (Javier et al., 1988a) have shown that the R13-1 recombinant was $10^3$ fold less neurovirulent than either of the wild type parental viruses despite a comparable efficiency of replication in mouse brain to that of the parental viruses. Marker rescue of unit length R13-1 DNA and cloned type 1 EcoRI d fragments (0.079-0.192 m.u.) spanning the region from 0.11-0.14 m.u. generated viruses with the wild type neurovirulence phenotype.

Another region of the HSV genome has been implicated in neuroinvasiveness. Thompson et al. (1986) have shown that a
cosmid clone containing the HindIII a fragment (0.25-0.53 m.u.) of strain 17 syn + in cotransfection with full length KOS DNA, known to be less neurovirulent than most other HSV-1 strains (Dix et al., 1983), yielded recombinants with enhanced neuroinvasiveness for mice following footpad inoculation. Javier et al. (1986) reported that simultaneous inoculation of mice on the rear footpad with two non-neuroinvasive viruses (HSV-1 strains ANG and KOS) resulted in the deaths of 62% of animals. Studying the events responsible for pathogenesis of this virus mixture Sedarati et al. (1988) investigated the replication capacity and spread of virus within specific tissue and found that the amount of neuroinvasive virus mixture had increased within the spinal cords and brains of infected mice compared to ANG and KOS strains which are defective in this capacity. Their findings suggested that the neuroinvasiveness of the virus mixture was a consequence of complementation as well as the generation and selection of neuroinvasive recombinants in the spinal cords of mice.

Recent work by Goodman et al. (1989) has shown that HSV-1 strain ANG DNA contains at least two distinct neuroinvasive regions designated INV-1 (0.49-0.64 m.u.) and INV-II (0.32-0.42 m.u.) containing functions which can be transferred by DNA cotransfection to confer mesodermal invasiveness and virulence to the avirulent HSV-1 17 syn + on the chorioallantoic membrane (CAM) of chicken embryos. The genes in the region INV-1 (0.49-0.64 m.u.) include the virion function associated with shut-off of host cell protein synthesis (Morse et al., 1978). The 5' end of the gC gene also maps within this region and gC is highly type divergent in terms of both sequence and antigenicity (Spear,
In addition the genes encoding RR and ICP10 reside within this region (Schaffer et al., 1987). The region INV-II (0.32-0.42 m.u.) contains genes encoding gB (Bzik et al., 1984) and its associated syn 3 mutation locus (Ruyechan et al., 1979).

Sedarati and Stevens (1987) have examined the biological properties of HSV-1 strains F, HF and HFEM compared to HSV-1 17 syn+. They found that the three strains of HSV (F, HF and HFEM) were defective in replication in mouse cells, had reduced neurovirulence for mice following intracranial inoculation and were completely avirulent following footpad inoculation. In coinfection experiments, strain F complemented strains HF and HFEM but the latter two strains did not complement each other. All three strains were found to complement the neuroinvasive KOS emphasizing the multigenic nature of HSV virulence.

Centifanto-Fitzgerald et al. (1982), studying the patterns of ocular disease produced by HSV using the rabbit eye model system, identified a region of the HSV-1 genome between 0.71-0.83 m.u. involved in stromal disease. In addition a study by Oakes et al. (1986) using intertypic recombinants, has shown that HSV-1 DNA sequences between 0.31-0.44 m.u. were necessary for recombinant viruses to spread from the cornea to the central nervous system of mice following ocular inoculation. Similarly Day et al. (1987) showed that a region important in DNA replication between 0.4-0.44 m.u. of HSV-1 strain 17 syn+ was involved in spread of virus from the cornea to the central nervous system following ocular inoculation of mice. This region contains ori_L, DNA polymerase and a part of the major DBP (Quinn and McGeoch, 1985; Weller et al., 1985).
The tree shrew has also been used as an animal model to define HSV genes involved in virulence. The HSV-1 strain HFEM, which has a deletion of about 4.1 kb between 0.76-0.79 m.u., is apathogenic for tree shrews after intraperitoneal inoculation (Rosen and Darai, 1985). Pathogenicity of strain HFEM was restored by cotransfection of its DNA and the BamHI b fragment (0.733-0.809 m.u.) from the pathogenic HSV-1 strain F (Rosen et al., 1985). Similarly insertion of the MluI DNA fragment (0.7615-0.789 m.u.) from HSV-1 strain F restored the intraperitoneal pathogenicity to strain HFEM (Rosen et al., 1986). A similar DNA fragment (MluI 0.761-0.786 m.u.), spanning the HpaI p sequences of the pathogenic strain F, has been shown to restore the intraperitoneal pathogenicity of HFEM for mice (Becker et al., 1986). Recent work on the neurovirulence of seven deletion mutants of HSV-1 showed that all were attenuated for virulence in mice following intracranial inoculation (Meignier et al., 1988). The genes deleted from six of these map in the S component of HSV-1 DNA and were IE4, US2, US3, gG, gE, US11 and IE5.

Recently Taha et al. (1989a; and this thesis), have shown that a variant (JH2604) of HSV-2 strain HG52, whose genome is deleted by approximately 1.5 kb within both copies of the BamHI v fragment between 0-0.02 and 0.81-0.83 m.u. (Harland and Brown, 1985), is completely non-neurovirulent for mice following intracranial inoculation. Correction of the deletion by wild type Xbal (e, f or g) or BamHI g fragments resulted in recombinants with wild type neurovirulence. Introduction of the JH2604 deletion back into the wild type genome resulted in non-neurovirulent recombinants, demonstrating that the deleted sequences in
the variant JH2604 determine neurovirulence. Sequence analysis has shown that the variant JH2604 is deleted by 1488 bp in both the IR_\text{L} and TR_\text{L} copy of BamHI v (Taha et al., 1989b). A similar region has recently been identified in HSV-1 strain 17 as being important in the determination of virulence in mice (Thompson et al., 1989).

1.9 Latency of HSV

Unlike many other human viruses which are eliminated by host mediated defence mechanisms soon after primary infection, HSV has evolved a complex strategy of replication and survival whereby it may remain within neural or non-neural tissues for long periods of time in a latent state thereby evading the immune response. The latent phase of HSV infection is defined as isolation of infectious virus from explant cultures after a period of time but failure to detect infectious virus from cell homogenates of tissues or organs immediately post explantation.

The focal point of most clinical disease arising from HSV is the ability of the virus to interact with components of the peripheral nervous system. Following primary infection and active replication at peripheral sites, virus attaches to the sensory nerve terminals (Vahlne et al., 1978), enters them and travels centripetally via neural routes to sensory ganglia (Cook and Stevens, 1973). It is within the neurons of the sensory ganglia that virus becomes latent (Cook et al., 1974; Stevens, 1975). HSV has been recovered in humans and animals from explanted nervous tissue, and adrenal glands (Nesburn et al., 1972; Knotts et al., 1973; Cook and Stevens, 1976; Price et al., 1975; Warren et al., 1978). Evidence is accumulating which
suggests that peripheral non-neural sites of herpesvirus latency in humans and experimentally infected animals also exist. HSV-1 has been isolated in the absence of detectable clinical lesions from the ear skin, which was the initial site of inoculation, in 8% of mice latently infected with the virus though this was initially interpreted as reactivation from dorsal root ganglia (Hill et al., 1980). HSV-2 and HSV-1 have both been recovered independently from the footpad as well as from the dorsal root ganglia of latently infected mice (Al-Saadi et al., 1983; Clements and Subak-Sharpe, 1983, 1988; Subak-Sharpe et al., 1984a, 1984b; Al-Saadi et al., 1988). In the guinea pig both HSV-1 and HSV-2 have been isolated from the site of primary infection (footpad and vagina) long after inoculation (Scriba, 1976, 1981; Donnenberg et al., 1980). However, in the guinea pig spontaneous reactivation is very common. HSV has been reactivated from cultured cells of explanted corneal tissue of rabbits (Cook et al., 1987) and mice (Openshaw, 1983). In humans, attempts to recover latent HSV from peripheral sites have been unsuccessful (Rustigian et al., 1966) apart from the isolation from human corneas removed prior to corneal transplantation, due to chronic stromal keratitis (Shimeld et al., 1982; Tullo et al., 1985; Cook, 1988).

The mechanism of initiation, maintenance and reactivation of latent HSV has been extensively studied (Wildy et al., 1982; Hill, 1985) but is still not fully understood. The molecular investigation of viral genes expressed during the latent state has been difficult since only a minority of cells in neural tissue harbour latent virus (Kennedy et al., 1983). During the latent phase, the viral genome appears to be present in circular or
concatameric forms rather than the linear molecules found in intact virions (Rock and Fraser, 1983). During the latent phase there have been no confirmed claims of the detection of any HSV gene expression. Recently HSV-specific transcripts have been detected during HSV-1 latency in ganglia of seropositive patients (Croen et al., 1987; Steiner et al., 1988; Stevens et al., 1988) and in experimentally infected mice (Deatly et al., 1987; Puga and Notkins, 1987; Spivack and Fraser, 1987; Stevens et al., 1987; Wagner et al., 1988) and rabbits (Rock et al., 1987; Wechsler et al., 1988).

The HSV-1 transcripts present in sensory ganglia of latently infected animals and humans originate from the long repeat region of the viral genome which are present as two copies per genome. At least three viral transcripts (latency associated transcripts- LAT), 2.0, 1.5 and 1.45 kb are present during HSV-1 latency in humans and experimentally infected animals (mice and rabbits) and map to a 3.0 kb region contained within the BamHI b and e fragments in the R_L region. These RNAs partially overlap the 3' terminus of the IEl gene but are transcribed in the opposite direction (Rock et al., 1987; Spivack and Fraser, 1987; Stevens et al., 1987; Deatly et al., 1988; Steiner et al., 1988; Wagner et al., 1988; Wechsler et al., 1988).

The DNA of the region from which transcription occurs during latency has been sequenced and, apart from IEl, does not contain any convincing protein-coding sequences (Perry and McGeoch, 1988). Moreover, most of the transcripts present during latency are not polyadenylated (Wagner et al., 1988). The LATs might modulate latency via control of IEl gene expression, possibly by interacting with the DNA
sequence of the gene or with IE1mRNA (Croen et al., 1987; Rock et al., 1987; Stevens et al., 1987). However, HSV deletion variants that lack all or part of the LATs are latency competent in laboratory animals (Javier et al., 1988b; Sedarati et al., 1989; Steiner et al., 1989). Thus these transcripts, the only HSV specified products so far detected in latently infected neurons, are not essential for the latency process in neurons, at least in animals.

Several studies have suggested that mutants of HSV-1 with defective TK have a reduced ability to establish latent infections in vivo. Moreover, studies using genetically engineered TK- deletion mutants have shown that the mutants can not establish either acute or latent ganglionic infection in mice (McDermott et al., 1984; Tenser and Edris, 1987). Similarly, an HSV-1 TK- mutant was shown to be latency negative in mice but positive in rabbits suggesting that the host cell may be a determinant in the establishment of latent infection (Meignier et al., 1988). In contrast, Efstathiou et al. (1989) have demonstrated by superinfection of mouse explanted/ganglia with wild type HSV-1, that a TK- deletion mutant was able to establish latent ganglionic infection suggesting that the virus-encoded TK is not essential for establishment of latent infection. Recently Leist et al. (1989) have reported that an HSV-1 variant harboring a deletion in the TK gene can establish latent infections in mice spinal ganglia. That variant could not be reactivated when spinal ganglia were cultured in vitro suggesting that the expression of the viral TK gene plays no major role in establishment of the latent state but it has a role in reactivation from explanted ganglia. Similarly Tenser et al. (1989) concluded that although HSV-1 TK-
mutants were able to establish latent infections in mouse ganglia, they failed to reactivate from explanted ganglia suggesting a role for TK in the reactivation process. Using an in vitro system to study latency, Russel and Preston (1986) have shown that infection of human foetal lung (HFL) cells with HSV-2 at the superoptimal temperature of \(42^\circ\text{C}\) results in a latent state which is stable on downshift of cultures to \(37^\circ\text{C}\). The latent virus can be reactivated by superinfection with HSV or CMV but not with adenovirus. Using this approach, Russel et al. (1987) have demonstrated that the superinfection of HSV-1 dll403, which has a large deletion in the IEl gene coding for VmwIE10 (Stow and Stow, 1986), can not reactivate latent HSV-2 suggesting a role for the IEl gene product in reactivation. Recently, Harris et al. (1989) using two mutants, have shown that adenovirus recombinants expressing HSV-1 VmwIE10 reactivate latent HSV-2 in vitro. The HSV-1 mutant which possesses a deletion in the carboxy-terminal region of VmwIE10 reactivated latent HSV-2, whereas the other HSV-1 mutant which has a deletion in the second exon did not, suggesting that VmwIE10 alone is required for reactivation of latent HSV-2 in vitro. Contrary to this, Clements and Stow (1989) have shown that dll403, which has reduced virulence for mice, is able to establish a latent infection in mice sensory ganglia following footpad inoculation and the latent virus can reactivate from explanted ganglia suggesting that the gene product of the IEl gene (VmwIE10) is dispensible for establishment and maintenance of latency and reactivation from the latent state.

1.10 HSV infection of the nervous system
1.10.1 HSV-1 encephalitis

The most important neurological disease caused by HSV-1 is an acute encephalitis which is the commonest type of fatal sporadic acute encephalitis occurring in man (Finelli, 1975). Beyond the fact that HSV-1 infection spreads within the brain causing progressive destruction of both neurons and glial cells, little is known of the pathogenesis of herpes encephalitis. The route of infection is likely to be an important factor in determining the topography of herpetic brain infection. HSV-1 can directly invade the brain of immunologically normal adults and produce an acute haemorrhagic necrotising encephalitis which is accompanied by high mortality and severe morbidity (Whitley et al., 1982a).

Two theories currently exist to explain the origin of the virus responsible for this devastating disease. Davis and Johnson (1979) speculated that HSV-1 encephalitis of adults represents reactivation of a latent endogenous virus from the trigeminal ganglia. Support for this hypothesis has been supplied by Whitley et al. (1982b) who demonstrated that brain and oral isolates recovered from five of eight patients with simultaneous encephalitis and oral lesions were identical when compared by DNA restriction enzyme analysis. Alternatively the rather consistent striking localisation of tissue destruction to the subfrontal and medial temporal regions of the brain led Johnson and Mims (1968) to speculate that this disease is a primary infection caused by an exogenous virus which gains access to the central nervous system by the olfactory route. Evidence obtained from experimental animal models of focal HSV-1 encephalitis produced by virus inoculation of the olfactory
bulb or nasal mucosa would tend to support this hypothesis (Anderson and Field, 1983; Schlitt et al., 1986; Stroop and Schaefer, 1986).

On the other hand, a number of animal studies have demonstrated that after inoculation of HSV-1 by a variety of routes there is a predilection for certain brain regions suggesting a selective vulnerability of these regions (Anderson and Field, 1983; Tomlinson and Esiri, 1983; McFarland and Hotchin, 1987).

1.10.2 HSV-2 encephalitis and meningitis

HSV-2 may produce severe neurological infections in infants infected at the time of birth who develop disseminated herpetic infection with hepatic and adrenal necrosis and diffuse encephalitis (Johnson, 1982). In adolescents and adults, primary infection is occasionally complicated by an acute self-limiting benign meningitis often associated with outbreaks of genital disease (Corey, 1984). The pathogenesis of HSV-2 meningitis is uncertain. Unlike HSV-1, HSV-2 can be recovered from both cerebrospinal fluid (CSF) and blood (Craig and Nahmias, 1973) of adults suffering from aseptic meningitis. Whether all cases of this illness are associated with viraemia remains to be determined. Nevertheless, it is generally accepted that HSV-2 meningitis is a consequence of reactivation from sacral ganglia of virus which subsequently seeds the CSF. Complications of HSV-2 meningitis include intermittent or permanent paralysis associated with transverse myelitis of the spinal cord.

An exception to the more benign nature of HSV-2 in adults is seen in patients with immunodeficiency. Fatal
disseminated herpesvirus infections, including encephalitis (Sutton et al., 1974) and severe even fatal meningoencephalitis associated with HSV-2 as well as HSV-1 have been reported in patients undergoing intensive immunosuppressive therapy (Johnson, 1982).

1.11 Pathology of HSV encephalitis

There is marked necrosis in HSV encephalitis with petechial haemorrhage accounting for the earlier term, acute necrotising encephalitis. Microscopically, haemorrhagic necrosis with mononuclear inclusion bodies in the neurons and glial cells is seen (Drachman and Adams, 1962). Viral antigen distribution in human cases of herpes encephalitis was analysed using immunoperoxidase techniques (Esiri, 1982). The analysis showed that HSV-1 antigens were detected in the medial and inferior temporal lobes, hippocampus, amygdaloid nuclei, olfactory cortex, insula and cingulate gyrus. In a number of cases antigens were detected in glial cells of the olfactory tracts. The grey matter was predominantly affected, but antigens and inflammation extended also into the white matter. Viral antigens could be visualised early in the disease and by the fourth week, antigens were largely cleared and replaced by inflammatory cells. Using a combination of immunoperoxidase staining and in situ hybridisation it has been possible to show localisation of viral antigens and viral nucleic acid in the same cell allowing the distinction between productive and non-productive viral infections (Kennedy et al., 1988). Viral antigens and HSV RNA were detected in the same astrocytes, glial cells and macrophages.

In experimentally infected animals, viral antigen
distribution in the central nervous system depends on the portal of virus entry (Anderson and Field, 1983; Chrisp et al., 1989) and the animal species (Stroop and Schaefer, 1986). Hayashi et al. (1986) have reported hydrocephalus in mice following intracranial inoculation with HSV-1. These brains showed dilation of the ventricles with irregular walls devoid of ependymal lining cells and proliferation of subependymal astrocytes. Mild mononuclear cell infiltration was also commonly seen in the subarachnoid space of hydrocephalic mice.

1.12 HSV and ocular diseases

HSV is endemic in the world with 60-70% of children aged 5 years and 90% of adults having neutralising antibody against HSV (Smith et al., 1967). However, only 20-30% are estimated to manifest clinical disease and less than 1% exhibit ocular disease (Kaufman et al., 1983). The virus is the most common cause of corneal ulcer and corneal blindness in developing countries (Foster and Duncan, 1981). The two types of HSV are implicated in ocular disease. Approximately 98% of non-neonatal ocular infection is caused by HSV-1 (Neumann-Haefelin et al., 1978) while 70-80% of neonatal ocular infection is from HSV-2 (Nahmias et al., 1970).

HSV ocular disease occurs as primary or recurrent infections. The most common manifestations of primary ocular disease are the infection of the eyelids and conjunctivi which are characterised by vesicle formation on the lid and acute follicular conjunctivitis respectively. Epithelial keratitis (involvement of the cornea) in the primary HSV infection, which is a self limiting disease,
usually follows the onset of follicular conjunctivitis resulting in keratoconjunctivitis (Grayson, 1983). In neonates, HSV ocular manifestations include keratoconjunctivitis and retinitis. Unilateral or bilateral cataracts associated with HSV neonatal infection is thought to develop secondary to uveitis or from direct viral invasion of the lens (Gibis and Burde, 1971).

The clinical manifestations of recurrent HSV ocular disease include blepharitis, conjunctivitis and keratitis. The latter differs from that in primary HSV ocular infection in that keratitis extends to the stroma and endothelium resulting in permanent visual loss (Verdier and Krachmer, 1984).

Using animal model systems, such as rabbits, mice and guinea pigs for experimental HSV ocular infection, has provided valuable information on the pathogenesis of the disease (Nesburn et al., 1967; Hill et al., 1975; Wander et al., 1987).
Cells

Baby hamster kidney clone 13 (BHK-21 C13) cells (Macpherson and Stoker, 1962) and BALB/c mouse embryo fibroblast (3T3) cells (Flow Laboratories) were used.

Viruses

Herpes simplex virus type 2 (HSV-2) strain HG52 (Timbury, 1971) and plaque purified stocks of HG52 (Taha et al., 1988) were used throughout this study. The HSV-2 (HG52) deletion variants used were JH2603, JH2604, JH2605, JH2606, JH2607, JH2608, JH2609, JH2610 and JH2611 (Harland and Brown, 1988), characterised (Harland and Brown, 1985) under their previous designation of HG52XD86, HG52XD192, HG52XD85/5, HG52XD85/4, HG52X163X12, HG52X163X14, HG52X163X21, HG52X163X3 and HG52X163X3X53 respectively. Herpes simplex virus type 1 (HSV-1) Glasgow strain 17 syn+ (Brown et al., 1973) and the HSV-2 thymidine kinase negative mutant (TK^{-7}), obtained from D. Dargan, were also used.

Tissue culture media

BHK-21 C13 cells were cultured in Eagle's medium (Gibco Biocult.) containing twice the normal concentration of vitamins and amino acids, 100 units/ml penicillin, 100 μg/ml streptomycin, 5% (v/v) tryptose phosphate broth and 10% (v/v) calf serum (ETC10). 3T3 cells were grown in Dulbecco's Modified Eagle's medium (Flow Laboratories) containing 10% (v/v) newborn bovine serum and 2mM L-glutamine (DMEM10). Other media used during this study were;
Emet/5C2  Eagle's medium containing 20% the normal concentration of methionine plus 2% calf serum
PIC  phosphate free Eagle's medium containing 1% calf serum
EHu5  Eagle's medium containing 5% human serum
EMC5  Eagle's medium containing 1.5% methyl cellulose and 5% calf serum

**Agar and bacterial growth media**

- **2X YT broth**: 85mM NaCl, 1% (v/v) Difco bactotryptone, 1% yeast extract
- **L-broth**: 170mM NaCl, 1% (v/v) Difco bactotryptone, 0.5% (w/v) yeast extract
- **L-broth agar**: L-broth containing 1.5% (w/v) agar
- **Top agar**: 1% (w/v) agar in water

**Plasmids**

Plasmid pAT153 (Twigg and Sherratt, 1980) was used as the cloning vector and the pGZ1 plasmid containing the HG52 BamHI g fragment (0.81-0.85 m.u.) was supplied by A. Davison.

**Sera**

Normal goat serum and biotinylated anti-rabbit IgG were supplied by Vector Laboratories (USA). Polyvalent rabbit antiserum to HSV was supplied by Dako Ltd.

**Experimental animals**

Three week old BALB/c mice, both sexes, (Bantin and Kingman) were used in this study.
Stains
Giemsa stain

1.5% (w/v) suspension of Giemsa in glycerol, heated at 56°C for 120 min and diluted with an equal volume of methanol.

Eosin

0.5% solution of eosin Y in distilled water.

Haematoxylin

1g haematoxylin, 50g potassium alum, 0.2g sodium iodate, 1g citric acid and 50g chloral hydrate dissolved in 1000ml water with gentle heat.

Enzymes

Restriction endonucleases were obtained from Bethesda Research Laboratories (BRL). E. coli polymerase I (Klenow), T4 DNA ligase, calf intestinal phosphatase (CIP) were supplied by Boehringer Corporation Limited. Protein kinase and lysozyme were purchased from Sigma Chemicals Company.

Radiochemicals

All radiochemicals were obtained from Amersham International plc at indicated specific activity;

[α-32P] dNTP’S 3000 Ci/mmol
35S-methionine 800 Ci/mmol
32P-orthophosphate 200 mCi/mmol
[Me-3H] thymidine 60 mCi/mmol

Solutions and buffers
Phosphate buffered saline-A (PBS-A)

170 mM NaCl, 3.4 mM KCl, 1 mM Na$_2$HPO$_4$, 2 mM KH$_2$PO$_4$, pH 7.2.

Phosphate buffered saline (PBS)

PBS-A supplemented with 6.8 mM CaCl$_2$ and 4.9 mM MgCl$_2$.

PBS/calf serum

PBS containing 5% calf serum.

Tris-saline

140 mM NaCl, 30 mM KCl, 280 mM Na$_2$HPO$_4$, 1 mg/ml glucose, 0.0015% (w/v) phenol red, 25 mM Tris-HCl (pH 7.4), 100 units/ml penicillin, 100 ug/ml streptomycin.

10% Formal buffered saline

A stock solution of 40% formaldehyde to which 9% NaCl has been added. The working solution (10%) consists of one part of stock to nine parts water kept over marble chips for buffering.

Trypsin

0.25% (w/v) Difco trypsin dissolved in Tris-saline.

Versene

0.6 mM EDTA dissolved in PBS containing 0.002% (w/v) phenol red.

Trypsin-Versene

One volume of 0.25% trypsin plus four volumes versene.

Saturated phenol
Phenol was saturated by mixing 2:1 with phenol saturation buffer (10mM Tris-HCl pH 7.5, 10mM EDTA, 100mM NaCl).

**Phenol : chloroform (1 : 1)**

This is a 1 : 1 mixture of phenol and chloroform.

**Chloroform : isoamyl alcohol (24 : 1)**

This is a 24 : 1 mixture of chloroform and isoamyl alcohol.

**TBE**

89mM Tris base, 89mM Boric acid, 2mM EDTA pH 8.3.

**TE**

10mM Tris-HCl, 0.1mM EDTA pH 8.0.

**Restriction enzyme buffers**

The buffers used were as recommended by BRL or Maniatis (1982).

**Chemicals**

M13 single strand primer, unlabelled nucleotides, 2', 3' dideoxyribonucleoside triphosphates were supplied by Pharmacia Ltd. Wacker silicone was provided by Wacker-Chemical Company, Munich. Repelcote (2% solution of dimethyldichlorosilane in 1, 1, 1,- trichloroethane) was supplied by Hopkin and Williams, England. Avidin biotinylated horseradish peroxidase complex (ABC) was obtained from Vector Laboratories USA. DNA blotting membrane (HybondN) was purchased from Amersham International.
Other chemicals were supplied by BDH Chemicals UK or Sigma Chemicals Company and were of analytical grade.
2.1 Growth of cells

BHK-21 C13 cells were grown in 80 oz roller bottles containing 100ml ETC10 at 37°C in an atmosphere of 5% CO₂ in air. Confluent cells were harvested by washing twice with versene and once with trypsin-versene and resuspended in 20ml ETC10. The cells from one roller bottle (3x10⁸) are enough to seed 10 bottles (2x10⁶). 3T3 cells were grown in a similar way using DMEM10 and were split 1 in 3.

2.2 Cell storage

Cells were harvested as described in section 2-1, pelleted and resuspended in ETC10 (for BHK-21 C13 cells) or DMEM10 (for 3T3 cells) containing 10% (v/v) DMSO. Cells were aliquoted into black cap vials at a concentration of 10⁷/ml and frozen slowly to -140°C. Cells were recovered by thawing quickly and resuspended in ETC10 or DMEM10.

2.3 Growth of virus stocks

Virus stocks were propagated in BHK-21 C13 cells grown in 80 oz roller bottles. The growth medium was removed and the cells were infected at a multiplicity of infection (moi) of 0.003 plaque forming units (pfu) per cell, in 20ml ETC5. After 3-4 days incubation at 31°C, when extensive cytopathic effect (cpe) had developed, the cells were shaken into the medium and pelleted at 2000 rpm for 10 min at 4°C in a Fison's Coolspin centrifuge. The pellet was resuspended in 5ml of supernatant medium, sonicated in a bath sonicator (50W at 4°C) and centrifuged as before. The cell debris pellet was discarded and the supernatant was the cell
associated virus stock. The original supernatant from the 2000 rpm spin was centrifuged at 12000 rpm for 2 h at 4°C in a Sorval GSA rotor and the pellet resuspended in 5ml of the supernatant was sonicated. This was termed supernatant virus. Virus stocks were aliquoted in 1ml volumes and stored at -70°C. Stocks were checked for sterility and titrated at 37°C or 31°C.

2.4 Sterility checks on virus and cell stocks

Cell or virus stocks were checked for bacterial contamination by streaking on blood agar plates in duplicate and incubating at 37°C and 31°C for 5 days. The cell and virus stocks were considered sterile if no contamination was detected on the plates.

2.5 Titration of virus stocks

Serial ten-fold dilutions of virus stocks were made in PBS/calf serum and 0.1ml of each dilution was added to 80% confluent BHK-21 C13 cells in 50mm petri-dishes from which the growth medium had been removed. After absorption at 37°C for 1 h, monolayers were overlaid with 4ml of EHu5 or EMC5 and incubated at 37°C for 2 days or 31°C for 3 days. Monolayers were fixed and stained with Giemsa at room temperature (RT) for 30 min and plaques were counted using a dissecting microscope.

2.6 Preparation of virion DNA (HSV)

Virion DNA was prepared as described by Wilkie (1973) and Stow and Wilkie (1976). Virus infected BHK-21 C13 cells in 80 oz roller bottles (section 2.3) were harvested after exhibiting extensive cpe and pelleted at 2000 rpm for 10 min
in a Fison's Coolspin centrifuge. The supernatant was kept on ice and the cell pellet resuspended in RSB (10mM KCl, 1.5mM MgCl₂, 10mM Tris-HCl pH 7.5) containing 0.5% (v/v) Nonidet P40 (NP40), was incubated on ice for 10 min and centrifuged at 2000 rpm for 3 min to remove the nuclei and cell debris. The pellet from this step was resuspended in RSB/NP40 and treated as above. The two cytoplasmic supernatants were pooled with the clarified virus infected cells medium and centrifuged at 12000 rpm in a Sorval GSA rotor for 2 h at 4°C. The virus pellet was resuspended by sonication in 8ml of NTE (10mM Tris-HCl pH 7.5, 10mM NaCl, 1mM EDTA) and lysed by addition of SDS and EDTA to a final concentration of 2% (w/v) and 10mM respectively. Virus DNA was gently extracted twice with an equal volume of saturated phenol and once with chloroform : isoamyl alcohol (24 : 1 v/v) and precipitated by the addition of two volumes of ethanol. The DNA was pelleted at 2000 rpm for 10 min, dried in a vacuum desiccator and redissolved in water containing 50 ug/ml RNase A. The DNA was quantitated by agarose gel electrophoresis using a standard DNA of known concentration.

2.7 Virus particle counts

An aliquot of a virus stock was mixed with an equal volume of latex beads and the same volume of phosphotungstic acid. A sample was spotted on a parlodium grid, air dried and visualised under the electron microscope. The number of virus particles and latex beads was counted and the concentration of particles in the virus stock calculated.

2.8 Purification of single plaque isolates

Virus stocks were titrated as described (section 2.5)
and cell monolayers with the fewest plaques (5-10 plaques) were washed twice with PBS/calf serum. Individual separated plaques were picked into 500ul PBS/calf serum, sonicated and stored at -70°C. To grow a plate stock, a BHK-21 C13 monolayer was infected with 100ul of the plaque solution and incubated at 37°C until the cpe was complete. The monolayer was harvested using rubber policemen, sonicated and stored at -70°C. Individual plaques were purified an additional three times prior to further analysis. To passage the plaque stocks, BHK-21 C13 monolayers in 50mm petri-dishes were inoculated at low moi and incubated at 37°C. Cells were harvested, sonicated and released virus stored at -70°C.

2.9 Virus growth properties in vitro

One step growth experiments were carried out as described by Brown and Harland (1987). Confluent 3T3 or BHK-21 C13 cells in 35mm petri-dishes were infected at a moi of 5 pfu/cell and incubated at 37°C or 38.5°C for 1 h. Cells were washed twice with PBS/calf serum, overlaid with 2ml of ETC5 and incubated at 37°C or 38.5°C. Samples were harvested at 0, 2, 4, 6, 8, 12, and 24 h post infection, sonicated and virus yields titrated on BHK-21 C13 cells at 37°C.

In multi-step growth experiments, cells were infected at a moi of 0.002 pfu/cell. At 0, 24, 48, 72, and 96 h post infection, cells were harvested, sonicated and titrated as before. Twenty four hour yield experiments were carried out by infecting cells at a moi of 5 pfu/cell. Cells were harvested after 24 h and virus titrated as above.
2.10 Virus growth properties in vivo

Virus growth experiments in vivo were carried out essentially as described by Thompson et al. (1983). Virus stocks (10^5 pfu/mouse) were inoculated into the left cerebral hemisphere of 3 week old BALB/c mice of both sexes (section 2.11). At 0, 12, 24, 48, 72, 96, 120, and 144 h post infection, two surviving mice from each time point were sacrificed and their brains were removed aseptically and homogenised in 1ml PBS/calf serum using a Dounce homogeniser (Quick Fit, England). 0.2ml of the resulting suspension was titrated for infectious virus on BHK-21 C13 cells at 37°C as described (section 2.5).

2.11 Animal inoculation

Three week old BALB/c mice of both sexes were used. Mice were anaesthetised with ether and 0.025ml of the appropriate virus dilution in PBS/calf was inoculated into the central region of the left cerebral hemisphere. Groups of four to eight mice were inoculated with a single dilution of each virus stock (between 10^2-10^7 pfu/animal). The virus stocks were always retitrated on BHK-21 C13 cells on the day of inoculation to determine the precise quantity of virus inoculated. Mice were observed daily for 21 days after inoculation and their clinical states recorded. The 50% lethal dose value (LD_{50}) was calculated according to the formula of Reed and Muench (1938) on the basis of deaths between day 3 and 21. Using the intraperitoneal or footpad routes, mice were inoculated with 0.1ml of appropriate virus dilutions and the LD_{50} calculated as before.

2.12 Preparation and isolation of ^32P-labelled virus DNA
This method is a modification of that described by Lonsdale (1979). BHK-21 C13 cells, in linbro wells in PIC medium, were infected at a moi of 10 pfu/cell. After 1 h absorption at 37°C, the virus was removed and the cells washed with and maintained in PIC for 2 h at 31°C. Fifty uCi of 32P-orthophosphate was added per well and incubation continued for a further 48 h at 31°C. Cells were lysed by addition of SDS at a final concentration of 2.5% (v/v) and incubated at 37°C for 10 min. DNA was extracted once with an equal volume of saturated phenol and precipitated with two volumes of ethanol. The DNA was dried at 37°C for 10 min and redissolved in 200ul water. 20ul was digested with appropriate restriction enzymes and run on agarose gels (0.5%-1.2%) for 24 h at 40V. Gels were air dried and autoradiographed using Kodak XS-1 film.

2.13 Thymidine kinase assay

The method used was a modification of that of Jamieson and Subak-Sharpe (1974). BHK-21 C13 cells in 35mm petri-dishes were infected at a moi of 20 pfu/cell. After absorption for 1 h at 37°C, cells were overlaid with 2ml of ETC5 and incubated for 6 h at 37°C. Cells were washed twice with cold PBS, scraped into 1ml cold PBS and pelleted in a microfuge for 2 min. The pellet was resuspended in 150ul ice cold lysis buffer (20mM Tris-HCl pH 7.5, 2mM MgCl₂, 10mM NaCl, 0.5% (v/v) NP40, 6.5mM 2-mercaptoethanol), maintained on ice for 5 min, mixed briefly and placed on ice for a further 5 min. The samples were centrifuged and the supernatant retained and stored at -70°C. 5ul of extract was mixed with the reaction buffer in a total volume of 50ul (0.5M Na₂PO₄ pH 6.0, 100mM MgCl₂, 2mM dTTP, 100mM ATP, 5ul
aqueous [Me-$^3$H] thymidine 1 mCi/ml). After incubation for 1 h at 30°C, the reaction was stopped by the addition of EDTA and thymidine at a final concentration of 20mM and 1mM respectively. The samples were heated for 3 min at 100°C and placed on ice for 3 min. After centrifugation, 40ul of the supernatant was spotted onto DE81 discs and washed three times (10 min each at 37°C) with 4mM ammonium formate pH 6.0 and 10uM thymidine. After a further two washes with ethanol, the discs were dried and radioactivity due to [3H] thymidine was determined using a scintillation counter.

2.14 Preparation and analysis of HSV infected cell polypeptides

The method was essentially that described by Marsden et al. (1976). Confluent BHK-21 C13 cells in 35mm petri-dishes were infected at a moi of 20 pfu/cell. After absorption for 1 h at 37°C, the monolayers were washed twice with Eagle's medium containing 20% the normal concentration of methionine and 2% calf serum (Emet/5C2) and the same medium was used to overlay the monolayers. After 4 h incubation at 37°C, 100 uCi/plate of $^{35}$S-methionine was added and incubation continued at 37°C for 24 h. Samples were washed twice with PBS, harvested into 500ul sample buffer (150mM Tris-HCl pH 6.7, 6.28% (w/v) SDS, 0.15% (v/v) 2-mercaptoethanol, 0.31% (v/v) glycerol, 0.1% (w/v) bromophenol blue) and after boiling for 5-10 min, were analysed by SDS-PAGE (described in section 2.15).

2.15 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)

Two glass plates separated by a 1.5mm thickness perspex
spacer, were cast vertically and sealed with teflon tape. Two types of resolving gels were used (i) single concentration gels containing the appropriate amount of acrylamide cross-linked with 2.5% (w/w) N, N'-methylene bisacrylamide in resolving gel buffer (375mM Tris-HCl pH 8.9, 0.1% (w/v) SDS) and (ii) gradient gels containing 5%-12.5% gradient acrylamide cross-linked with 5% (w/w) N, N'-methylene bisacrylamide in resolving gel buffer. Ammonium persulphate (APS) and N, N, N', N'-tetramethylethylene-diamine (TEMED) were added to a final concentration of 0.006% (w/v) and 0.004% (v/v) respectively prior to pouring. After polymerisation, gels were overlaid with butan-2-ol to get a smooth top surface which was then washed off with deionized water. The stacking gels contained 5% acrylamide (cross-linked with the same ratio of N, N'-methylene bisacrylamide used in resolving gel) in stacking gel buffer (0.11mM Tris-HCl pH 6.7, 0.1% (w/v) SDS). APS and TEMED were added to the stacking gel solutions as above and a teflon coated comb was inserted prior to pouring. Samples were boiled for 5-10 min in sample buffer, loaded and electrophoresed in tank buffer (52mM Tris, 53mM glycine, 0.1% (w/v) SDS) at 60mA for 3-4 h (Marsden et al., 1976, 1978). Gels were fixed, stained for 1 h by shaking in methanol : water : acetic acid 50 : 43 : 7 in the presence of 0.2% (w/v) Coomassie Brilliant Blue R250. Gels were destained for 1-2 h in methanol : water : acetic acid 5 : 88 : 7, dried under vacuum and exposed for autoradiography at RT.

2.16 Agarose gel electrophoresis

Agarose gels (0.5%-1.2%) were prepared in 250ml 1X TBE
buffer (89mM Tris, 89mM boric acid, 2mM EDTA). The solutions were poured onto glass plates (125cm x 85cm) in which (12-15) tooth combs were placed. After setting, gels were transferred to horizontal tanks containing 1X TBE. In the case of non-radioactive samples, TBE contained 5 ug/ml ethidium bromide. Gels were elecrophoresed at 50V overnight.

2.17 Restriction enzyme digestion

Viral DNA was digested with appropriate restriction enzymes (2-5 units/ug DNA), in the presence of 1X recommended buffer, in a final volume of 40ul and incubated at 37°C for 2-16 h. The reaction was stopped by the addition of 20% restriction enzyme stop solution (RE stop) (5X TBE, 100mM EDTA, 10% (w/v) Ficoll, 0.1% (w/v) bromophenol blue) prior to electrophoresis (Maniatis et al., 1982).

2.18 Elution of DNA fragments from agarose gels

The DNA was digested with appropriate restriction enzymes and elecrophoresed on agarose gels in the presence of 5 ug/ml ethidium bromide. The gel was visualised under long wave UV light and the appropriate fragment cut out using a sharp scalpel. The isolated gel slice was placed in an electrophoresis chamber containing 0.1X TBE. The DNA was electroeluted from the agarose gel onto the dialysis membrane of the electrophoresis chamber (preboiled in 0.1X TBE for 10 min) at 200V for 1 h. The DNA was collected, extracted with phenol : chloroform (1 : 1) and precipitated at -20°C with one volume isopropyl alcohol and 0.1 volume sodium acetate. DNA was washed with 70% ethanol, dried in a
vacuum desiccator and redissolved in water.

2.19 Transfection of viral DNA by calcium phosphate precipitation

Transfection was performed as described by Stow and Wilkie (1976). Calcium chloride (final concentration 130 mM) was added to a solution containing 0.2-μg DNA and 10 μg/ml calf thymus carrier DNA in HEBS buffer pH 7.05 (130 mM NaCl, 4.9 mM KCl, 1.6 mM Na₂HPO₄, 5.5 mM D-glucose, 21 mM Hepes). The samples were left for 5 min at RT to allow a fine suspension to develop. This suspension was added to drained 80% confluent BHK-21 C13 cells in 50 mm petri-dishes. After incubation at 37°C for 45 min, cells were overlaid with ETC5. At 4 h post infection, cells were treated with 25% (v/v) DMSO in HEBS buffer for 4 min at RT. DMSO was then removed from monolayers by washing the cells twice with ETC5 after which incubation was continued at 37°C for 3-4 days until extensive cpe had developed. The cells were scraped into the medium, disrupted by sonication and stored at -70°C. The transfected plate stocks were titrated and single plaques isolated for further analysis as described before (section 2.8). For correction of the genomic deletion in the variants, wild type fragments spanning the deletion were added to the transfection mixture at a 5, 10, and 20 fold molar excess over the intact deletion variant genomes. When the cpe was complete, cells were harvested as described above. To introduce the deletion into the HG52 wild type genome, the fragments containing the deletion were added at 5, 10, and 20 fold molar excess with the intact wild type genomes.
2.20 Transfection and in vivo selection

The transfection procedure was described in section 2.19 and the method of in vivo selection used was a modification of that described by Thompson et al. (1983). Serial ten fold dilutions of transfected plate stocks were made in PBS/calf serum, and 0.025ml of each dilution was inoculated intracranially into the left cerebral hemisphere of 3 week old BALB/c mice (usually two mice per dilution). Mice were observed daily and those which died from encephalitis were dissected and their brains removed and homogenised in 1ml PBS/calf serum. For virus isolation, 0.2ml of the brain homogenate was inoculated onto BHK-21 C13 cells in 50mm petri-dishes at 37°C. Cells were harvested after extensive cpe had developed and the virus isolates were plaque purified three times (section 2.8) prior to further analysis.

2.21 Glycerol stocks of bacteria

Bacterial stocks were prepared from 10ml standing cultures grown overnight at 37°C in L-broth containing ampicillin (100 ug/ml). The bacterial stocks were pelleted at 5000 rpm for 5 min at 4°C and pellets were resuspended in L-broth containing 50% (v/v) glycerol.

2.22 Construction of recombinant plasmids

Linearised plasmid vector pAT153 (Twigg and Sherratt, 1980) was treated with calf intestinal phosphatase at a concentration of 5 units/ug plasmid DNA. After incubation at 37°C for 1 h, the DNA was extracted twice with phenol : chloroform (1 : 1), once with chloroform and precipitated with two volumes of ethanol in the presence of 0.1 volume 3M
sodium acetate. The DNA pellet was washed with 70% ethanol, dried and resuspended in an appropriate amount of water to give 40 ng/ul. A 3-4 times molar excess of the purified HSV DNA fragment relative to the phosphatase treated vector (40ng) was ligated overnight at 15°C in a 20ul ligation reaction containing 2 units of T4 DNA ligase and 1X ligase buffer (10mM Tris-HCl pH 7.5, 10mM MgCl₂, 10mM DTT, 1mM ATP).

2.23 Transformation of bacterial cells with plasmid DNA

This procedure was based on the method described by Cohen et al. (1972). Host bacterial cells, E. coli strain DH5 (Hanahan, 1985) were grown to an optical density at 630 (OD₆₃₀) of 0.3 and pelleted by centrifugation at 8000 rpm for 10 min at 4°C in a Sorval SS34 rotor. The pellet was resuspended in a half volume of ice cold 50mM CaCl₂ and incubated on ice for 20 min. The cells were repelleted and resuspended in a tenth volume of ice cold 50mM CaCl₂. Plasmid DNA (20-100ng) was incubated with CaCl₂ shocked cells on ice for 1 h. The cells were heat shocked at 42°C for 2 min and transferred to 1ml L-broth grown with shaking at 37°C in an orbital shaker for 1 h. 100ul of each sample were spread on L-broth agar plates containing 100 ug/ml ampicillin and incubated overnight at 37°C. Single bacterial colonies were picked from the plates and analysed (section 2.24).

2.24 Small scale isolation of plasmid DNA

Bacteria from a single colony were grown overnight in an orbital shaker at 37°C in 1.5ml L-broth containing 100 ug/ml ampicillin. The cells were pelleted at 10000 rpm for 2 h in
a microfuge and resuspended in 350ul STET buffer (8% (w/v) sucrose, 0.5% Triton X-100, 50mM EDTA pH 8.0, 10mM Tris-HCl pH 8.0) and 25ul of lysozyme (10 mg/ml) was added (Holmes and Quigley, 1981). This mixture was boiled for 1 min and centrifuged at 10000 rpm for 10 min. The supernatant containing the plasmid DNA was precipitated with an equal volume of isopropyl alcohol and 0.1 volume of 3M sodium acetate on ice for 15 min and subsequently pelleted at 10000 rpm for 5 min. The DNA pellet was washed with 70% ethanol, dried in a vacuum desiccator and redissolved in water containing 10 ug/ml RNase A.

2.25 Large scale isolation of plasmid DNA

The method is basically that described by Birnboim and Doly (1979) as modified by Maniatis et al. (1982). Single bacterial colonies from L-broth agar plates or 25ul from bacterial glycerol stocks were inoculated into 10ml L-broth containing 100 ug/ml ampicillin and incubated at 37°C overnight in an orbital shaker. 2ml of the overnight culture was inoculated into 350ml L-broth and shaken overnight at 37°C. The bacteria were pelleted at 5000 rpm for 15 min at 4°C in a Sorval GSA rotor. The culture pellet was resuspended in 6ml of freshly prepared (25mM Tris-HCl pH 8.0, 10mM EDTA, 15% (w/v) sucrose, 2 mg/ml lysozyme) and incubated on ice for 20 min. 12ml of freshly made 0.2M NaOH, 1% SDS (w/v) was added and incubation continued on ice for 10 min. Ice cold 3M sodium acetate pH 4.6 was added and incubation continued on ice for 20 min. The cell debris was pelleted at 15000 rpm for 15 min in a Sorval SS34 rotor at 4°C and RNase A was added to the supernatant at a final concentration of 50 ug/ml. After
incubation at 37°C for 20 min, DNA was extracted twice with an equal volume of phenol : chloroform (1 : 1 v/v), once with an equal volume of chloroform and precipitated by the addition of 2 volumes of ethanol overnight at -20°C. The DNA pellet was washed with 70% ethanol, dried in a vacuum desiccator and resuspended in water. The DNA was quantitated by comparing to a known standard.

2.26 Transfer of DNA fragments to nitrocellulose

The procedure followed was that of Southern (1975). The agarose gel containing the separated DNA fragments was placed in gel soak I (200mM NaOH, 600mM NaCl) for 1 h to denature the DNA and neutralised in gel soak II (1M Tris-HCl pH 8.0, 0.59M NaCl) for 1 h. The gel was then transferred onto sheets of Whatman 3mm filter paper presoaked in 10X SSC (1X SSC is 15mM trisodium citrate, 150mM NaCl). A sheet of Hybond blotting membrane, cut to the exact size of the gel, was placed on top of the gel followed by a similar sized sheet of Whatman 3mm filter paper wetted with blotting buffer. A stack of absorbant paper towels was placed onto the Whatman filter paper and finally a weight was placed on top. After 12-24 h, the Hybond blotting membrane was air dried and UV cross-linked for 2-5 min at a wave length of 312nm (the DNA side down on a transilluminator).

2.27 Hybridisation procedure

The Hybond blotting membrane was prehybridised at 75°C for a minimum of 2 h in a sealed plastic bag containing hybridisation buffer [6X SSC, 6X Denhardt’s buffer(1X Denhardt’s is 0.02% polyvinyl-pyrrolidone, 0.02% Ficoll), 0.1 mg/ml salmon sperm DNA, 10mM Tris-HCl pH 7.5]. The
solution was replaced by fresh hybridisation buffer containing nick translated $^{32}$P-labelled DNA (see section 2.28) and hybridisation was allowed to proceed for 48 h at 75°C. The Hybond blotting membrane was removed and washed 3 times, each for 45 min, at 60°C in washing buffer (2X SSC, 0.1% (w/v) SDS, 5mM Na$_2$HPO$_4$ pH 7.0). The membrane was air dried and placed in contact with Kodak XS-1 film at RT.

2.28 In vitro $^{32}$P-labelling of DNA by nick translation

The method was as described by Rigby et al. (1977). DNA (0.5µg) to be used as a probe was labelled in a reaction containing 2 units of DNA polymerase I, 50mM Tris-HCl pH 7.8, 5mM MgCl$_2$, 10mM dTT, $10^{-4}$ mg/ml DNase, 10 µg/ml BSA, 2uCi [$\alpha-^{32}$P] dCTP, 2uCi [$\alpha-^{32}$P] dGTP, 0.2mM dATP and 0.2mM dTTP in a final volume of 30ul. Nick translation was carried out at 15°C for 2 h. The DNA was precipitated on dry ice for 15 min with 0.6 volume of isopropyl alcohol and 0.1 volume of 3M sodium acetate. The DNA pellet was resuspended in 30ul water and reprecipitated with isopropyl alcohol and sodium acetate. The resultant pellet was redissolved in 10ul water and 80% formamide and denatured by boiling at 100°C for 5 min.

2.29 Construction of recombinant M13

The double stranded replicative form (RE) of bacteriophage M13 mp18 and mp19 (Norrander et al., 1983) was prepared as for plasmids (section 2.25). The fragments were prepared for insertion into M13 by digestion of pAT153 containing the inserts with HincII-XhoI. The fragments were eluted from the gel as described (section 2.18). The vector was linearised with SmaI-SalI and 40ng was incubated with a
120-160ng of the DNA insert with 2 units of T4 DNA ligase in ligase buffer (see section 2.22) for 24 h at 15°C (Sanger et al., 1980).

2.30 Transfection of bacterial cells with M13

E. coli strain JM101 (Messing, 1979) were grown in 2X YT broth to an OD$_{630}$ of 0.3 and calcium shocked as described (section 2.23). The ligation mixture was added to 0.2ml aliquots of the calcium shocked cells and incubated on ice for 1 h. The sample was heated to 42°C for 5 min and 0.2ml of an overnight standing culture of E. coli strain JM101 was added. 3ml of melted top agar at 42°C containing 20ul of 2.5% isopropyl-D-thiogalactoside (IPTG) and 25ul of 2% 5-chloro-4-bromo-3-indolyl-β-D-galactoside (BCIG) in dimethyl formamide was added to the sample and the mixture poured onto 90mm L-broth agar plates and incubated at 37°C overnight.

2.31 Growth and extraction of recombinant M13 clones

An overnight standing culture of E. coli strain JM101 was used to inoculate 2X YT broth (1:100). This was dispensed in 1.5ml aliquots into 25ml universal bottles. The recombinant M13 clones (colourless) plaques were tooth picked from the plates into the broth and incubated at 37°C for 5-6 h with shaking. The solution was then transferred to an eppendorf tube and centrifuged at 10000 rpm for 5 min in a microfuge to pellet the bacteria. The supernatant (0.8ml) was transferred to another eppendorf tube and the phage was precipitated by addition of 200ul of 20% polyethylene glycol (PEG Mr 6000) in 2.5M NaCl for 30 min at RT. After centrifugation at 10000 rpm for 5 min, the
supernatant was removed. Following a brief centrifugation, any remaining supernatant was removed with a glass capillary tube. The phage pellet was resuspended in 100ul TE and extracted with 50ul phenol equilibrated with TE and precipitated by the addition of 2 volumes of ethanol and 0.1 volume 3M sodium acetate. The phage DNA was pelleted by centrifugation at 10000 rpm for 5 min, washed with 70% ethanol, dried thoroughly in a vacuum desiccator, redissolved in 50ul TE and stored at -70°C (Sanger et al., 1980).

2.32 Sequence analysis of recombinant M13 clones

Sequence analysis was carried out using the dideoxynucleotide chain termination method of Sanger et al. (1977). The single stranded DNA template (2ul) was annealed to 2.5ng of M13 single stranded primer in the presence of annealing buffer (10mM Tris-HCl pH 8.5, 10mM MgCl$_2$) in a volume of 10ul at 37°C for 30 min. To the annealed DNA, 2 units of Klenow DNA polymerase I was added and the mixture aliquoted in 2ul fractions into four wells of a U-bottomed microtiter plate corresponding to the specific T, C, G and A reactions of each clone. An equal volume of the nucleotide mixture containing dNTP’s and specific ddNTP’s (see Table 2.1), 1ul of 11.8uM dATP, 0.3uCi [³²P] dATP was added to each well and the reaction allowed to proceed for 15 min at RT. The reaction was chased by the addition of 2ul chase solution (0.5mM uniform mixture of all four dNTP’s) and incubation was continued for 30 min at RT. The reaction was stopped by the addition of 2ul formyl dye mixture (0.1% bromophenol blue (w/v), 0.1% xylene cyanol (w/v) in deionised formamide). The plate was heated for 1 min at
Table 2.1. Nucleotide concentration in DNA sequencing reaction

<table>
<thead>
<tr>
<th>Sequencing solutions</th>
<th>dG-0</th>
<th>dA-0</th>
<th>dT-0</th>
<th>dC-0</th>
</tr>
</thead>
<tbody>
<tr>
<td>dNTP's concentration</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(5 mM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dTTP</td>
<td>20</td>
<td>1</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>dCTP</td>
<td>20</td>
<td>20</td>
<td>1</td>
<td>20</td>
</tr>
<tr>
<td>7-deaza dGTP</td>
<td>20</td>
<td>20</td>
<td>20</td>
<td>1</td>
</tr>
<tr>
<td>10X TE</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>H₂O</td>
<td>540</td>
<td>370</td>
<td>370</td>
<td>370</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sequencing mix</th>
<th>dN-O mix</th>
<th>ddNTP's</th>
<th>H₂O</th>
</tr>
</thead>
<tbody>
<tr>
<td>T-sequence</td>
<td>250</td>
<td>250 (600uM ddTTP)</td>
<td>0</td>
</tr>
<tr>
<td>C-sequence</td>
<td>250</td>
<td>57.5 (140uM ddCTP)</td>
<td>197.5</td>
</tr>
<tr>
<td>G-sequence</td>
<td>250</td>
<td>77.5 (200uM ddGTP)</td>
<td>172.5</td>
</tr>
<tr>
<td>A-sequence</td>
<td>250</td>
<td>62.5 (140uM ddATP)</td>
<td>187.5</td>
</tr>
</tbody>
</table>
100°C and electrophoresis was carried out through polyacrylamide gels.

2.33 Electrophoresis and autoradiography of sequencing gels

Vertical plates 40 x 20 x 0.03cm in size were used and spacer, gel combs were cut from plasticard. The notched plate was treated with repelcote. The plain plate was treated with 0.5% (v/v) Wacker silicone in 0.3% (v/v) acetic acid and ethanol (Garoff and Ansorge, 1981), which bonds the acrylamide to the plate. Generally, electrophoresis was carried out through 6% acrylamide gels. In this system the top mix used was 0.5X TBE, 6% acrylamide (electran grade), 9M urea (McGeoch et al., 1986). APS and TEMED were added to the top mix to a final concentration of 0.016% (w/v) and 0.16% (w/v) respectively, the contents were poured, the gel comb was inserted and the gel rested in a nearly horizontal position until polymerisation was complete. The tape was removed from the bottom of the gel and the plates set with 0.5X TBE in both the top and bottom tank of the gel kit. Before loading the DNA samples, gel wells were flushed with 0.5X TBE and the gel was run at a constant power of 40W for 2 h. After electrophoresis, the plates were dismantled and the gel, bonded to the plain plate, immersed in a 10% acetic acid bath for 30 min to fix the DNA and remove the urea from the gel. The gel was dried down on the plate in an oven at 125°C for 1-2 h and exposed against Kodak XS-1 film at RT.

2.34 Accumulation and handling of the sequence data

DNA sequence data was handled and interpreted using the Institute of Virology's VAX/VMS computer running the GCG software (Devereux et al., 1984). The gel readings were
read and typed into the account using the EDIT programme which stores data from gel readings under a chosen file name. The data was converted into GCG sequences using the FROMSTADEN programme. The gel readings were compared against each other using the programme BESTFIT to determine overlapping. The gel readings were aligned and compared against known sequences currently held using the BESTFIT and GAP programmes.

2.35 Tissue preparation for histopathology

Infected brains from dissected mice were removed and fixed in 10% formal buffered saline. The brain tissues were cut into blocks, dehydrated in a graded series of ethanol (50%, 70%, 90% and 100%) and embedded in paraffin wax. Several sections (6-7 microns thick) from each block were cut, mounted, baked for 24 h at 37°C followed by 30-60 min at 60°C and stained with either haematoxylin and eosin (H & E) or by immunoperoxidase staining.

2.36 Immunohistochemistry

The method used was essentially that described by Kennedy et al. (1985). Paraffin embedded sections were deparaffinised and dehydrated through xylene (two times, 30 min each) and graded ethanol series (50%, 70%, 90% and 100%, 5 min each) respectively. Sections were washed for 10 min in PBS and incubated for 30 min with 0.3% hydrogen peroxide in methanol to stop the endogenous peroxidase activity. Following washing twice with PBS (10 min each), sections were incubated with blocking serum (3% normal goat serum in PBS) for 30 min. The excess of blocking serum was washed off and sections were incubated for 30 min with primary
antibody (polyvalent rabbit antiserum to HSV) diluted 1:100 in PBS. Sections were washed twice with PBS and incubated with secondary antibody (biotinylated anti-rabbit IgG) diluted 1:100 in PBS for 30 min. After washing twice with PBS, sections were incubated with avidin biotinylated horseradish peroxidase complex (ABC) for 30 min.

Visualisation of the reaction was carried out using 3, 3'-diaminobenzidine tetrahydrochloride (0.5 mg/ml in PBS) containing 0.03% hydrogen peroxide for 5 min until the colour developed. Sections were washed with tap water, counterstained in haematoxylin for 30-60 seconds, dehydrated as before, mounted and examined under the light microscope.
CHAPTER 3
3.1 Virulence variation within the elite laboratory stock of HSV-2 strain HG52

3.1.1 Introduction

HSV is a neurotropic virus that spreads centripetally in the nervous system from the primary site of infection (Cook and Stevens, 1973). In humans, invasion of the nervous system frequently leads to a latent infection in sensory ganglia, and in rare instances fatal encephalitis (Baringer and Swoveland, 1973; Fenner et al., 1974; Johnson, 1982). The virus-host interaction is highly complex and influenced by the genotype of both virus and host. As direct study of HSV virulence in humans under experimental conditions is impossible, various animal model systems have been used. Previous work with animals has shown that most HSV strains, following different routes of inoculation, have the capacity to cause encephalitis and ultimately death. However, some isolates fail to kill the animals (Richards et al., 1981; Dix et al., 1983; Sedarati and Stevens, 1987). Heterogeneity of individual virus strains in functions required for replication of virus at the periphery and/or for spread to the central nervous system may be the cause of such differences. These functions might influence the pathogenesis of HSV at a variety of points; replication at the peripheral site, neural entry, spread within the nervous system and escape from immunological control. Though the intracranial route of inoculation may be criticised for being artificial, it has the clear advantage of bypassing many of the steps identified above as possibly subject to variation.
HSV-2 strains are normally more virulent than those of HSV-1 when inoculated intragenitally, intraperitoneally or intracranially into experimental animals (Plummer et al., 1968; McKendall, 1980; Richards et al., 1981; Scriba and Tatzber, 1981). However the HSV-2 strain HG52 is less virulent than several other HSV-2 strains (Thompson and Stevens, 1983a). It has been shown that the elite stock of HG52 contains variants with detectable deletions in the genome at a frequency of 24% (Harland and Brown, 1985). It should be emphasised that HSV-2 strain HG52 is not unique in this respect, genomic variation having also been observed in other laboratory strains e.g HSV-2 strain 168 (Esparaza et al., 1974; J. Harland, personal communication).

3.1.2 Isolation of single plaque stocks

In order to determine the basis for variation in neurovirulence we have evaluated the neurovirulence of single plaque stocks picked from HG52. The elite stock of HG52 was derived from an initial single plaque from a patient isolate which was plaque purified three times before being inoculated into a 20 oz bottle and finally two rounds of growth in 20 burrlers - all in BHK-21 C13 cells (Timbury, 1971). This elite laboratory stock of HSV-2 strain HG52 was plated out on BHK-21 C13 cells and twenty well separated plaques were picked at random from plates containing no more than 20 plaques. The virus had been grown in the presence of 5% human serum to neutralise released virus and to prevent the spread of plaques. The medium containing human serum was washed off thoroughly before picking plaques. The virus from each plaque was passaged twice at 37°C in BHK-21 C13 cells (see method section 2.8), to increase the titre
before immediately growing a large scale stock at 31°C (see method section 2.3). All the plaque stocks were of a typical HSV-2 mixed syncytial/non-syncytial morphology. At each passage the DNA from each of the twenty virus stocks was subjected to restriction endonuclease digestion using the enzymes Xbal, BglII, EcoRI, HindIII, HpaI and BamHI (see method section 2.17). The results showed no apparent differences in the sizes of fragments and distribution of sites in the DNA of the twenty plaque stocks. The BamHI profiles of four independent plaque stocks are shown in Figure 3.1 as representative examples. The BamHI g and z bands which differed in size in individual plaque stocks are located in the joint and repeat regions of the genome and are known variable fragments (Davison and Wilkie, 1981).

3.1.3 Neurovirulence of single plaque stocks

To determine the neurovirulence of the individual plaque stocks, ten were selected at random for mice inoculation. Groups of six to eight 3 week old BALB/c mice were inoculated with either $10^3$, $10^4$ or $10^5$ pfu/mouse of each of the plaque stocks intracranially (0.025ml of virus) into the left cerebral hemisphere after anaesthetising (see method section 2.11). In this series of experiments no mice died before day three following inoculation. The 50% lethal dose ($LD_{50}$) was calculated on the basis of deaths between days 3 and 21 according to the formula of Reed and Muench (1938). The $LD_{50}$ values of the plaque stocks are shown in Table 3.1. The stocks were assigned to one of three classes of neurovirulence depending on the $LD_{50}$ values. Class I of high virulence ($LD_{50} < 10^3$ pfu/mouse) contains plaque stocks 17 and 14. Class II of intermediate virulence ($LD_{50} 10^3-10^4$
Figure 3.1

Autoradiographs of BamHI digests of viral DNA $^{32}\text{P}$-labelled in vivo (1.2% agarose) of plaque purified stocks of HG52 (from left to right, 8, 12, 11 and 14). Letters refer to specific fragments.
Table 3.1. LD_{50} values after intracranial inoculation of plaque purified stocks of HG52

<table>
<thead>
<tr>
<th>Plaque number</th>
<th>Particle : pfu</th>
<th>LD_{50} (pfu/mouse)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>24 : 1</td>
<td>4x10^4</td>
</tr>
<tr>
<td>2</td>
<td>10 : 1</td>
<td>7x10^4</td>
</tr>
<tr>
<td>3</td>
<td>50 : 1</td>
<td>2x10^4</td>
</tr>
<tr>
<td>4</td>
<td>294 : 1</td>
<td>1.5x10^4</td>
</tr>
<tr>
<td>7</td>
<td>235 : 1</td>
<td>1.5x10^4</td>
</tr>
<tr>
<td>8</td>
<td>14 : 1</td>
<td>3x10^5</td>
</tr>
<tr>
<td>11</td>
<td>281 : 1</td>
<td>1.5x10^4</td>
</tr>
<tr>
<td>12</td>
<td>168 : 1</td>
<td>10^4</td>
</tr>
<tr>
<td>14</td>
<td>9 : 1</td>
<td>&lt;10^3</td>
</tr>
<tr>
<td>17</td>
<td>6 : 1</td>
<td>&lt;10^3</td>
</tr>
</tbody>
</table>

3 week old BALB/c mice were used (6 mice/dose).
0.025ml of virus was inoculated.
pfu/mouse) contains plaque stocks 1, 2, 3, 4, 7, 11 and 12 and class III of low virulence (LD$_{50} > 10^5$ pfu/mouse) contains plaque stock 8.

To determine whether the difference in the LD$_{50}$ values of the plaque stocks was related to the number of viral particles within the stocks, particle counts were performed (see method section 2.7) and the particle : pfu ratios are presented in Table 3.1. All the plaque stocks had particle : pfu ratios within the acceptable range for HSV-2. There is no correlation between the particle : pfu ratio and virulence of the plaque stocks 2, 8, 14 and 17 all having ratios of 14 : 1 or less.

Eleven separate virus isolates were recovered from the brains of individual mice immediately after death. The mice had been inoculated with different plaque stocks at a variety of doses. Brain tissue was homogenised and 0.2ml of the homogenate inoculated onto BHK-21 C13 cells (see method section 2.10) from which virus stocks were made. The DNA from each of the eleven virus isolates was subjected to restriction endonuclease analysis using the enzymes Xbal, BgII, EcoRI, HindIII, HpaI and BamHI. There were no apparent differences in the restriction enzyme patterns of each virus isolate compared to the initial infecting viruses. The BamHI profiles of the DNA of five independent virus isolates are shown as representative examples in Figure 3.2.

Two plaque stocks categorised as being of high virulence (14 and 17), one of intermediate virulence (2) and one of low virulence (8) were chosen for further study on the basis of their LD$_{50}$ values and particle : pfu ratios. To confirm their LD$_{50}$ values and compare with that of the elite stock,
Autoradiographs of BamHI digests of viral DNA $^{32}P$-labelled \textit{in vivo} (1.2\% agarose) of viruses recovered from the brain tissue of dead mice (from left to right, 12, 7, 7, 14 and 17). Letters refer to specific fragments.
0.025ml of each of the above plaque stocks was inoculated intracranially into the left cerebral hemisphere of 2-3 week old BALB/c mice at doses ranging from $10^2$-10$^5$ pfu/mouse and the LD$_{50}$ values determined as before (see method section 2.11). The results are shown in Table 3.2 and are comparable with the results obtained in the first experiment (see Table 3.1). In addition the LD$_{50}$ value of the elite stock of HG52 was determined and found to be $<10^2$ pfu/mouse.

The clinical signs produced in mice following intracranial inoculation were closely observed. Some mice became hunched with ruffled fur and ceased to be active with death following rapidly. These signs were seen within 2-3 days following inoculation with the high virulence stocks at doses of $10^4$-10$^5$ pfu/mouse, but developed more slowly after inoculation with high virulence stocks at lower doses of $10^2$-$10^3$ pfu/mouse or with virus stocks of low or intermediate virulence at doses of $10^2$-10$^5$ pfu/mouse. The mice also showed a wide range of neurological signs, for example, fits and limb paralysis of varying severity. Some mice which showed severe neurological signs were killed according to the regulations for conducting animal experimentation.

3.1.4 Virulence analysis using the intraperitoneal route of infection

The LD$_{50}$ values of the plaque stocks 14, 17, 2 and 8 were also examined using the intraperitoneal route of inoculation. Virus stocks were inoculated intraperitoneally at doses of $10^5$-$10^7$ pfu/mouse (0.1ml of virus) into 3 week old BALB/c mice (see method section 2.11). HSV-1 strain 17 syn+ (Brown et al., 1973) was also used in this experiment.
Table 3.2. LD<sub>50</sub> values after intracranial inoculation of selected plaque purified stocks and the elite stock of HG52

<table>
<thead>
<tr>
<th>Plaque number</th>
<th>LD&lt;sub&gt;50&lt;/sub&gt; (pfu/mouse)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>2x10&lt;sup&gt;4&lt;/sup&gt;</td>
</tr>
<tr>
<td>8</td>
<td>&gt;10&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td>14</td>
<td>&lt;10&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>17</td>
<td>5x10&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
<tr>
<td>HG52*</td>
<td>&lt;10&lt;sup&gt;2&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

* Non-plaque purified elite stock.

2-3 week old BALB/c mice were used (6 mice/dose).
0.025ml of virus was inoculated.
as a positive control with a known \(LD_{50}\) value. The results shown in Table 3.3 demonstrate a clear difference between the \(LD_{50}\) value of the HSV-2 strain HG52 and the HSV-1 strain \(17\ syn^+\). The plaque stocks of HG52 (14, 17, 2 and 8) showed differences in the \(LD_{50}\) value which were comparable to the differences in the \(LD_{50}\) value following intracranial inoculation. Virus stocks 14 and 17 had \(LD_{50}\) value of \(10^5\) pfu/mouse while stocks 2 and 8 were avirulent with \(LD_{50}\) value of \(>10^7\) pfu/mouse. An unexpected finding was inversion of the dose response curves; though mice died at low dose (\(10^5\) pfu/mouse) none died at higher doses (\(10^6\) - \(10^7\) pfu/mouse). These findings were seen only with the elite stock of HG52 and the plaque purified stocks (14, 17, 2 and 8).

3.1.5 Replication efficiency in vitro and in vivo

The replication efficiencies of the plaque stocks (14, 17, 2 and 8) and the elite stock of HG52 were tested in vitro and in vivo. One step growth experiments were carried out in BHK-21 C13 cells at 37°C (see method section 2.9) and the results are shown in Figure 3-3. Each stock grew well and there was no difference in the timing of the growth cycle or the yield from any of the plaque stocks compared to the elite stock of HG52.

The possibility that the observed differences in the \(LD_{50}\) value of the individual plaque stocks was due to differential abilities to replicate in mouse brain was tested. The plaque stocks (14, 17, 2 and 8) and the elite stock of HG52 were inoculated at doses of \(10^5\) pfu/mouse into the left cerebral hemisphere of 3 week old BALB/c mice. At daily intervals post inoculation, mice were sacrificed
Table 3.3. \( LD_{50} \) values after intraperitoneal inoculation of selected plaque purified stocks of HG52, elite stock of HG52 and HSV-1 strain 17 \( syn^+ \)

<table>
<thead>
<tr>
<th>Plaque number</th>
<th>( LD_{50} ) (pfu/mouse)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
<td>( 10^5 )</td>
</tr>
<tr>
<td>14</td>
<td>( 10^5 )</td>
</tr>
<tr>
<td>8</td>
<td>( &gt;10^7 )</td>
</tr>
<tr>
<td>2</td>
<td>( &gt;10^7 )</td>
</tr>
<tr>
<td>HG52</td>
<td>( &gt;10^6 )</td>
</tr>
<tr>
<td>HSV-1 (17 ( syn^+ ))</td>
<td>( 10^5 )</td>
</tr>
</tbody>
</table>

3 week old BALB/c mice were used (6 mice/dose). 0.1ml of virus was inoculated.
One step growth curves of plaque stocks 14, 17, 2, 8 and the elite stock of HG52 in BHK-21 Cl3 cells (50mm monolayers 4×10^6 cells) at 37°C. The cells were infected at a moi of 5 pfu/cell. After 45 min absorption, cells were washed, overlaid with ETC5 and incubated at 37°C. Cultures were harvested at the times indicated and the virus titre measured by plaque assay on BHK-21 Cl3 cells is given per ml (10^6 cells). ○ HG52 ; □ plaque stock 14 ; ■ plaque stock 17 ; △ plaque stock 2 ; ● plaque stock 8.
(usually 2 mice/time point), their brains removed, homogenised and assayed for virus by titration on BHK-21 C13 cells at 37°C. The \textit{in vivo} growth curves are presented in Figure 3.4. Plaque stocks 14, 17 and the elite stock of HG52 replicated while plaque stocks 2 and 8 replicated poorly. To determine whether the inefficient brain replication of plaque stocks 2 and 8 was specific to the brain cells or generalised to all mouse cells at the accepted body temperature of mice i.e 38.5°C, comparative one step growth experiments of plaque stocks (14, 17, 2 and 8) were carried out in BALB/c mouse embryo fibroblast (3T3) cells at 38.5°C, and the virus yield titrated on BHK-21 C13 cells at 37°C (see method section 2.9). The results are given in Figure 3.5. The plaque stocks (14, 17, 2 and 8) showed no replication and the virus titre diminished with time. The 3T3 cells appear to be non-permissive for HG52 at 38.5°C. The plaque stocks (14, 17, 2 and 8) were not temperature sensitive. Twenty four hour yield experiments (see method section 2.9) of plaque stocks 14, 17, 2 and 8 gave titres of $4 \times 10^7$, $6 \times 10^7$, $6.5 \times 10^7$ and $5 \times 10^7$ pfu/ml at 31°C and $3 \times 10^7$, $4 \times 10^7$, $3.5 \times 10^7$ and $3 \times 10^7$ pfu/ml respectively at 38.5°C.

3.1.6 Effect of passage on neurovirulence of individual stocks

To determine whether the plaque stocks (14, 17, 2 and 8) which had been categorised for virulence retained their virulence category following passage in BHK-21 C13 cells, they were passaged five times at low moi (see method section 2.8) and ten plaques were picked from each stock. Virus stocks were made from each of these ten plaques and their
Replication kinetics of plaque stocks 14, 17, 2, 8 and the elite stock of HG52 in mouse brain in vivo. Three week old BALB/c mice were inoculated intracranially into the left cerebral hemisphere with 0.025ml containing $10^5$ pfu of virus. At the time indicated post infection, surviving mice were sacrificed (2 mice/time point), their brains were removed, homogenised and the resulting homogenate was titrated for virus on BHK-21 C13 cells at 37°C. O HG52 ; □ plaque stock 14 ; ■ plaque stock 17 ; △ plaque stock 2 ; ● plaque stock 8.
Infectious virus titre (pfu/brain)

Time post infection (h)

- Infectious virus titre (pfu/brain)
  - 10^2
  - 10^3
  - 10^4
  - 10^5
Figure 3.5

One step growth curves of the plaque stocks 14, 17, 2 and 8 in 3T3 cells at 38.5°C. Cells were infected at a moi of 5 pfu/cell. After absorption for 45 min at 37°C, the monolayers were washed, overlaid with ETC5 and incubated at 38.5°C. Cultures were harvested at the times indicated and the virus titre, measured by plaque assay on BHK-21 C13 cells, is given per ml (10^6 cells). □ plaque stock 14 ; ■ plaque stock 17 ; △ plaque stock 2 ; ● plaque stock 8.
DNAs analysed using six different restriction enzymes. The results showed no apparent differences in the pattern of each DNA stock and the BamHI profiles of four independent plaque stocks and the elite stock of HG52 are shown as representative examples in Figure 3.6. Two stocks each from the plaque stocks 2, 8 and 14 and four from the plaque stock 17 at the 5th passage were chosen at random and inoculated intracranially into the left cerebral hemisphere of 3 week old BALB/c mice at doses of $10^2$-$10^5$ pfu/mouse (0.025ml of virus) and the LD$_{50}$ values were determined as before (see method section 2.11). The results are presented in Table 3.4. The virus stocks derived from the intermediate (plaque stock 2) and low (plaque stock 8) virulence stocks remained stably of intermediate or low virulence. The virus stocks derived from the high (plaque stocks 14 and 17) virulence stocks were more heterogeneous. Some demonstrated intermediate levels of virulence (10$^3$-10$^4$ pfu/mouse) e.g. virus stocks 14/3, 14/4 and 17/1 while others retained their levels of virulence. These results clearly demonstrated the virulence heterogeneity within the stock of HSV-2 strain HG52 and reemphasised the necessity of working with well characterised plaque purified stocks when assessing virulence. The high virulence plaque stock 17 was chosen as the baseline to study the effect of defined deletions in HG52 on virulence.

3.2 Virulence of deletion variants of HSV-2 strain HG52

3.2.1 Introduction

The identification of viral genes that control pathogenic properties in vivo, and the elucidation of their functions are of fundamental importance to an understanding
Autoradiographs of BamHI digests of viral DNA $^{32}$P-labelled *in vivo* (1.2% agarose) of the 5th passage plaque purified stocks and the elite stock of HG52 (from left to right), HG52, 8/10, 14/4, 17/1, and 17/3. Letters refer to specific fragments.
Table 3.4. LD$_{50}$ values after intracranial inoculation of the 5th passage of the selected plaque purified stocks of HG52

<table>
<thead>
<tr>
<th>Plaque number</th>
<th>LD$_{50}$ (pfu/mouse)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2/7</td>
<td>&gt;10$^5$</td>
</tr>
<tr>
<td>2/8</td>
<td>&gt;10$^5$</td>
</tr>
<tr>
<td>8/4</td>
<td>&gt;10$^5$</td>
</tr>
<tr>
<td>8/10</td>
<td>2.1x10$^4$</td>
</tr>
<tr>
<td>14/3</td>
<td>3.9x10$^4$</td>
</tr>
<tr>
<td>14/4</td>
<td>2x10$^3$</td>
</tr>
<tr>
<td>17/1</td>
<td>3x10$^3$</td>
</tr>
<tr>
<td>17/3</td>
<td>5.5x10$^2$</td>
</tr>
<tr>
<td>17/8</td>
<td>&lt;10$^2$</td>
</tr>
<tr>
<td>17/9</td>
<td>&lt;10$^2$</td>
</tr>
</tbody>
</table>

3 week old BALB/c mice were used (6 mice/dose). 0.025ml of virus was inoculated.
of the basic molecular mechanism of HSV pathogenesis. Over
the past several years, many laboratories have been involved
in studies of HSV genes and gene products specifically
related to neurovirulence. Most of these studies were
carried out on HSV-1 using deletion mutants, temperature
sensitive (ts) mutants, monoclonal antibody resistant (mar)
mutants, drug resistant mutants and intertypic recombinants.
Very little is known about HSV-2 genes or gene products
associated with neurovirulence.

A series of HG52 variants with deletions in the internal
long repeat (IR\textsubscript{L}) or short unique/terminal short repeat
(U\textsubscript{S}/TR\textsubscript{S}) regions of the genomes were studied to define the
role of the deleted genes in HSV neurovirulence using the
mouse model system. The size and location of the deletions
and growth characteristics of the variants have been
reported by Harland and Brown (1985) and Brown and Harland
(1987). The fact that the variants were not impaired in
their lytic growth cycle demonstrated that the deleted genes
were not essential for growth in vitro. Figure 3.7 shows a
schematic map of the HG52 genome with the location of the
IR\textsubscript{L} deletions in the variants under study. The variants
used were as follows: their nomenclature when first
published is given in brackets.

JH2603 (HG52XD86): has a 3.75 kb deletion which includes the
BamHI p/f site at 0.775 m.u. Most or all of the deleted
sequences are within IR\textsubscript{L} and probably span the U\textsubscript{L}/IR\textsubscript{L}
junction. The deletion must remove at least part of the
coding region of the immediate early gene 1 (IE\textsubscript{L})
(0.785-0.81 m.u.) which codes for the immediate early
polypeptide VmwIE\textsubscript{118} (Preston \textit{et al.}, 1978; Easton and
Clements, 1980).
Structure of the HG52 genome (top line) showing $U_L$ and $U_S$ flanked by $TR_L/IR_L$ and $IR_S/TR_S$ respectively. The second line shows an expansion of the Xbal $q$ fragment (0.7-0.83 m.u.). The positions of the 'a' sequence and the transcripts for IE1 and IE2 genes are indicated. The third line shows the positions of the BamHI sites within Xbal $q$. The location and the extent of the deletions in the variants is indicated. JH2604 is the only variant which contains a deletion in both copies of the $R_L$. 
**JH2604 (HG52XD192):** has a 1.5 kb deletion in TR\textsubscript{L} and IR\textsubscript{L} within both copies of the BamHI \textit{v} fragment (0-0.02 and 0.81-0.83 m.u.).

**JH2605 (HG52XD85/5):** has a deletion of 5.5 kb within IR\textsubscript{L} including the BamHI p/f site and probably the U\textsubscript{L}/IR\textsubscript{L} junction.

**JH2606 (HG52XD85/4):** has 9 kb deletion encompassing the BamHI p/f site, and the BamHI \textit{p} and \textit{v} fragments excluding the 'a' sequences. The deletion extends from approximately 0.76 to 0.83 m.u. including the total coding region of the IE1 gene and the U\textsubscript{L}/IR\textsubscript{L} junction.

A diagrammatic representation of the location and extent of the deletions in the U\textsubscript{S} and TR\textsubscript{S} components of the genome in the altered variants is shown in Figure 3.8. All have lost the Xbal site at 0.7 m.u. The variants analysed are as follows: their nomenclature when first published is given in brackets.

**JH2607 (HG52XD163X12):** has a deletion of 7.75 kb extending from approximately 0.94-0.994 m.u. The genes deleted are US10, US11 and US12 coding for polypeptides of Mr 33K, 21K/22K, and VmwIE12 respectively (Watson \textit{et al.}, 1979; Marsden \textit{et al.}, 1982; Dalziel and Marsden, 1984; Lee \textit{et al.}, 1982), one copy of IE3 coding for VmwIE182 (Morse \textit{et al.}, 1978) and one copy of the short origin of replication (orig\textsubscript{S}) (Stow and McMonagle, 1983).

**JH2608 (HG52X163X14):** has a deletion of 7.5 kb including the genes US10, US11 and US12. The deleted sequences have been replaced by inverted duplication of U\textsubscript{S}/IR\textsubscript{S} sequences between 0.83-0.91 and 0.94-1.2 m.u. such that the short repeat region is extended by 6 kb on either side. This means that this variant has two copies of the genes US1, US2, US3, US4...
Figure 3.8

XbaI map for the DNA of HSV-2 strain HG52 (top line) from Cortini and Wilkie (1978), showing the position of XbaI sites. The location of the deletion in the variants is indicated and the positions of the lost XbaI sites (X) are also shown in each genome below the top line.

The origin of the joint fragments is as follows; \( a = c + h, \)
\( b = c + i, \)
\( d = g + h, \)
\( f = g + i. \)
coding for Vm\text{w}IE68, a protein of unknown function, protein kinase and glycoprotein G respectively (McGeoch et al., 1985 and 1987; McGeoch and Davison, 1986; Frame et al., 1986b) and the coding region of US5 (McGeoch et al., 1985).

JH2609 (HG52X163X21): is the same as JH2608 except that it contains additional HindIII and EcoRI sites at 0.94 m.u. and has lost the XbaI site at 0.91 m.u.

JH2610 (HG52X163X3): has lost the XbaI site at 0.91 m.u. resulting in fusion of XbaI h and j.

JH2611 (HG52X163X53): has lost all the XbaI sites (0.45, 0.7, 0.91 and 0.94 m.u.).

3.2.2 Neurovirulence of the deletion variants

Neurovirulence of the HG52 deletion variants was assayed by intracranial inoculation of 3 week old BALB/c mice at doses ranging from $10^3$-10$^7$ pfu/mouse (5-6 mice/dose). The mice were monitored for 3 weeks following inoculation and the LD$_{50}$ values calculated (see method section 2.11). The results are shown in Table 3.5. The LD$_{50}$ of the wild type elite stock of HG52 is shown for comparison. Most of the deletion variants exhibited reduced neurovirulence and can be segregated into three groups. The first group with an LD$_{50}$ value of >10$^7$ pfu/mouse, classified as avirulent includes JH2604. The second group with an LD$_{50}$ value of 10$^5$-10$^6$ pfu/mouse classified as of reduced virulence includes JH2610, JH2608, JH2609, JH2605 and JH2606. The third group with an LD$_{50}$ value of 10$^4$ pfu/mouse classified as attenuated includes JH2611, JH2607 and JH2603. These results indicate that the capacity of all the variants to kill mice following intracranial inoculation was reduced with LD$_{50}$ values ranging between 10$^4$-10$^7$ pfu/mouse compared
0.25mL of virus was inoculated.

3 week old BALB/c mice were used.

ND not determined.

* Number of deaths/number of animals inoculated.

<table>
<thead>
<tr>
<th>ID 50 plaque units/mouse</th>
<th>10^3</th>
<th>10^5</th>
<th>10^6</th>
<th>10^7</th>
<th>10^8</th>
<th>10^9</th>
</tr>
</thead>
<tbody>
<tr>
<td>5X10^4</td>
<td>ND</td>
<td>6/6</td>
<td>6/6</td>
<td>6/0</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>4.2X10^5</td>
<td>5/5</td>
<td>5/5</td>
<td>5/0</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>10^5</td>
<td>ND</td>
<td>9/6</td>
<td>9/3</td>
<td>9/0</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>2X10^6</td>
<td>ND</td>
<td>9/6</td>
<td>9/2</td>
<td>9/0</td>
<td>9/0</td>
<td>ND</td>
</tr>
<tr>
<td>10^7</td>
<td>ND</td>
<td>9/6</td>
<td>9/3</td>
<td>9/0</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>5X10^7</td>
<td>5/5</td>
<td>5/4</td>
<td>9/0</td>
<td>9/0</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>10^8</td>
<td>ND</td>
<td>5/5</td>
<td>5/2</td>
<td>9/0</td>
<td>9/0</td>
<td>ND</td>
</tr>
<tr>
<td>10^9</td>
<td>ND</td>
<td>6/1</td>
<td>6/0</td>
<td>9/0</td>
<td>9/0</td>
<td>9/0</td>
</tr>
<tr>
<td>10^10</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>

Table 3.5. ID50 values after intracranial inoculation of the deletion variants of strain HG52.
to $<10^2$ pfu/mouse for the HG52 elite stock. Comparing these results with the range of neurovirulence results obtained for individual plaque stocks of HG52 indicated that the $LD_{50}$ values of all the deletion variants except JH2604 and JH2610 fell within the range of the parental HG52.

It had previously been shown that although not temperature sensitive the deletion variants in $U_{S}/TR_{S}$ were temperature restricted at 38.5°C (Brown and Harland, 1987) the ambient body temperature of mice. As any impairment in neurovirulence may have been attributed to this restriction it was decided to concentrate on the variants with deletions in $IR_{L}$ i.e JH2603, JH2604, JH2605 and JH2606. These variants displayed reduced neurovirulence. JH2603 was chosen as a model in cotransfection experiments and to test whether the deletion in the variant JH2603 has any effect on neurovirulence. The deletion in the variant JH2603 was shown to be 3.75 kb in $IR_{L}$ within the Xbal g fragment. In order to introduce the deletion into the genome of plaque 17 stock of HG52, purified DNA from the the variant JH2603 was digested and the Xbal g fragment (0.7-0.83 m.u.) containing the deletion was excised, eluted and cotransfected with intact plaque 17 stock genome (see method section 2.19). The fragment was used at a 5, 10 and 20 fold molar excess over the intact plaque 17 stock DNA. Fifty plaques were picked, grown into plate stocks and the DNAs of twenty five were digested with Xbal (see method section 2.17) and their restriction profiles studied. One designated R17XD86 showed a profile indicating that the fragment containing the deletion had recombined into the wild type genome. After three rounds of plaque purification, Xbal digestion confirmed that recombination
had occurred and that the deletion in JH2603 had been inserted. The results are shown in Figure 3.9. The recombinant R17XD86 (lane 2) shows that the Xbal g and the Xbal q containing joint fragments (e and f) were now running at the positions of the equivalent bands in JH2603 (lane 3) and not in their normal wild type position (lane 1). The recombinant was inoculated intracranially into 3 week old BALB/c mice at doses ranging from $10^2$ to $10^5$ pfu/mouse (see method section 2.11). As controls, the highly neurovirulent plaque 17 stock of HG52 and JH2603 were used at doses ranging from $10^2$-$10^3$ and from $10^2$-$10^5$ pfu/mouse respectively. The results given in Table 3.6 showed that the recombinant had an LD$_{50}$ value of $3.5\times10^4$ pfu/mouse which is the same as the variant JH2603 indicating that the sequences deleted in JH2603 had an effect on neurovirulence.

In conclusion, the results indicate that all the deletion variants of HG52 analysed had reduced neurovirulence following intracranial inoculation of 3 week old BALB/c mice with LD$_{50}$ values ranging $10^4$-$10^7$ pfu/mouse compared to $<10^2$ pfu/mouse for the wild type elite stock of HG52.

3.3 Analysis of the deletion variant JH2604

3.3.1 Neurovirulence of JH2604

The DNA structure of the deletion variant JH2604 has been described in detail by Harland and Brown (1985). Essentially the genome has a deletion of approximately 1.5 kb in both copies of BamHI v located between 0-0.02 and 0.81-0.83 m.u. in TR$_L$ and IR$_L$ respectively. The relevant restriction maps for HG52 are shown in Figure 3.10 (Cortini and Wilkie, 1978). To determine the neurovirulence of
Figure 3.9

Autoradiographs of Xbal digests of viral DNA $^{32}\text{P}$-labelled \textit{in vivo} (0.5% agarose) of HG52 (lane 1), RL7XD86 (lane 2) and JH2603 (lane 3). Letters refer to specific fragments, arrowheads indicate the positions where fragments are missing and stars indicate novel fragments.
Table 3.6. LD$_{50}$ values after intracranial inoculation of plaque 17 stock of HG52, JH2603 and the recombinant R17XD86 Virus plaque 17 virus plaque 17 stock of HG52, JH2603 and the recombinant R17XD86

<table>
<thead>
<tr>
<th>Virus</th>
<th>Virus dose (pfu)/animal</th>
<th>LD$_{50}$ (pfu/mouse)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10$^2$</td>
<td>10$^3$</td>
</tr>
<tr>
<td>Plaque 17</td>
<td>2/6*</td>
<td>5/6*</td>
</tr>
<tr>
<td>JH2603</td>
<td>0/6</td>
<td>0/6</td>
</tr>
<tr>
<td>R17XD86</td>
<td>1/6</td>
<td>0/6</td>
</tr>
</tbody>
</table>

+ Number of deaths/number of animals inoculated.
* ND not determined.

3 week old BALB/c mice were used.

0.025ml of virus was inoculated.
Restriction endonuclease maps for the DNA of HSV-2 strain HG52 from Cortini and Wilkie (1978). The origin of the joint fragments is as follows. XbaI: a =c+h, b =c+i, e =q+h, f =q+i. HindIII: c =i+k, d =i+k, f =i+m, g =j+m. EcoRI: b =f+k, c =h+k, d =f+m, e =h+m. BglII: a =d+k, b =d+m, e =h+k, f =h+m. HpaI: b =f+(S), e =g+(S). KpnI: b =c+r, e =f+r. BamHI: g =v+u.
JH2604 compared to the parental HG52 elite stock, experiments were carried out to estimate the LD<sub>50</sub> values in mice. Twenty five ul aliquots of HG52 at doses of 10<sup>2</sup>-10<sup>5</sup> pfu/mouse and JH2604 at doses of 10<sup>5</sup>-10<sup>7</sup> pfu/mouse were inoculated into the left cerebral hemisphere of 3 week old BALB/c mice of each sex. Deaths were scored between days 3 and 21 post inoculation and the LD<sub>50</sub> values calculated (see method section 2.11). The results are shown in Table 3.7.

The elite parental stock of HG52 showed an LD<sub>50</sub> value of <10<sup>2</sup> pfu/mouse which was comparable to that determined previously and to the LD<sub>50</sub> value of <10<sup>3</sup> pfu/mouse calculated for the plaque purified, plaque 17, stock of HG52 (see results section 3.1). The LD<sub>50</sub> value of JH2604 was greater than 10<sup>7</sup> pfu/mouse; at a dose of 10<sup>7</sup> pfu/animal, only one animal out of nine died and no others showed signs of encephalitis or any other symptoms of illness or distress. Also, two mice each infected with 10<sup>8</sup> pfu/mouse of JH2604 remained healthy after inoculation. Thus the deletion variant JH2604 was at least 10<sup>6</sup> fold less neurovirulent than the parental stock of HG52. The particle : pfu ratios of 54 : 1 for HG52 and 71 : 1 for JH2604 are comparable and fall within the normal range of values for HSV-2. Following footpad inoculation (see method section 2.11) the variant JH2604 failed to kill any of the mice (15 mice) inoculated at doses of 10<sup>6</sup>, 10<sup>7</sup> and 10<sup>8</sup> pfu/mouse giving an LD<sub>50</sub> value of >10<sup>8</sup> pfu/mouse.

3.3.2 Growth of JH2604 in vivo

To determine whether the low neurovirulence of JH2604 was due to failure of replication in the mouse brain, the growth of the virus in vivo was tested. Samples of HG52 and
Table 3.7. Neurovirulence of HG52 and JH2604 in BALB/c mice following intracranial inoculation

<table>
<thead>
<tr>
<th>Virus</th>
<th>Virus dose (pfu)/animal</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$10^2$</td>
</tr>
<tr>
<td>HG52</td>
<td></td>
</tr>
<tr>
<td>JH2604</td>
<td></td>
</tr>
</tbody>
</table>

+ Number of deaths/number of animals inoculated.

* ND not determined.

** Particle : pfu 54 : 1.

*** Particle : pfu 71 : 1.

3 week old BALB/c mice were used.

0.025ml of virus was inoculated.
JH2604 (10^5 pfu/mouse) were inoculated into the left cerebral hemisphere of 3 week old BALB/c mice of both sexes. At 0, 24, 48, 72, 96, 120 and 144 h post infection, two mice were killed and their brains were removed, homogenised and the resulting suspension sonicated and assayed by plaque titration on BHK-21 C13 cells at 37°C (see method section 2.5). The results plotted in Figure 3.11 show that the parental HG52 grew well in the mouse brain with the titre continuing to rise at 120 h post inoculation; by 144 h all the mice had died from encephalitis. In contrast, the variant JH2604 failed to show any replication and the titre diminished progressively with time. These results indicated that the variant JH2604 was specifically restricted in the nervous system due to a replication deficiency in mouse brain cells.

3.3.3 Growth of JH2604 in vitro

The deletion variant JH2604 grows like wild type in a single cycle growth experiment in BHK-21 C13 cells at 37°C (Harland and Brown, 1985); the parental elite stock of HG52 is somewhat temperature restricted at 38.5°C in that, though displaying exponential growth, the highest titre of virus reached by 12 h post infection is not appreciably higher than the starting titre immediately post absorption (Brown and Harland, 1987). The variant JH2604 is not temperature sensitive but is impaired in single cycle growth experiments at 38.5°C to the same extent as the parental HG52. The titre of the JH2604 stock used for all experiments was 4x10^7 pfu/ml at 31°C and 3x10^7 pfu/ml at 38.5°C. HG52 stock generally gives a lower titre compared to HSV-1 strain 17 syn+, due to the fact that HG52 is mainly cell associated.
**Figure 3.11**

**In vivo** growth kinetics of HG52 and JH2604. Three week old BALB/c mice were inoculated into the left cerebral hemisphere with 25ul of virus containing $10^5$ pfu/mouse. At indicated times post infection, two surviving mice from each time point were sacrificed. The brain tissue was removed and homogenised; the resulting cell suspension was sonicated and released infectious virus titrated on BHK-21 C13 cells at 37°C. ○ HG52 ; ● JH2604.
To determine whether JH2604 was temperature sensitive in mouse cells at the accepted ambient body temperature of mice i.e. 38.5°C, comparative one step growth experiments were carried out in BALB/c mouse embryo fibroblast (3T3) cells at 38.5°C (see method section 2.9), and the virus yield was titrated on BHK-21 C13 cells at 37°C. Results are given in Figure 3.12 and show that the parental HG52 replicated poorly, reaching a titre comparable to the input titre by 8 h post infection and then diminished. The variant JH2604 showed little evidence of replication and the virus titre progressively fell by 2 logs with time. In one step growth experiments performed at 37°C in 3T3 cells (Figure 3.13), the parental HG52 demonstrated some replication by 24 h post infection while JH2604 failed to replicate. Since it was possible that HG52 grows more slowly in 3T3 cells, multistep growth experiments were performed at 37°C in 3T3 cells. The results are shown in Figure 3.14 and again the parental HG52 showed some replication and reached its highest titre by 24 h post infection. The variant JH2604 failed to replicate and the titre dropped by 4 logs with time. It is concluded that BALB/c 3T3 cells are poor hosts for replication of HSV-2 strain HG52 although some replication of wild type virus does occur; these cells are totally non-permissive for the deletion variant JH2604 both at 37°C and 38.5°C.

3.3.4 Infected cell polypeptide synthesis by JH2604

It has been shown previously that JH2604 synthesises normal amounts of HSV-induced immediate early polypeptides under immediate early conditions (Harland and Brown, 1985). To determine whether the deletion in JH2604 affected any
Figure 3.12

Single cycle growth kinetics of HG52 (O) and JH2604 (●) in 3T3 cells at 38.5°C. Cells were infected at a moi of 5 pfu/cell. After absorption, cells were washed, overlaid with ETC5 and incubated at 38.5°C. At various times post infection, cells were harvested, virus was released by sonication and titrated on BHK-21 Cl3 cells at 37°C. The titre is given per ml (10⁶ cells).
Figure 3.13

One step growth curves of HG52 and JH2604 in 3T3 cells at 37°C. Cells were infected at a moi of 5 pfu/cell. Following absorption, cells were washed, overlaid with ETC5 and incubated at 37°C. Cells were harvested at times indicated and the virus titre measured by plaque assay on BHK-21 C13 cells at 37°C is given per ml (10^6 cells). O HG52 ; ● JH2604.
Figure 3.14

Multistep growth kinetics of HG52 and JH2604 in 3T3 cells at 37°C. Cells were infected at a moi of 0.002 pfu/cell. After absorption, cells were washed, overlaid with ETC5 and incubated at 37°C. At various times post infection, cells were harvested, virus released by sonication, titrated on BHK-21 Cl3 cells at 37°C and the titre is given per ml (10^6 cells). O HG52 ; ● JH2604.
other detectable polypeptide synthesis, the infected cell polypeptides of HG52 and JH2604 were labelled with $^{35}$S-methionine and analysed by SDS-PAGE (see method section 2.15). The results are shown in Figure 3.15. There were no detectable differences between the infected cell polypeptides synthesised by HG52 (lanes 1 and 6) and by JH2604 (lanes 2 and 5) compared to the mock infected cells (lanes 3 and 4) indicating that the deletion in JH2604 does not affect detectable general polypeptide synthesis.

### 3.3.5 Thymidine kinase synthesis by JH2604

It is widely accepted that the expression of virus-encoded thymidine kinase (TK) enzyme activity is necessary for the maximum demonstration of virulence phenotype by HSV (Field and Wildy, 1978). To determine whether the lack of neurovirulence of JH2604 was due to a mutation in TK synthesis, TK assays were performed on HG52, JH2604 and a known TK-negative mutant (TK$^{-7}$) using the method described in section 2.13. The results of two separate experiments are shown in Table 3.8. With the TK-negative mutant (TK$^{-7}$) the $^3$H counts per minute (cpm) were marginally below the background (mock infected) levels in both experiments, while the wild type HG52 gave counts of 3.4 and 2.4 times the background levels and the variant JH2604 gave counts of 3.6 and 3.0 times the mock infected levels. Thus JH2604 is at least as efficient as HG52 in synthesizing the TK enzyme and therefore the avirulent phenotype of JH2604 was not due to lack of expression of TK enzyme activity.

### 3.3.6 Correction of the deletion in JH2604
Autoradiographs of infected cell polypeptides induced in BHK-21 Cl3 cells, labelled with $^{35}$S-methionine from 4-24 h post infection and separated on SDS-PAGE using single 10% (lanes 1 and 3) and gradient 5-12.5% (lanes 4 and 6) concentrations of acrylamide gels. HG52 (lanes 1 and 6); JH2604 (lanes 2 and 5) and mock infected (lanes 3 and 4). Numbers refer to the apparent molecular weight ($x10^{-3}$) of HSV-2 infected cell polypeptides.
<table>
<thead>
<tr>
<th>Virus</th>
<th>Radioactivity (cpm)/μg protein</th>
<th>Experiment 1</th>
<th>Experiment 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mock infected</td>
<td>2573</td>
<td>3460</td>
<td></td>
</tr>
<tr>
<td>TK⁻⁷ (17)</td>
<td>2216</td>
<td>2812</td>
<td></td>
</tr>
<tr>
<td>HG52</td>
<td>8713</td>
<td>8424</td>
<td></td>
</tr>
<tr>
<td>JH2604</td>
<td>9265</td>
<td>10645</td>
<td></td>
</tr>
</tbody>
</table>

Table 3.8. TK assays on HG52, JH2604 and TK⁻⁷ viruses
The strategy employed to correct the deletion in the genome of JH2604 and subsequent isolation of recombinants is shown in Figure 3.16. Essentially unit length JH2604 genomes and restriction endonuclease fragments spanning the deletion from the HG52 genome were cotransfected onto BHK-21 C13 cells. The progeny viruses were allowed to amplify until the cpe was complete. Cultures were harvested independently, titrated out and plaques were picked, grown into plate stocks and their DNAs were analysed by restriction endonucleases using the method of Lonsdale (1979). Recombinant viruses were isolated, plaque purified, their DNA profiles and LD_{50} values determined (see method section 2.11). In this study purified DNA from the highly neurovirulent plaque 17 stock of HG52 (LD_{50} <10^3 pfu/mouse) was digested with Xbal and the Xbal q and g containing joint fragments (e and f) were excised and after purification by electroelution (see method section 2.18) were used independently in cotransfection experiments with the intact JH2604 DNA. The deletion in JH2604 was shown to be within Xbal g and the q joint fragments (e and f). The Mr of fragment Xbal q (0.7-0.83 m.u.) is 1.3x10^6; that of Xbal e (g+h 0.83-0.91 m.u.) is 2.1x10^6 and of f (g+i 0.94-1.0 m.u.) is 1.9x10^6. In cotransfection experiments the fragments were used at a 5, 10 and 20 fold molar excess to the intact JH2604 DNA. Although the deletion in JH2604 is only 1x10^6 Mr (1.5 kb) in both copies of BamHI v, these large Xbal fragments were used to facilitate recombination between the fragment and the intact genome (the larger the fragment, the greater the chance of recombination occurring) as no selection system was available. Two hundred plaques were picked, and the DNA of 46 of these was digested with Xbal;
Strategy employed to correct the deletion in the variant JH2604 in vitro.
Intact JH2604 genomes \( \rightarrow \) Xbal RE fragments from HG52

Amplification in culture (BHK-21 C13 cells)

\[
\text{Pick plaques} \rightarrow \text{RE analysis} \rightarrow \text{Isolation of the recombinants} \rightarrow \text{Plaque purification} \rightarrow \text{RE analysis} \rightarrow \text{Neurovirulence of the recombinants (LD}_{50}\text{ values)}
\]
four of these digests showed profiles indicating that the deletion in Xbal \( q \) had been corrected, as the \( q, e \) and \( f \) bands ran in the normal wild type position. Three were from cotransfections using a 20 fold molar excess of Xbal \( e \) and the fourth from a plate in which Xbal \( f \) had been cotransfected at a 20 fold molar excess with JH2604 DNA. After three rounds of plaque purification, Xbal digestion confirmed that recombination had occurred and that the deletion in JH2604 had been corrected. The recombinants were designated R17(192)E pl. 8, R17(192)E pl. 14, R17(192)E pl. 15 and R17(192)F pl. 10. Figure 3.17 shows Xbal profiles of the four recombinants (lanes 2-5) compared to HG52 (lane 1) and JH2604 (lane 6). Xbal digestion demonstrated that the deletion had been corrected in IR\( _L \) i.e within Xbal \( q \). The size of the other Xbal fragment containing BamHI \( v \) (i.e \( c, 45 \times 10^6 \) Mr) is such that an alteration in size of Mr \( 1 \times 10^6 \) would not be detectable. Therefore HindIII and HpaI digestion was carried out. The results are shown in Figure 3.18. BamHI \( v \) in TR\( _L \) is located within HpaI \( q \), and BamHI \( v \) in IR\( _L \) is located within HpaI \( f \). The variant JH2604 shows \( f \) and \( q \) deleted by approximately \( 1 \times 10^6 \) Mr (lane 6) compared to \( f \) and \( q \) of HG52 (lane 1). The size of the HpaI \( q \) and \( f \) containing joint fragments (\( b \) and \( c \)) are so large that a deletion of \( 1 \times 10^6 \) Mr would not be detectable. In the recombinants HpaI \( f \) and \( q \) have returned to their wild type positions (lanes 2-5). BamHI \( v \) in TR\( _L \) is located within HindIII \( i \), and in IR\( _L \) within HindIII \( j \). Therefore with the variant JH2604, HindIII \( i \) and \( j \) and the \( i \) and \( j \) containing joint fragments i.e \( c, d, f \) and \( q \) (lane 12) are deleted compared to the corresponding HG52 fragments (lane 7). In the recombinants, \( i, j, c, d, f \) and \( q \) have all
Figure 3.17

Autoradiographs of restriction digests of viral DNA $^{32}$P-labelled in vivo. Xbal digestion (0.5% agarose) of HG52 (lane 1), Rl7(192)E pl. 8 (lane 2), Rl7(192)E pl. 14 (lane 3), Rl7(192)E pl. 15 (lane 4), Rl7(192)F pl. 10 (lane 5) and JH2604 (lane 6). Letters refer to specific fragments, arrowheads indicate the positions where fragments are missing and $e'$, $f'$, $g'$ indicate novel fragments.
Figure 3.18

Autoradiographs of restriction digests of viral DNA $^{32}$P-labelled *in vivo*. HpaI (lanes 1 to 6) and HindIII (lanes 7 to 12) digestion of HG52 (lanes 1 and 7), JH2604 (lanes 6 and 12), R17(192)E pl. 8 (lanes 2 and 8), R17(192)E pl. 14 (lanes 3 and 9), R17(192)E pl. 15 (lanes 4 and 10) and R17(192)F pl. 10 (lanes 5 and 11). Letters refer to specific fragments, arrowheads indicate the positions where fragments are missing and f', g' etc. indicate novel fragments.
returned to their wild type positions (lanes 8-11). The HpaI and HindIII digests demonstrate that the deletion has been corrected in both copies of BamHI v i.e in TRL and IRL. The TK phenotype of the recombinants was tested by TK assays (see method section 2.13) to ensure that no secondary mutation affecting virulence had occurred and the results are shown in Table 3.9. The recombinants were as efficient as the wild type in synthesizing the TK enzyme.

3.3.7 Neurovirulence of the R17(192) recombinants

To determine their neurovirulence, the three times plaque purified recombinants were inoculated intracranially into the left cerebral hemisphere of 3 week old BALB/c mice at doses ranging from $10^2$ to $10^6$ pfu/mouse. As controls the highly neurovirulent plaque 17 stock of HG52 and JH2604 were used at doses ranging from $10^2$-$10^5$ and $10^5$-$10^7$ pfu/mouse respectively. The results are given in Table 3.10 show that all four recombinants have regained neurovirulence with LD$_{50}$ values ranging from $10^3$ to $3x10^5$ pfu/mouse. These LD$_{50}$ values are within the range of the values of the individual plaque stocks of HG52 ($<10^2$-$3x10^5$ pfu/mouse) (see section 3.1). The avirulent phenotype of JH2604 has been confirmed with an LD$_{50}$ value of $>10^7$ pfu/mouse. The particle : pfu ratios of the recombinants are shown in Table 3.10 and are within the acceptable range for HSV-2. The avirulent phenotype of JH2604 has therefore been corrected by insertion of wild type sequences replacing the deletion in both copies of the BamHI v fragment.

The range of the LD$_{50}$ values obtained with the recombinants in which the deletion has been corrected suggest either (i) there are sequences apart from those
Table 3.9. TK assays on the R17(192) recombinants, R192(17) recombinants, HG52 and TK⁻⁷

<table>
<thead>
<tr>
<th>Virus</th>
<th>Radioactivity (cpm)/ug protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mock infected</td>
<td>2352</td>
</tr>
<tr>
<td>TK⁻⁷</td>
<td>2115</td>
</tr>
<tr>
<td>HG52</td>
<td>8220</td>
</tr>
<tr>
<td>R17(192)E p1. 8</td>
<td>7924</td>
</tr>
<tr>
<td>R17(192)E p1. 14</td>
<td>8140</td>
</tr>
<tr>
<td>R17(192)E p1. 15</td>
<td>8080</td>
</tr>
<tr>
<td>R17(192)F p1. 10</td>
<td>7982</td>
</tr>
<tr>
<td>R192(17)E p1. 2</td>
<td>9630</td>
</tr>
<tr>
<td>R192(17)E p1. 5</td>
<td>8356</td>
</tr>
</tbody>
</table>
0.025ml of virus was inoculated.
3 week old BALB/c mice were used.
+ Number of deaths / number of animals inoculated.

<table>
<thead>
<tr>
<th>Group</th>
<th>Dose (pfu)</th>
<th>Animals (animals)</th>
<th>Deaths</th>
<th>ND / Animals</th>
</tr>
</thead>
<tbody>
<tr>
<td>3x10^5</td>
<td>ND</td>
<td>3 / 3</td>
<td>3 / 3</td>
<td>3 / 3</td>
</tr>
<tr>
<td>3x10^5</td>
<td>ND</td>
<td>3 / 3</td>
<td>6 / 6</td>
<td>ND</td>
</tr>
<tr>
<td>1x10^5</td>
<td>ND</td>
<td>ND</td>
<td>12 / 12</td>
<td>6 / 6</td>
</tr>
<tr>
<td>3x10^5</td>
<td>ND</td>
<td>6 / 6</td>
<td>11 / 11</td>
<td>9 / 9</td>
</tr>
<tr>
<td>2x10^2</td>
<td>ND</td>
<td>ND</td>
<td>0 / 0</td>
<td>ND</td>
</tr>
</tbody>
</table>

Calculation: Virus dose (pfu) / Animals

Table 3.10: ID50 values after intracranial inoculation of the R17(192) recombinants
deleted in JH2604 which act either in conjunction with or independently of those between 0–0.02 and 0.81–0.83 m.u. to determine neurovirulence or (ii) the DNA stock of HG52 plaque 17 is heterogeneous, in that viruses arising from individual genomes have different virulence potential. The latter would mean that the virus population of HG52 plaque 17 despite its recent purification contains a genome mixture with virulence LD$_{50}$ values similar to those of the individual plaque stocks of the elite HG52 laboratory stock (<10$^3$–3x10$^5$ pfu/mouse). To determine whether this was the case, a DNA stock of HG52 plaque 17 was transfected and five well separated progeny plaques were isolated. Virus stocks from the five plaques were inoculated into 3 week old BALB/c mice at doses ranging from 10$^2$–10$^4$ pfu/mouse and the LD$_{50}$ values were determined (see method section 2.11). The results in Table 3.11 show that the LD$_{50}$ values of these plaque stocks were <10$^2$ to >10$^4$ pfu/mouse confirming the virulence heterogeneity within the stock of HG52 plaque 17.

3.3.8 Introduction of the JH2604 deletion into the HG52 genome

Having confirmed that the avirulent phenotype of JH2604 could be corrected by insertion of wild type fragments to correct the deletion, reciprocal experiments were carried out to determine whether removal of the relevant sequences from HG52 resulted in an avirulent phenotype. In order to insert the deletion in JH2604 into the wild type genome, purified DNA from JH2604 was digested with Xbal and the three fragments g, e and f were excised and purified from the gel (see method section 2.18). The three fragments were independently used in cotransfection experiments with intact
Table 3.11. LD$_{50}$ values after intracranial inoculation of the plaque stocks picked from transfected HG52 plaque 17 DNA

<table>
<thead>
<tr>
<th>Plaque number</th>
<th>Virus dose (pfu)/animal</th>
<th>LD$_{50}$ (pfu/mouse)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10$^2$</td>
<td>10$^3$</td>
</tr>
<tr>
<td>17/1</td>
<td>0/5$^+$</td>
<td>3/5</td>
</tr>
<tr>
<td>17/2</td>
<td>3/5</td>
<td>5/5</td>
</tr>
<tr>
<td>17/3</td>
<td>0/5</td>
<td>0/5</td>
</tr>
<tr>
<td>17/4</td>
<td>0/5</td>
<td>0/5</td>
</tr>
<tr>
<td>17/5</td>
<td>1/5</td>
<td>3/5</td>
</tr>
</tbody>
</table>

$^+$ Number of deaths/number of animals inoculated.

3 week old BALB/c mice were used.

0.025ml of virus was inoculated.
DNA from HG52 plaque 17 stock (high neurovirulence) at a 5, 10 and 20 fold molar ratio. No selection system was used to isolate recombinants when 200 plaques were picked. Of the DNA of 40 of these digested with Xbal, two showed Xbal profiles indicating that the fragment containing the deletion had recombined into the wild type genome (Figure 3.19 lanes 2 and 3) in that the g, e and f bands were now running at the positions of the equivalent bands in JH2604 (lane 4) and not in their normal wild type positions (lane 1). HpaI and HindIII digestion (Figure 3.20) confirmed that the deletion was in both copies of R<sub>L</sub> in that HpaI g and f (lanes 2 and 3) and HindIII i, j, c, d, f and g (lanes 6 and 7) were running below their normal wild type positions (lanes 1 and 5). The recombinants were plaque purified three times, their restriction profiles confirmed and virus stocks were grown. The recombinants were as efficient as wild type in synthesizing TK enzyme (Table 3.9). The recombinants were designated R192(17)E pl. 2 and R192(17)E pl. 5.

3.3.9 Neurovirulence of the R192(17) recombinants

To determine their neurovirulence, the two recombinants R192(17) were independently inoculated intracranially into the left cerebral hemisphere of 3 week old BALB/c mice at doses of 10<sup>5</sup>-10<sup>7</sup> pfu/mouse. Control infections with the HG52 plaque 17 stock and JH2604 were performed at the same time. The results are shown in Table 3.12. It can be seen that each of the recombinants had an LD<sub>50</sub> value of >10<sup>7</sup> pfu/mouse i.e the same as that of the non-neurovirulent deletion variant JH2604. The particle : pfu ratios of the recombinants are shown in Table 3.12 and were comparable to
Autoradiographs of restriction digests of viral DNA $^{32}P$-labelled \textit{in vivo}. Xbal digestion (0.5% agarose) of HG52 (lane 1), Rl92(17)E pl. 2 (lane 2), Rl92(17)E pl. 5 (lane 3) and JH2604 (lane 4). Letters refer to specific fragments, arrowheads indicate the positions where the fragments are missing and $e'$, $\xi'$ etc. indicate novel fragments.
Figure 3.20

Autoradiographs of restriction digests of viral DNA $^{32}$P-labelled \textit{in vivo}. HpaI (lanes 1 to 4) and HindIII (lanes 5 to 8) digestion of HG52 (lanes 1 and 5), Rl92(17)E pl. 2 (lanes 2 and 6), Rl92(17)E pl. 5 (lanes 3 and 7) and JH2604 (lanes 4 and 8). Letters refer to specific fragments, arrowheads indicate the positions where fragments are missing and c', d' etc. indicate novel fragments.
0.025ml of virus was inoculated.
3 week old BALB/c mice were used.

<table>
<thead>
<tr>
<th>Recombinant</th>
<th>Number of deaths/number of animals inoculated</th>
</tr>
</thead>
<tbody>
<tr>
<td>R192(17)E 2.7</td>
<td>37:1 ND ND</td>
</tr>
<tr>
<td>R192(17)E 2.7</td>
<td>96:1 ND ND</td>
</tr>
<tr>
<td>R192(17)E 2.7</td>
<td>6:1 ND ND</td>
</tr>
<tr>
<td>H925 P1.17</td>
<td>71:1 ND ND</td>
</tr>
<tr>
<td>JH2604</td>
<td>ND ND ND</td>
</tr>
</tbody>
</table>

* ND not determined

Table 3.12. LD50 values after intracranial inoculation of the R192(17) recombinants
that of wild type. These results imply that the sequences within the 3 kb terminal portion of $R_L$ probably within BamHI $v$ are required for neurovirulence of HSV-2 strain HG52.

3.3.10 In vivo selection

The JH2604 deletion had been shown to be within the BamHI $v$ fragment (0-0.02 and 0.81-0.83 m.u.) (Harland and Brown, 1985) but we chose to correct or insert the deletion using large XbaI fragments because of the small size of the relevant BamHI fragment and the lack of a selection system. The position of the relevant BamHI, XbaI, HindIII and HpaI fragments is seen in Figure 3.21. Using the large XbaI fragments is open to the criticism that as well as replacing the deleted sequences, the recombinants could also have contained other sequences from the cotransfecting XbaI e or f and that the observed effect on neurovirulence was not due to the deletion but to a secondary mutation. To counter this argument, correction of the deletion by a small fragment BamHI g i.e $v$ (0.81-0.83 m.u.) + $u$ (0.83-0.85 m.u.) using an in vivo selection system in BALB/c mice was carried out. The strategy employed to correct the deletion using an in vivo selection system and isolation of recombinants was a modification of that described by Thompson et al. (1983) and is summarised in Figure 3.22. Since the variant JH2604 does not kill mice due to its lack of a biologically selectable marker i.e failure of replication in mouse brain, any deaths will be due to recombination of the JH2604 genome with a restriction endonuclease fragment of HG52 which displays the desired phenotype (neurovirulence) and the genotype of the recombinants can then be defined by restriction endonuclease analysis. In this study intact JH2604 genomes were
Structure of the HSV-2 strain HG52 genome (top line) showing $U_L$ and $U_S$ flanked by $TR_L/IR_L$ and $IR_S/TR_S$ respectively. The positions of the relevant BamHI, XbaI, HpaI and HindIII fragments are indicated.
Strategy employed for correction of the deletion in the variant JH2604 using *in vivo* selection in mice.
Intact JH2604 genomes

BamHI RE fragments from HG52

Amplification in culture (BHK-21 C13 cells)

Intracranial inoculation of mice

Isolation of virus from brain tissue

Reinfect mice (LD<sub>50</sub> values)

RE analysis

Plaque purification

RE analysis

Neurovirulence of the recombinants (LD<sub>50</sub> values)
cotransfected in BHK-21 C13 cells with different molar ratios (1, 5 and 10 fold) of the BamHI g fragment of the highly neurovirulent plaque 17 stock of HG52 (see section 3.1). When extensive cpe was apparent the cells were harvested, sonicated and the resulting virus suspension serially diluted. Twenty five ul was inoculated intracranially into the left cerebral hemisphere of 3 week old BALB/c mice (2 mice/dilution). By three days post infection, two mice had died, one inoculated with the virus from a transfection plate infected with a 10 fold molar excess of BamHI g and the other from a transfection with a 5 fold molar excess of BamHI g. The brain of the mouse inoculated with the products of the 10 fold BamHI g transfection plate was necrotic and could not be used. The brain of the other dead mouse was removed, homogenised and 0.2ml of the resulting suspension inoculated onto BHK-21 C13 cells in a 50mm petri-dish. The infected plate was harvested, the virus released by sonication and used to reinfect mice intracranially to determine its LD\textsubscript{50} value. This stock gave a LD\textsubscript{50} value of <10\textsuperscript{3} pfu/mouse. The DNA of the plate stock was subjected to restriction enzyme analysis and the HindIII and HpaI DNA profiles are shown in Figure 3.23. The analysis showed that the virus recovered from the brain (lanes 3 and 6) was a mixture of JH2604 (lanes 2 and 5) and HG52 (lanes 1 and 4). Therefore the plate stock of the virus recovered from the brain was titrated out on BHK-21 C13, separate plaques were picked, plate stocks from each were made and their DNA analysed by HindIII and HpaI digestion. Two plaque stocks that showed a HG52 profile were subjected to three rounds of stringent plaque purification and a stock of virus was grown from each after
Figure 3.23

 Autoradiographs of restriction digests of viral DNA \(^{32}\)P-labelled \textit{in vivo}. HpaI (lanes 1 to 3) and HindIII (lanes 4 to 6) digestion of HG52 (lanes 1 and 4), JH2604 (lanes 2 and 5) and virus recovered from the brain (lanes 3 and 6). Letters refer to specific fragments and stars indicate novel fragments.
the third round. The recombinants were designated recombinant 1 and 2. HindIII and HpaI DNA profiles of the two virus stocks are shown in Figure 3.24 and it can be seen that the two recombinant viruses (lanes 1, 2, 5 and 6) have DNA structures equivalent to the wild type HG52 (lanes 4 and 8) and not the deletion variant JH2604 (lanes 3 and 7). The two recombinant viruses were each inoculated intracranially into the left cerebral hemisphere of 3 week old BALB/mice at doses of $10^2$, $10^3$ and $10^4$ pfu/mouse (5 mice/dose) and their $LD_{50}$s determined. The results are shown in Table 3.13. It can be seen that for both recombinants, all infected mice died at a dose of $10^2$ pfu/mouse giving an $LD_{50}$ value for each of $<10^2$ pfu/mouse. Using the approach of in vivo recombinant selection HSV-2 function(s) associated with at least $10^6$ fold increase in neurovirulence have been localised. The fact that the two recombinants isolated contained the DNA region (BamHI g fragment) in both copies of the $R_L$ from the highly neurovirulent plaque 17 stock of HG52 demonstrate unequivocally that the sequences within BamHI g are required for JH2604 to restore its neurovirulence to the level of wild type virus.

3.4 Sequence analysis of the fragment containing the deletion in the variant JH2604

3.4.1 Size variability of the BamHI g (v + u) joint fragment of the variant JH2604

JH2604 had been shown to contain a deletion of approximately 1.5 kb in each copy of BamHI v fragment between 0-0.02 and 0.81-0.83 m.u. (Harland and Brown, 1985). It was initially thought that the deletion in both copies of BamHI v may not have been identical but that the variant had
Figure 3.24

Autoradiographs of restriction digests of viral DNA
$^{32}$P-labelled in vivo. HpaI (lanes 1 to 4) and HindIII
(lanes 5 to 8) digestion of recombinant viruses (lanes
1, 2, 5 and 6), JH2604 (lanes 3 and 7) and HG52 (lanes 4
and 8). Letters refer to specific fragments and stars
indicate novel fragments.
Table 3.13. LD<sub>50</sub> values after intracranial inoculation of the in vivo recombinants

<table>
<thead>
<tr>
<th>Virus</th>
<th>Virus dose (pfu)/animal</th>
<th>LD&lt;sub&gt;50 &lt;/sub&gt;(pfu/mouse)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>10&lt;sup&gt;2&lt;/sup&gt;</td>
<td>10&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>Recombinant 1</td>
<td>5/5</td>
<td>5/5</td>
</tr>
<tr>
<td>Recombinant 2</td>
<td>5/5</td>
<td>5/5</td>
</tr>
</tbody>
</table>

+ Number of deaths/number of animals inoculated.
3 week old BALB/c mice were used.
0.025ml of virus was inoculated.
lost at least 150 bp of equivalent sequences from both copies of \( R_L \). Therefore it was important to delimit the deletion and sequence the fragment spanning the deletion to know its exact location. BamHI digestion of JH2604 DNA shows that the BamHI \( g \) fragment \((v + u)\) is missing from its normal position and appears to run in two positions (1) just above the \( l \) fragment and (2) just above the \( m \) fragment (Figure 3.25). These two fragments were excised and purified from a 1.2% agarose gel (see method section 2.18), and cloned into the BamHI site of pAT153 plasmid (see method section 2.22). Two positive clones designated 22 and 28 were isolated. Southern blot analysis of a BamHI digest using nick translated intact HG52 genomes as the probe (see method section 2.28) showed hybridization to one band in clone 22 running just above the BamHI \( l \) fragment and one band in clone 28 running just above the BamHI \( m \) fragment (Figure 3.26). When clone 22 DNA was nick translated and used as a probe in Southern blots with BamHI digested DNA of HG52, JH2604, clone 22 and clone 28, it can be seen that; with HG52 there is positive hybridization to BamHI \( v \), \( u \) and \( g \); with JH2604 there is positive hybridization to \( u \) and to the two bands running coincidentally with BamHI \( l \) and \( m \). It is assumed that the small size of the deleted \( v \) fragment precludes its identification on this gel. With clones 22 and 28 there is hybridization to two bands, the lower one representing the pAT153 DNA and the upper one in each case the deleted BamHI \( g \) fragment running coincidentally with BamHI \( l \) and \( m \) respectively. The variation in the mobility of the fragments in clones 22 and 28 could be due to either (a) the deletion in each case being a different size or (b) variability in the copy number.
Figure 3.25

Autoradiographs of restriction digests of viral DNA $^{32}$P-labelled *in vivo*. BamHI digestion (1.2% agarose) of JH2604 (lane 1) and HG52 (lane 2). Letters refer to specific fragments, arrowheads indicate the positions where the fragments are missing and stars indicate novel fragments.
Figure 3.26

Autoradiographs of Southern blots containing BamHI restriction fragments of clone 28 (lanes 1 and 5), clone 22 (lanes 2 and 6), JH2604 (lanes 3 and 7) and HG52 (lanes 4 and 8) to which nick translated probes have been hybridised. The probes were the recombinant plasmid clone 22 (lanes 1 to 4) and HG52 DNA (lanes 5 to 8). Letters refer to specific fragments.
of the reiterated sets of sequences known to exist in this region of the genome (Davison and Wilkie, 1981).

3.4.2 Subcloning of BamHI g of the variant JH2604 into M13 bacteriophage and nucleotide sequencing

The wild type HG52 BamHI g fragment has been shown to be 5815 bp in length extending from IRs to IRL (D. J. McGeoch, unpublished results). There is a HincII site at nucleotide position 3053 within the 'a' sequence and a XhoI site at nucleotide position 5069 just upstream of the 5' end of the IE1 gene (Figure 3.27). Plasmids containing the JH2604 BamHI g inserts were cut with XhoI-HincII giving a fragment of 516 bp in size (2016 bp in the case of wild type BamHI g fragment) in both cases and the remainder of the BamHI g fragments were normal. This indicated that (1) the deletion in JH2604 was contained completely within the XhoI-HincII fragment, (2) the deletion as predicted from restriction endonuclease analysis was approximately 1.5 kb in size and (3) both copies of BamHI v contained a deletion with apparently identical end points and size.

These 516 bp fragments were ligated into the Smal-SalI sites of M13 mpl8 and mpl9 phage and the ligated DNA was transfected into E. coli strain JM101 (see method section 2.30). The nucleotide sequence of the M13 clones was determined by the dideoxynucleotide chain termination method (see method section 2.32). Sequencing of clones 22 and 28 showed homology to the wild type sequence, starting at the HincII site (3053) and continuing for 30 bp to nucleotide position 3083 (Figure 3.28). There is then a deletion of 1488 bp and homology starts again at nucleotide position 4571 and continues with no alteration to the XhoI site at
Figure 3.27

Structure of the HG52 genome (top line) showing $U_L$ and $U_S$ flanked by $TR_L/IR_L$ and $IR_S/TR_S$ respectively. The second line shows an expansion of the BamHI $g$ fragment (0.81-0.85 m.u.) which is 5815 bp. The position of the 'a' sequence and the transcript of the IEl gene is indicated. The bottom line shows the positions of HincII and XhoI sites within BamHI $g$. 


Figure 3.28

Portion of an autoradiograph of a 6% sequencing gel showing the cloning site (3053) within the 'a' sequence and the start (3083) and end (4571) of the deletion in JH2604. Sequencing products were separated on denatured polyacrylamide gels (Sanger et al., 1980) containing 9M urea (McGeoch et al., 1986).
The deletion includes one copy of the 17 bp direct repeat (DRl) element of the 'a' sequence, AGTCCCCGTCCCTGCCGC and four copies of a 19 bp sequence, CCCCTCCGACCCCCCTGACG starting at position 3771 (D. McGeoch, unpublished results). The deletion terminates 522 bases upstream of the 5' end of the IEl gene.

Sequence analysis showed that the nucleotide sequences deleted, and hence the size of the deletion in both clones 22 and 28 were identical indicating that the difference in the mobility of the remnant of BamHI g in each clone was due to variable copy numbers of the reiterated sequences outwith the deleted region.

HincII also cuts BamHI g at nucleotide position 1237 within BamHI u. XhoI in addition to cutting BamHI g at 5069 cuts within BamHI u at nucleotide position 1769 (Figure 3.27). This 532 bp sequence within BamHI u was sequenced and shown to be identical to that of HG52 with no point mutations, deletions or insertion. In total 2548 bp of the JH2604 BamHI g fragment have been sequenced and shown to be identical except for the deletion. However a point mutation within the remaining 3267 bp can not be excluded.

It is concluded from the nucleotide sequence analysis and the in vivo studies that the sequences within the 1488 bp fragment located between 0-0.02 in TR₈ and 0.81-0.83 m.u. in IR₈ of HSV-2 strain HG52 confer neurovirulence for BALB/c mice. The analysis clearly demonstrates a function in vivo for the deleted sequences which may suggest that the region is protein coding.

3.5 Neuropathology

In order to study the morphological changes produced by
the elite stock of HG52 and the variant JH2604 and the
distribution of the viral antigens in mice brains,
experiments were carried out in 3 week old BALB/c mice.
Mice were inoculated intracranially into the left cerebral
hemisphere (see method section 2.11) with virus stocks ($10^5$
pfu/mouse) and at 0, 24, 48, 72, 96, 120, 144, and 168 h
post infection, two surviving mice from each time point were
sacrificed and their brains were removed and processed for
histopathology and immunohistochemistry (see method sections
2.35 and 2.36). Two mice were inoculated intracranially
with PBS/calf serum as a control.

3.5.1 Macroscopic examination of brains infected with
JH2604 and HG52

In 20% of the brains it was possible to identify the
site of intracranial inoculation over the lateral aspect of
the left cerebral hemisphere. There were no intracranial
complications and in particular there was no evidence that
the intracranial pressure had been high during life.

3.5.2 Microscopic examination of paraffin sections of brains
infected with JH2604 and HG52

For the controls, they were normal and there was no
evidence of inflammation, hydrocephalus or intracranial
herniation (Figure 3.29). The nature and severity of
neurohistological changes in the brains inoculated with
either HG52 or JH2604 are shown in Table 3.14. At 24 h post
infection, all the mice brains inoculated with either the
elite stock of HG52 or JH2604, showed a mild degree of
lymphocytic infiltration of the meninges. This infiltration
was most conspicuous at the base of the brain. In all other
Figure 3.29

Paraffin embedded section of normal mouse brain. Figure shows normal white matter H & E X430.
<table>
<thead>
<tr>
<th>Virus</th>
<th>Hydrorhaphus</th>
<th>Brachygnathus</th>
<th>Euphalaga</th>
<th>Tympanitic</th>
<th>Lympnhoctytic</th>
<th>Survivial</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>(Cd) +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>(Cd) +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>(Cd) +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>(Cd) +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>(Cd) +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>(Cd) +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+</td>
<td>(Cd) +</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3.14: Nature and Severity of Neurorhaphagia changes in brains inoculated with the elite stock of HG52 and JH2604.
aspects the brains looked normal and there was no evidence of hydrocephalus. At 48 h post infection, the brains inoculated with HG52 showed abnormality limited to a mild lymphocytic infiltration of the basal meninges. In contrast, the brains inoculated with the variant JH2604 showed in addition to the basal meninges, focal infiltration of the walls of the third ventricle by lymphocytes and an associated mild enlargement of the ventricular system. By 72 h post infection, the brains inoculated with HG52 showed small foci of necrotising encephalitis in the internal capsule and thalamus of the left cerebral hemisphere. Even though these lesions appeared to be associated with the site of inoculation, their absence in the earlier time points clearly indicated a response by the brain to the inoculation. By 96 h post infection, however, the lesions were larger and bilateral (Figure 3.30), affecting both grey and white matter. Within these areas there was focal necrosis of all neurons and glia, vacuolation of the white matter, swelling of the related astrocytes and a mild infiltration by neutrophil polymorphs. Some of the related blood vessels appeared to be highly cufféd by macrophages. There was also a moderate amount of lymphocytic infiltration of the basal meninges.

In contrast, the changes in the cerebral hemisphere of the brains infected with JH2604 at 72 h and 96 h post infection were different in that there was no evidence of necrotising encephalitis, even at the site of inoculation. There was, however, an encephalitis with mild cuffing of small vessels, largely by lymphocytes, but also with occasional macrophages (Figure 3.31). This perivascular cuffing was limited to the site of inoculation and was
Paraffin embedded section of mouse brain inoculated intracranially with HSV-2 strain HG52 96 h post infection. Figure shows focus of acute necrotising encephalitis in which there is a vacuolation of the neuropile, necrosis and fragmentation of glia with mild infiltration by lymphocytes and neutrophil polymorphs H & E X430.
Paraffin embedded section of mouse brain inoculated intracranially with the deletion variant JH2604 96 h post infection. The figure shows localised infiltration of lymphocytes and macrophages, and perivascular cuffing of blood vessel. In contrast to Figure 3.30 notice the complete absence of necrosis H & E X430.
associated with a mild basal lymphocytic meningoencephalitis and a marked focal infiltration at the ependymal wall by lymphocytes. There was evidence of mild hydrocephalus. At 120 h and 144 post-infection, the extent of histological changes in both R557 and R555 infected brains remained unchanged though the amount increased over time. For example, in R557 infected brains there were multiple foci of necrotizing encephalitis widely scattered throughout the brain. In the brains infected with R555, the changes were more focal at the ependymal surface similar to those noted in earlier time points. These changes consisted of widely distributed and perivascular cuffing by lymphocytes. In R555 infected brains, there was a variable but moderate amount of inflammatory reaction of the basal meninges and an extension of the inflammatory process from the meninges along the leptomeningeal vessels. In this latter site there was also mild and reactive astrocyta response, but no evidence of neuronal involvement. There was
associated with a mild basal lymphocytic meningitis and a marked focal infiltration of the ventricular walls by lymphocytes. There was evidence of mild hydrocephalus. At 120 h and 144 post infection, the nature of histological changes in both HG52 and JH2604 infected brains remained unchanged though the amount increased over time. For example, in HG52 infected brains there were multiple foci of necrotising encephalitis widely scattered throughout the grey and white matter of both the cerebral hemispheres and hindbrains. By 122 h post infection, the changes were more easily seen with considerable proliferation of microglia, macrophage formation and a sprinkling of neutrophil polymorphs. There was also both hypertrophy and hyperplasia of astrocytes. Oligodendroglia were difficult to recognise and there was vacuolation of myelinated fibers. There was a small amount of perivascular cuffing by lymphocytes, changes that were also seen in relation to the walls of the ventricular system. There was a mild degree of hydrocephalus and small numbers of lymphocytes were present in the basal meninges. Similar foci of necrosis were also seen in the brain stem and cortex of the cerebellum.

The changes in the brains infected with JH2604 at 120 h and 144 h post infection were different from HG52 though similar to those noted at earlier time points in this study. These changes consisted of widely distributed foci of perivascular cuffing by lymphocytes. In addition, there was a variable but moderate amount of lymphocytic infiltration of the basal meninges and an extension of this inflammatory process from the meninges along the intracortical vessels. In this latter site there was also glial and astrocytic response, but no evidence of neuronal necrosis. There was
also perivascular infiltration by lymphocytes and all brains had developed a moderate degree of hydrocephalus. By 168 h post infection, only the brains inoculated with JH2604 were available since no mice had survived at that time point with HG52. The changes were similar to those described earlier. The only possible quantitative change was an increased amount of perivascular infiltration by lymphocytes which resulted in a moderate degree of ventricular enlargement.

3.5.3 Immunohistochemistry of paraffin sections of brains infected with JH2604 and HG52

In control brains there was no evidence of staining in various cell types of the brain, its meningeal covering or the ependymal lining of the ventricles (Figure 3.32). In the brains infected with HG52 at 24 h and 48 h post infection, positive staining was seen in some astrocytes along the line of inoculation as well as in some of the ependymal cells of the third ventricle. Similar changes were seen in the JH2604 infected brains in which positive staining was limited to the immediate vicinity of the site of inoculation and one or two ependymal cells in the wall of the third ventricle. By 96 h post infection the HG52 infected brains showed a positive staining of astrocytes not only to the site of inoculation, but also in and around the foci of necrotising encephalitis (Figure 3.33). Some of the staining appeared to be intranuclear and intracytoplasmic but where the cells had undergone necrosis, chromagen appeared to be extracellular. Prior treatment with trypsin removed much of the staining from the foci of necrosis but left positive staining in what appeared to be both astrocytes and nerve cells. Apart from staining of a few
Figure 3.32

Paraffin embedded section of normal mouse brain immunostained with avidin biotinylated horseradish peroxidase rabbit anti-HSV 1:100. Notice the complete absence of staining in the white matter X430.
Figure 3.33

Paraffin embedded section of mouse brain inoculated intracranially with HSV-2 strain HG52 96 h post infection and immunostained with avidin biotinylated horseradish peroxidase rabbit anti-HSV 1:100. Positive staining (brown) is seen in both viable and necrotic nuclei and extracellularly in the neuropile X430.
opandyval cells, there was no positive staining elsewhere in the forebrain. There was, however, positive staining of both Purkinje cells and related reactive astrocytes in the 
fovea of early necrosis within the tissue of the cerebellum.

The changes in JAVS infected tissues at 72 h and 96 h post infection were different, positive staining being limited to astrocytes in the immediate vicinity of the site of inoculation (Figure 7.3). A few exceptional cells in the
ependymal cells, there was no positive staining elsewhere in the forebrain. There was, however, positive staining of both Purkinji cells and related reactive Bergmann glia in foci of early necrosis within the cortex of the cerebellum.

The changes in JH2604 infected brains at 72 h and 96 h post infection were different, positive staining being limited to astrocytes in the immediate vicinity of the site of inoculation (Figure 3.34), a few ependymal cells in the wall of the third ventricle and related subependymal astrocytes. There was no evidence of staining of neuronal cells, either within the forebrain or hindbrain. The remainder of the brain appeared normal. The patterns of positive staining in the brains infected either with HG52 or JH2604 at 120 h and 144 h post infection were different but similar to those identified in the earlier time points. In the HG52 infected brains, it was possible to see positive staining in the astrocytes and nerve cells in the immediate vicinity of the foci of necrotising encephalitis in both forebrain and cerebellum.

These results clearly demonstrated that the variant JH2604 is restricted in its growth in brain cells especially in neuronal cells.
Paraffin embedded section of mouse brain inoculated with the deletion variant JH2604 96 h post infection and immunostained with avidin biotinylated horseradish peroxidase rabbit anti-HSV 1:100. Positive staining (brown) is limited to astrocytes along the line of inoculation X430.
DISCUSSION

The aim of this thesis was to identify gene(s) involved in neurovirulence of HSV-2 strain HG52 in the mouse model system by analysis of the effect in vivo of deletion variants of the virus. Before studying biological properties such as latency and virulence of defined deletion variants in an animal model system, it is essential to determine the phenotype of the parental wild type virus in the system under study. Therefore we have evaluated the neurovirulence of individual plaque stocks isolated from the elite laboratory stock of HG52 to determine the baseline from which to evaluate the neurovirulence of the HG52 deletion variants.

The ten individual stocks isolated from the elite stock of HG52 showed differences in their LD$_{50}$ values following intracranial inoculation of 3 week old BALB/c mice. On the basis of the LD$_{50}$ values compared with that of the elite stock of HG52, the plaque stocks were subdivided into three classes of neurovirulence; low with a LD$_{50}$ value $>10^5$ pfu/mouse, intermediate with a LD$_{50}$ value $10^3-10^4$ pfu/mouse and high with a LD$_{50}$ value of $<10^3$ pfu/mouse. None were designated as avirulent. The difference between low and high virulence stocks is over 3 logs. The same differences in the LD$_{50}$ values between high and low virulence stocks were seen using the intraperitoneal route of inoculation. Although HG52 showed a normal dose response curve following intracranial inoculation, the inversion of the dose response curve following intraperitoneal inoculation was unexpected. This inversion of the HG52 dose response curve is an observation which is specific for HSV-2 strain HG52, since
HSV-1 strain 17 showed a normal dose response curve. The reason for the inversion is unclear and is possibly due to the intraperitoneal route of inoculation. It has been shown that intraperitoneal infection with HSV-2 is an excellent inducer of macrophage phagocytosis activity in mice (Armerding et al., 1981). The activated macrophages, possibly induced by the local IFN generated or by the virus infection alone, might be required for resistance to an intraperitoneal infection. Injecting a high dose of virus intraperitoneally could result in activation of more macrophages and production of high levels of IFN which may result in resistance to infection. Although this explanation might be correct for a high infectious dose, it does not fit with the lower dose of virus.

Passaging of the single plaque stocks in vitro at 37°C showed in some cases a shift from high to intermediate virulence whereas the phenotype of low virulence was generally retained after repeated passage at 37°C. The shift from high to intermediate virulence could result from the presence of a mixture of the three classes of virulence in the high virulence stocks, despite their plaque purification. Therefore, in an in vivo experiment, the score would be for high virulence. When the high virulence stocks were passaged in vitro i.e. in the absence of in vivo selection pressure they segregated into the three virulence classes. This explanation has been supported by the virulence heterogeneity of high virulence stocks during cotransfection experiments which will be discussed later.

Thompson and Stevens (1983a), using 4–6 week old Swiss Webster mice, found the LD$_{50}$ value of the elite stock of HG52 to be $10^4$ pfu/mouse following intracranial inoculation.
Five plaques were isolated and stocks from these passaged four times at 31°C or 37.5°C. Those passaged at 31°C retained their low virulence, however, after passage at 37.5°C, virulence increased in four cases and in one case remained low. Similar findings have also been observed in HSV-2 strain Curtis (Thompson and Stevens, 1983a). It is clear from these findings that there is virulence heterogeneity within HSV-2 stocks, a finding we have now clearly confirmed, quantitated and extended. As Thompson and Stevens (1983a), showed the effect of temperature on selection of virulent HSV-2 stocks, Goodman and Stevens (1986) have demonstrated that passage of HSV-1 strain 17 in vitro in chick embryo fibroblast cells enhanced the virulence of the virus for chick embryos in vivo suggesting that in vitro passage of HSV potentiated, rather than attenuated virulence. In our hands, there was no such effect of temperature and passage in vitro on virulence of HSV-2 strain HG52. Our findings are similar to those reported in PRV by Lomniczi et al. (1984).

Restriction endonuclease analysis of the DNAs of the isolated plaque stocks was carried out at different passage numbers using a range of restriction enzymes and no differences were seen in the size and distribution of fragments. In addition, the DNAs of virus stocks reisolated from mice brains retained their original restriction endonuclease profiles. Restriction endonuclease analysis however can not detect point mutations or small changes (deletions/insertions <150 bp) in the viral genome which could be possible sources of variation in the biological behaviour of the virus in vivo. The particle : pfu ratios of the plaque stocks can not be evoked to explain the
differences in biological behaviour. Using the two criteria of restriction endonuclease profile and particle: pfu ratio, all of the ten plaque stocks used to infect animals were classified as wild type.

The replication kinetics of the individual plaque stocks have shown that the observed difference in neurovirulence was due to inefficient replication in mouse brain in vivo as the plaque stocks 17 and 14 (high virulence) replicated with kinetics similar to the elite stock of HG52, while plaque stock 8 (low virulence) replicated poorly (see Figure 3.4). The replication capacities of plaque stocks 17 and 14 in mouse brain were specific for brain tissue as they did not show differential replication kinetics in vitro in BHK-21 C13 cells. Therefore, the restriction of the growth of the low virulence stock appeared to be specific and not generalised. The results obtained with individual plaque stocks clearly demonstrate that the laboratory strain HG52 is heterogeneous with respect to neurovirulence in mice. HG52 is not unique in this respect as it has been shown that both virulent and avirulent stocks of HSV-1 strain KOS exist (Dix et al., 1983). Although the elite stock of HG52 was initially derived by rigorous plaque purification of a patient isolate, it is heterogeneous not only in terms of neurovirulence, but also contains a proportion of viable virus with aberrant genomic structures comprising at least 24% of the population (Harland and Brown, 1985; 1988; Brown and Harland, 1987).

The basis for the variation in an important biological property is unclear but one possible reason is the presence of point mutations, deletions and/or insertions in the genome which can not be detected by restriction endonuclease
analysis. Such changes in the viral genome might affect any of the stages in the viral replication. Our results emphasise the importance of working with well characterised parental virus when assessing the biological behaviour of mutants.

Having confirmed the heterogeneity within HG52, the plaque stock 17 has been used as the prototype virus and its LD<sub>50</sub> value has been taken as the baseline from which to evaluate the neurovirulence of the deletion variants.

The nervous system is a critical target for HSV infection. The relationship between HSV and the peripheral nervous system is usually benign in that the virus remains latent in the neurons of dorsal root ganglia from which it reactivates intermittently. However, when HSV invades the central nervous system the likely outcome is a fatal encephalitis. It is therefore important to determine those genes of HSV which predispose it to invade and destroy nervous tissue. Viral genes controlling neurovirulence have only been identified recently and various laboratories have predominantly implicated the viral sequences between 0.7-0.83 m.u. (Thompson and Stevens, 1983b; Thompson et al., 1985; Rosen et al., 1986; Javier et al., 1987). This region contains the whole of IR<sub>L</sub> and part of UL and the genes encoded therein are one copy of IEl and UL50 to UL56 (Clements et al., 1979; Whitton et al., 1983; Perry et al., 1986; McGeoch et al., 1988). The mapping of virulence genes has come from the analysis of intertypic HSV recombinants constructed between low an high virulence strains of HSV using cloned viral fragments (Thompson et al., 1983; 1985). Deletion variants more readily allow defined regions of the genome to be studied for their neurovirulence properties.
The deletion variants analysed in this study have deletions ranging from 1.5 kb to 9 kb in the TR/L/IRL and US/TRS regions of the genome. All the deletion variants had reduced pathogenicity for mice following intracranial inoculation and depending on their LD\textsubscript{50} values they fell into three classes of neurovirulence with LD\textsubscript{50} values ranging from 10\textsuperscript{4}\textendash 10\textsuperscript{7} pfu/mouse. The variants deleted in the US/TRS regions are JH2607, JH2608, JH2609, JH2610 and JH2611. The size and extent of the deletion in these variants relied mainly on restriction endonuclease and Southern blot analysis (Brown and Harland, 1987). As no sequence data was available at the time of their isolation, the exact sequences deleted in each variant remains unresolved at present making the interpretation of the neurovirulence results slightly difficult.

The variants JH2607, JH2608 and JH2609 had LD\textsubscript{50} values of 10\textsuperscript{4}, 2.5\times10\textsuperscript{5} and 10\textsuperscript{5} pfu/mouse respectively and the feature they have in common is the loss of the US10, US11 and US12 genes. These LD\textsubscript{50} values are at least 3 logs higher than the HG52 plaque 17 LD\textsubscript{50} value (<10\textsuperscript{2} pfu/mouse) implying a role for the US10, US11 and US12 genes either individually or cummulatively in neurovirulence. In addition the variant JH2607 has lost one copy of the IE3 gene and one copy of ori\textsubscript{S} and comparing its LD\textsubscript{50} value (10\textsuperscript{4} pfu/mouse) with those of JH2608 (2.5\times10\textsuperscript{5} pfu/mouse) and JH2609 (10\textsuperscript{5} pfu/mouse) indicated that the deletion of one copy of the IE3 gene and one copy of ori\textsubscript{S} had no effect on neurovirulence. The LD\textsubscript{50} values of the variants JH2608 and JH2609 are comparable (2.5\times10\textsuperscript{5} and 10\textsuperscript{5} pfu/mouse respectively). The additional changes in the genomes of JH2608 and JH2609 compared to JH2607 are extension of the
short repeat regions by 6 kb on either side as well as loss of the XbaI site at 0.91 m.u. in the variant JH2609 (Brown and Harland, 1987). The common features of the variants JH2609, JH2610 and JH2611 are the loss of XbaI sites at 0.7 and 0.91 m.u. (Brown and Harland, 1987). In addition the variant JH2611 has lost the XbaI sites at 0.45 and 0.94 m.u. (Brown and Harland, 1987). The DNA sequences around the XbaI sites at 0.45, 0.7 and 0.94 m.u. are not known for HSV-2, but in HSV-1 these sites lie within UL33, between UL49 and UL50 and in the intergenic region of US9 and US10 respectively (McGeoch et al., 1985: 1988). The DNA sequences around 0.91 m.u. in HSV-1 lie within the US4 gene, encoding gG (McGeoch et al., 1985). The glycoprotein gG in HSV-2 strain HG52 is encoded by the US4 gene. The XbaI site at 0.91 m.u. lies within the coding region of the gene (McGeoch et al., 1987). It has been shown that in the variants JH2610 and JH2611 neither gG-2 nor its precursor were synthesised, but two polypeptides migrating above the normal positions of gG-2 and its precursor were made, while the variant JH2609 failed to synthesise gG-2 or its precursor showing that gG-2 is not essential for virus growth in vitro (Harland and Brown, 1988). The variants JH2609, JH2610 and JH2611 had reduced pathogenicity for mice following intracranial inoculation having \(LD_{50}\) values of \(10^5\), \(4.2 \times 10^6\) and \(5 \times 10^4\) pfu/mouse respectively. These \(LD_{50}\) values are much higher than the \(LD_{50}\) value of the elite stock of HG52 (<\(10^2\) pfu/mouse), indicating the importance of gG-2 in neurovirulence. These results are consistent with the findings of Meignier et al. (1988) which showed that a gG\(^{-}\) mutant of HSV-1 strain F had reduced pathogenicity for mice.
Generally, the variants deleted in the U$_S$/TR$_S$ regions were shown to be temperature restricted at 38.5°C (Brown and Harland, 1987), so we can not rule out this growth disadvantage from contributing to reduced neurovirulence although Javier et al. (1988a) have shown that neurovirulence functions are independent of high titre virus replication in mouse brain.

The variants with deletion in IR$_L$/TR$_L$ were shown to grow normally in tissue culture in BHK-21 C13 cells (Harland and Brown, 1985). It has been shown that the IR$_L$ region of the HSV-1 strain 17 genome (Figure 4.1) contains the IE1 gene between 0.785-0.81 m.u. (Perry et al 1986) and the LAT transcripts between 0.782-0.796 m.u. running in the opposite orientation to the IE1 gene (Wagner et al., 1988; Perry and McGeoch, 1988). In HSV-1 strain F a gene has been proposed which codes for a polypeptide designated ICP34.5 in the same orientation as the IE1 gene (Chou and Roizman, 1986). Again, restriction endonuclease analysis and until recently the lack of sequence data for this region in the HG52 genome has not allowed precise determination of the extent of the deletions. The IE polypeptide analysis of the variant JH2603, whose genome is deleted by 3.75 kb in IR$_L$, showed a reduction in the amount of VmwIE18 synthesised in infected cells, supporting the conclusion that only one copy of the coding region of VmwIE18 had been deleted (Harland and Brown, 1985). Although the LAT transcripts have recently been identified in HSV-1 (see section 1.9), their existence in HG52 is under analysis. If they exist in the same positions as those identified in HSV-1, theoretically the deletion in JH2603 would remove one copy of the LAT transcripts in IR$_L$. The deletion in JH2605 is 5.5 kb, is
Gene organization of $\text{IR}_L$ in HSV-1 strain 17. The top line shows the $U_L$ (dotted line), $\text{IR}_L$ (open box), 'a' sequence (solid box) and $\text{IR}_S$ (dotted open box). Locations of the coding regions of genes (open boxes) and orientations of transcripts (arrows) for IEl (Perry et al., 1986), LAT (Wagner et al., 1988) and proposed ICP34.5 in strain F (Chou and Roizman, 1986) are indicated.

The minor LAT (Mitchell et al., 1990) is indicated by dotted arrow.
confined to IR\textsubscript{L} and removes the BamHI \( f/p \) site at 0.775 m.u. (Harland and Brown, 1985). Whether the deletion affects VmwIEll8 synthesis is unresolved. The deletions in the variants JH2603 and JH2605 may involve the UL\textsubscript{L}/IR\textsubscript{L} junction. The UL\textsubscript{L} gene adjacent to the UL\textsubscript{L}/IR\textsubscript{L} junction in HSV-1 strain 17 is UL56 (McGeoch et al., 1988) and it has already been implicated in intraperitoneal pathogenicity in tree shrews (Rosen et al., 1986) and mice (Becker et al., 1986). The deletion in the variant JH2606 is 9 kb in length and removes the UL\textsubscript{L}/IR\textsubscript{L} junction, the BamHI \( f/p \) site at 0.775 m.u., the total coding region for VmwIEll8 (Harland and Brown, 1985) and possibly the LAT transcripts. As in JH2603 and JH2605, there is also a possibility that UL56 is removed from the variant JH2606. The variant JH2604 which is deleted by 1.5 kb in both the TR\textsubscript{L} and IR\textsubscript{L} copies of BamHI \( v \) between 0-0.02 and 0.81-0.83 m.u. is the only variant in which IE polypeptide synthesis is not affected (Harland and Brown, 1985).

All the deletion variants in TR\textsubscript{L}/IR\textsubscript{L} had reduced pathogenicity for mice following intracranial inoculation with LD\textsubscript{50} values ranging from \( 10^4 \) to \( >10^7 \) pfu/mouse compared to \( <10^2 \) pfu/mouse for HG52. Therefore the variants were at least 3 logs and at most 6 logs less neurovirulent than the elite stock of HG52. These results imply that the genes in the IR\textsubscript{L} region of HG52 genome are important in the control of neurovirulence. Although the variants JH2603 and JH2606 had lost one copy of the IE1 gene, they still produced disease in mice. Recently Clements and Stow (1989) have shown that the mutant dll403, which contains a 2 kb deletion within both the TR\textsubscript{L} and IR\textsubscript{L} copies of the IE1 gene (Stow and Stow, 1986), had reduced virulence for mice following
intracranial and footpad inoculation.

The precise role of the LAT transcripts in latency is unresolved but their deletion results in impairment of virus reactivation from explanted latently infected ganglia (see section 1.9). Their role in neurovirulence is not yet known. However, preliminary latency experiments of the IR_L/TR_L deletion variants showed that all the variants were capable of establishing latent infection in dorsal root ganglia of mice, but they were impaired to a different extent in reactivation from latent infection (G.B. Clements, personal communication).

The variant JH2604, whose genome is deleted by 1.5 kb in both copies of the BamHI v fragment, was avirulent for mice with a LD_{50} value >10^7 pfu/mouse compared to <10^2 pfu/mouse for HG52 implicating the sequences between 0-0.02 and 0.81-0.83 m.u. in neurovirulence. As the DNA sequences between 0-0.02 and 0.81-0.83 m.u. deleted in JH2604 appeared to be important in neurovirulence and since no potential ORF has been clearly identified in this region in HSV-1 strain 17 or in HSV-2 strain HG52, it was important to characterise this variant in detail. It was calculated from restriction endonuclease analysis and Southern blot data that the variant JH2604 had a 1.5 kb deletion in both copies of the BamHI v fragment between 0-0.02 and 0.81-0.83 m.u. in TR_L and IR_L respectively (Harland and Brown, 1985). As no sequence data for this region of HG52 was available at the time of its isolation, the size and location of the deletion relied on restriction endonuclease and Southern blot analysis. It was thought that the same sequences were deleted from each copy of the BamHI v fragment but the size of the deletion (1.5 kb) and the size of the BamHI v
fragment (3 kb) did not preclude the deletion in each copy
being at least in part contiguous (Harland and Brown, 1985).

We have demonstrated that the variant JH2604 is
avirulent for 3 week old BALB/c mice on intracranial
inoculation with a LD\textsubscript{50} value $>10^7$ pfu/mouse compared to
$<10^2$ pfu/mouse for plaque stock 17. It also failed to kill
any mice following footpad inoculation at doses of $10^6$, $10^7$
and $10^8$ pfu/mouse giving a LD\textsubscript{50} value $>10^8$ pfu/mouse. In
protection experiments, JH2604 failed to produce zosteriform
spread of disease in mice following flank inoculation and
those mice were protected following the inoculation of a
lethal challenge of the HG52 elite stock by the same route
of inoculation (B. Rouse, personal communication to S.M.
Brown). The variant JH2604 and its parental HG52 grew
equally well in BHK-21 C13 cells at 37°C and is no more
temperature restricted at 38.5°C than HG52 (J. Harland,
personal communication). However, JH2604 failed to grow in
mouse 3T3 cells at both 37°C and 38.5°C, but as the elite
stock of HG52 also showed poor replication in these cells,
the apparent lack of growth of JH2604 is not significant.
It has recently been shown that using mouse 3T6 cells,
JH2604 grew as well as the HG52 elite stock (A.R. MacLean,
personal communication) and that the restriction in 3T3
cells was specific for this particular clone of cells and
not for mouse cells per se.

Of significance is the finding that JH2604 does not
replicate \textit{in vivo} in mouse brain. The elite stock of HG52
grows efficiently within the brain at the accepted ambient
mouse temperature of 38.5°C, reaching peak titres by 120 h
post infection with all the infected animals dying by 144 h
post infection. JH2604 showed some replication by 12 h and
24 h post infection, but by 48 h post infection the amount of infectious virus recovered from brains was over 1 log unit lower than the input virus measurable immediately post absorption. The growth kinetics of JH2604 in vivo in mouse brain and in vitro in BHK-21 C13 and 3T6 cells imply that JH2604 is specifically restricted in neural tissue and not generally restricted in murine or other cell types. These findings have been supported by neuropathological and immunohistochemical studies of brains infected with JH2604 and the elite stock of HG52.

The results of neuropathological studies showed a fundamental difference in the histopathological appearance of the two types of lesion produced by JH2604 and the wild type virus. The wild type virus being characterised by disseminated widely distributed foci of necrosis throughout the brain with minimum associated inflammatory cell response. In contrast to these changes, the microscopy of the brains infected with JH2604 was strikingly different with complete absence of necrotising encephalitis even at the site of inoculation. However, the lesion was characterised by perivascular cuffing of small vessels by a combination of lymphocytes and macrophages, these changes being limited to the site of inoculation or the ependymal lining of the ventricles. A probable consequence of the ependymitis that characterised the variant JH2604 was the development of hydrocephalus, a feature that was more often and readily seen in the JH2604 infected brain compared with the parental HG52. The hydrocephalus was probably due to a narrowing of cerebrospinal fluid pathways due to a combination of desquamating debris and the marked inflammatory cell infiltration, an appearance described
previously in HSV-1 infected mice (Hayashi et al., 1986). The distribution of the virus in the brain was determined by immunohistochemical studies which reflected the histological identification of the pathological process in the brains of infected animals. In JH2604 infected brains there was a positive staining (viral antigens) limited to astrocytes in the immediate vicinity of the site of inoculation with a few ependymal cells in the wall of the ventricular system. In contrast, HG52 infected brain showed a wide distribution of positive staining in neurons and astrocytes. These results confirmed that JH2604 has a blockage in its replication in neural cells. In the absence of JH2604 replication, the infiltrating lymphocytes and neutrophil polymorphs are hypothesised to clear the remaining input virus from the brain.

The mechanism by which a deletion of 1.5 kb in the JH2604 genome resulted in failure of replication in the central nervous system is not clear. The function of the deleted sequences is unlikely to be involved in attachment, penetration or uncoating because JH2604 is capable of establishing and reactivating from a latent infection in mice (G.B. Clements, personal communication), therefore JH2604 must be capable of entering neurons and expressing some of its genes despite the lack of growth in neural tissue. In this respect, Steiner et al. (1990) have recently shown that HSV-1 mutant in Vmw65 TIF (Ace et al., 1989) can establish latent infection in mice following eye infection in the absence of viral replication. Similar findings have also been observed in the avirulent RE6 (Thompson et al., 1989). The possible functions of deleted sequences might affect gene expression at one or more of
several stages; transcription, translation, DNA synthesis, packaging or encapsidation. Evidence of lower efficiency of translation in an attenuated poliovirus, which contains a mutation in the 5' non-coding region of its RNA that resulted in attenuated virus which failed to replicate in the mouse brain (LaMonica et al., 1987), has been reported (Svitkin et al., 1985).

It has been shown that viral encoded TK modulates virulence, since HSV without this enzyme is relatively non-neurovirulent. The TK phenotype of the variant JH2604 was indistinguishible from that of the parental HG52. The non-neurovirulence and lack of growth in mouse brain is therefore not a result of the virus lacking TK.

In order to determine the role of genomic information in the regions between 0-0.02 and 0.81-0.83 m.u. in neurovirulence, cotransfection experiments were carried out. The intact JH2604 DNA was cotransfected with the XbaI fragments of HG52 plaque stock 17 DNA containing sequences deleted from JH2604. The isolation of the recombinants, in which the deleted sequences had been replaced by equivalent sequences from the XbaI fragments, enabled the determination of whether the replaced sequences had a direct effect on neurovirulence. From 28 mice infected with R17(192)E pl. 8, the LD$_{50}$ value of the recombinant was calculated to be $2 \times 10^5$ pfu/mouse; from 40 mice infected with R17(192)E pl. 14, $1 \times 10^3$ pfu/mouse; from 28 infected with R17(192)E pl. 15, $3 \times 10^5$ pfu/mouse and from 46 infected with R17(192)F pl. 10, $3 \times 10^5$ pfu/mouse. These values are within the range of LD$_{50}$ values for individual plaque stocks of HG52 (see Table 3.1). There are two possibilities to explain the range of LD$_{50}$ values obtained with the recombinants, in which the deletion
has been corrected, either (i) there is another mutation outside the regions between 0-0.02 and 0.81-0.83 m.u. which precludes successful rescue of neurovirulence functions or (ii) the DNA stock of plaque 17 used for cotransfection produced virus which was heterogeneous with respect to neurovirulence. The latter was shown to be the case when five plaques picked from transfected plaque stock 17 DNA, showed LD$_{50}$ values ranging from <10$^2$ to >10$^4$ pfu/mouse (see Table 3.11). However, the deaths of 10/33 animals infected with Rl7(192) recombinants at a dose of 10$^5$ pfu/mouse and 10/15 with 10$^6$ pfu/mouse compared to 0/12 with 10$^5$ pfu/mouse, 0/12 with 10$^6$ pfu/mouse and 2/18 with 10$^7$ pfu/mouse of JH2604 point to the avirulent phenotype having been corrected by replacement of the deleted sequences within both copies of the BamHI v fragment or the exchange of sequences within the remainder of the XbaI e fragment (this will be discussed later). It obviously would have been more critical to correct the deletion in JH2604 by cotransfection with the BamHI q joint fragment (v + u) of HG52 plaque 17 DNA, but because this fragment is so small (4x10$^6$ Mr) and no selection system was available, we initially chose, to facilitate recombination by using large XbaI fragments.

The isolation of two recombinants in which the deletion in JH2604 has been introduced back into the HG52 plaque stock 17 genomes allowed the determination of how the reciprocal recombinants behaved following inoculation of mice. Intracranial inoculation of 18 mice with each recombinant produced an LD$_{50}$ value of >10$^7$ pfu/mouse in each case. This is identical to the LD$_{50}$ value determined from 42 animals infected at the same time with JH2604. These
results provided substantive evidence that the sequences deleted in JH2604 are involved in the determination of neurovirulence of HSV-2 strain HG52.

The possibility that Rl7(192) recombinants might contain other sequences from the contransfecting XbaI fragment of the plaque 17 stock of HG52 and the implication that besides the deleted sequences, the sequences within XbaI e and f were not equivalent in HG52 plaque 17 and JH2604 and that the observed effect on neurovirulence was not due to the deletion but to some other mutation, was tested. The deletion in the variant JH2604 has been corrected by the small BamHI q (v + u) joint fragment from plaque 17 DNA using in vivo selection in mice. The isolation of two recombinants that displayed plaque 17 neurovirulence with $\text{LD}_{50}$ values of $<10^2$ pfu/mouse, demonstrated that the sequences within the BamHI q fragment and probably within the BamHI v fragment are required to restore the neurovirulence of JH2604 to the level of HG52 plaque 17.

The BamHI v fragment of HG52 co-maps with the BamHI s fragment of HSV-1. The nucleotide sequence of the BamHI v fragment was not known at the time of animal experiments, but in HSV-1 strain 17 no complete genes had been identified in BamHI s (Perry and McGeoch, 1988). The 5' end and 500 bp from the end of the IEl gene are located within the BamHI s fragment. It has been shown previously that JH2604 makes VmwIEll8 (equivalent to VmwIEll0 in HSV-1) of normal size and in normal amounts compared to the parental HG52 (Harland and Brown, 1985), indicating that the deletion within the BamHI v fragment in both copies of Rl does not extend into the reading frame for the IEl gene. It has also been shown that the general infected cell poypeptides synthesised by
JH2604 are not identifiably different from those of HG52. In HSV-1 strain F, Chou and Roizman (1986) have reported a gene in $R_L$ coding for a polypeptide ICP34.5 whose promoter is in the terminal 'a' sequence. The same putative gene has not been identified in the sequences of HSV-1 strain 17 (Perry and McGeoch, 1988) and it is now known that its equivalent is not present in HG52 (D.J. McGeoch, personal communication). The in vivo analysis of the HG52 deletion variant JH2604 has demonstrated that at least 500 bp of the BamHI v fragment within or spanning 1500 bp of the terminal sequences of $R_L$ are required to confer neurovirulence for JH2604.

Towards the end of the experimental work described in this thesis, the BamHI g joint fragment of HG52 was sequenced and the sequence made available by Dr. D.J. McGeoch. It therefore became important to delimit the deletion in JH2604 by sequencing the fragment in which the deletion was located and to clarify the possibility of the presence of other mutations.

The isolation of two positive pAT153 clones containing the deleted JH2604 fragment and their restriction endonuclease analysis and subcloning, demonstrated that the deletion in each clone was approximately 1.5 kb and was contained within the HincII-XhoI (between nucleotide position 3053 to 5069) subfragment and had apparently identical end points and size. Sequence analysis confirmed that the sequences deleted in both clones were identical and were 1488 bp in length. The deletion included a complete copy of the 17 bp DRI element (AGTCCCCGTCCTGCCG) of the 'a' sequence, four copies of a 19 bp reiterated sequence (CCCCTCCGACCCCCTGACG) and stopped 522 bp upstream from the
5′ end of IEl gene. The variability in the mobility of the joint fragment spanning the deletion in both clones was confirmed as not being due to variation in the size of the deletion in each copy of the BamHI v fragment but possibly to variation in copy numbers of reiterated sets of sequences located in the repeats (see section 1.3.1). Such variation has been shown previously in HSV-2 strain HG52 (Davison and Wilkie, 1981) and in HSV-1 strain KOS (Wagner and Summers, 1978).

Whether the deleted sequences contain an ORF is under analysis. Chou and Roizman (1986) presented sequencing data and proposed that the region between the IEl gene and the 'a' sequence in HSV-1 strain F contains a gene in the same orientation as the IEl gene (see Figure 4.1). An antipeptide serum based on this predicted ORF identified a protein ICP34.5, in extracts of infected cells (Ackermann et al., 1986). When comparisons were made between the published sequence for this region in strain F and the equivalent region in HSV-1 strain 17, Perry and McGeoch (1988) found a number of differences including a difference in the copy number of a 9 bp tandem repeat family (10 complete copies in strain F and five in strain 17) and 20 points in HSV-1 strain 17 at which an addition or deletion breaks the proposed coding ORF. This led to the conclusion that the entire ORF proposed by Chou and Roizman (1986) was not genuinely protein coding. The data presented by Perry and McGeoch (1988) were thought to be consistent with their being protein coding sequences in this locality but they did not consider the analysis satisfactory enough to propose any gene layout.

The BamHI g joint fragment of HSV-2 strain HG52 has been
found to be 5815 bp in length (D.J. McGeoch, personal communication). The sequences deleted in the variant JH2604 are shown in Figure 4.2. When comparisons were made between these sequences and the published sequences for this region in HSV-1 strain 17, there is a degree of homology between the two sequences (D.J. McGeoch, personal communication).

The sequence arrangement in this region of HG52 is at present under critical analysis and it is thought that there is a potential ORF, but its precise end points have not been identified (D.J. McGeoch, personal communication).

The data presented in this thesis on correction and introduction of the deletion by a variety of methods suggests that the region deleted in the HSV-2 variant JH2604 must be protein coding. Support for the work in this thesis has recently come from Thompson et al. (1989) who showed that an HSV intertypic recombinant (RE6) was avirulent for mice and cotransfection followed by in vivo selection in mouse brain of RE6 DNA with a 1.6 kb cloned fragment mapping between 0.82-0.832 m.u. from the pathogenic HSV-1 strain 17 restored the neurovirulence phenotype of RE6.

FUTURE PROSPECTS

The information gained from this thesis is important both for further study of the molecular events controlling pathogenicity of HSV as well as the potential of the variant JH2604 for a prototype live vaccine.

As all the deletion variants analysed in this study had reduced pathogenicity for mice, it would be important to delimit the deletions by sequence analysis. The exact sequences deleted would be determined and marker rescue experiments correcting the deletions and analysis of
Figure 4.2

The sequences deleted in the variant JH2604. These sequences are a part of the BamHI g joint fragment of HG52 running from IR_S to IR_L (D.J. McGeoch, personal communication). The start (3083) and end (4571) of the deletion are indicated by stars. The 17 bp DR1 element is also indicated by the dotted box. The four copies of a 19 bp reiterated sequence are underlined.
resulting recombinants \textit{in vivo} would give a better understanding of the precise role of the deleted sequences in neurovirulence.

The variant JH2604 which is avirulent for mice and failed to replicate in mouse brain should be further investigated to determine the stage of blockage in viral replication in neural tissue. A combined immunohistochemical and transcriptional analysis of infected neuronal tissue should help in understanding where the blockage in viral replication occurs. In this respect it would be of great interest to determine the \textit{in vivo} functions of the deleted sequences in latent and acute ganglionic infections and examine the gene expression, if any, in neural cells.

Finally the identification of an ORF in the region deleted in JH2604 which has homology to equivalent sequences in HSV-1 identifies the avirulent phenotype of JH2604 probably being due to a functional protein. In this respect designing a variant in HSV-1 with a similar deletion as that in JH2604 as well as heterologous marker rescue would help in understanding the role of the region between 0-0.02 and 0.81-0.83 m.u. in neurovirulence of both HSV-1 and HSV-2.
REFERENCES
REFERENCES


different routes of infection. Journal of Neurological Sciences 60, 181-195.


BARTOSKI, M. AND ROIZMAN, B. (1976). RNA synthesis in cells infected with herpes simplex virus. XII. Differences in
the methylation patterns of viral RNA during the reproductive cycle. Journal of Virology 20, 583-588.


virus DNA. Virology 64, 547-560.


BROWN S.M., RITCHIE, D.A. AND SUBAK-SHARPE, J.H. (1973). Genetic studies of herpes simplex virus type 1. The isolation of temperature-sensitive mutants, their arrangement into complementation groups and
recombination analysis leading to a linkage map. Journal of General Virology 18, 329-346.


CHRISP, C.E., SUNSTRUM, J.C., AVERILL, D.R., LEVINE, M. AND GLORIOSO, J.C. (1989). Characterisation of encephalitis in adult mice induced by intracerebral inoculation of herpes simplex virus type 1 (KOS) and comparison with mutants showing decreased virulence. Laboratory Investigation 60, 822-830.


DEATLY, A.M., SPIVACK, J.G., LAVI, E., O'BOYLE II, D.R. AND FRASER, N.W. (1988). Latent herpes simplex virus type 1 transcripts in peripheral and central nervous system tissues of mice map to similar regions of the viral


Virology 57, 554-565.


FRINK, R.J., EISENBERG, R.J., COHEN, G.H. AND WAGNER, E.K. (1983). Detailed structural analysis of the protein of the herpes simplex virus type 1 genome encoding
glycoprotein C. Journal of Virology 45, 634-647.


type virus-induced congenital cataract. Archives of
Ophthalmology 85, 220-223.

GIBSON, M.G. AND SPEAR, P.G. (1983). Insertion mutants of
herpes simplex virus have a duplication of the
glycoprotein D gene and express two different forms of

York.

GLORIOSO, J., KEES, U., KUMEL, G., KIRCHNER, H. AND KRAMMER,
type 1 (HSV-1) glycoprotein gC as the immunodominant
antigen for HSV-1 specific memory cytotoxic
T-lymphocytes. Journal of Immunology 135, 575-582.

herpes simplex virus function that represses late gene
expression from parental viral genomes. Journal of
Virology 55, 357-365.

virus type 1 induced ribonucleotide reductase activity
is dispensable for virus growth and DNA synthesis:
Isolation and characterization of an ICP6 lacZ insertion

GOMPELS, U. AND MINSON, A. (1986). The properties and
sequence of glycoprotein H of herpes simplex virus type

GOODMAN, J.L., COOK, M.L., SEDERATI, F., IZUMI, K. AND
STEVENS, J.G. (1989). Identification, transfer and
characterization of cloned herpes simplex virus
invasiveness regions. Journal of Virology 63,


HOGGAN, M.D. AND ROIZMAN, B. (1959). The isolation and properties of a variant of herpes simplex producing multinucleated giant cells in monolayer cultures in the


JACOB, R.J., MORSE, L.S. AND ROIZMAN, B. (1979). Anatomy of herpes simplex virus DNA. XII. Accumulation of head-to-tail concatamers in nuclei of infected cells and their role in the generation of the four isomeric arrangements of viral DNA. Journal of Virology 29,


to establish latent infection in mice. Virology 76, 440-443.


LONGNECKER, R. AND ROIZMAN, B. (1986). Generation of an inverting herpes simplex virus type 1 mutant lacking the L-S junction a sequence, an origin of DNA synthesis, and several genes including those specifying glycoprotein E and alpha 47 gene. Journal of Virology 58, 583-591.


coordinates 0.609 through 0.614 in UL. Journal of Virology 62, 715-721.


MARSDEN, H.S., STOW, N.D., PRESTON, V.G., TIMBURY, M.C. AND
WILKIE, N.M. (1978). Physical mapping of herpes simplex
virus-induced polypeptides. Journal of Virology 28,
624-642.

MATHEWS, R.E.F. (1982). Classification and nomenclature of
viruses. Intervirology 17, 1-200.

Physical mapping of temperature-sensitive mutations of
herpes simplex virus type 1 using cloned restriction
endonuclease fragments. Journal of General Virology 64,
2261-2270.

MCDERMOTT, M.R., SMILEY, J.R., LESLIE, P., BROIS, J.,
female genital tract after intravaginal vaccination of
mice with an attenuated strain of HSV-2. Journal of
Virology 51, 747-753.

patterns of virus spread and neuropathology following
micro-injection of herpes simplex virus into the
hippocampus or cerebellum of mice. Journal of
Neurological Sciences 79, 225-265.

MCGEOCH, D.J. (1987). The genome of herpes simplex virus:
Structure, replication and evolution. Journal of Cell
Science 7 (Supplement), 5194-5222.

MCGEOCH, D.J. (1989). The genome of the human
herpesviruses: Contents, relationship and evolution.
Annual Review of Microbiology 43, 235-265.

MCGEOCH, D.J., DALRYMPLE, M.A., DAVISON, A.J., DOLAN, A.,
FRAME, M.C., MCNAB, D., PERRY, L.J., SCOTT, J.E. AND
TAYLOR, P. (1988). The complete DNA sequence of the
long unique region in the genome of herpes simplex virus


establishment of latency by genetically engineered deletion mutants of herpes simplex virus type 1. Virology 162, 251-254.


monoclonal antibodies inhibit cell fusion induced by herpes simplex virus type 1. Virology 129, 218-224.


Openshaw, H.R. (1983). Latency of herpes simplex virus in
ocular tissue of mice. Infection and Immunity 39, 960-962.


PARA, M.F., BAUCKE, R.B. AND SPEAR, P.G. (1980). Immunoglobulin G (Fc) binding receptors on virions of herpes simplex virus type 1 and transfer of these receptors to the cell surface by infection. Journal of Virology 34, 512-520.


PEREIRA, L., WOLFF, M.H., FENWICK, M. AND ROIZMAN, B.


PUGA, A. AND NOTKINS, A.L. (1987). Continued expression of a poly (A)^+ transcript of herpes simplex virus type 1 in
trigeminal ganglia of latently infected mice. Journal of Virology 61, 1700-1703.


QUINN, J.P. AND MCGEOCH, D.J. (1985). DNA sequence of the region in the genome of herpes simplex virus type 1 containing the genes for the DNA polymerase and the major DNA binding protein. Nucleic Acids Research 13, 8143-8163.


RIXON, F.J. (1977). Studies on herpes simplex virus DNA


RIXON, F.J. AND MCCEOCH, D.J. (1984). A 3' co-terminal family of mRNAs from the herpes simplex virus type 1 short region: Two overlapping reading frames encode unrelated polypeptides one of which has a highly reiterated amino acid sequence. Nucleic Acids Research 12, 2473-2487.


Cells expressing herpes simplex virus glycoprotein gC but not gB, gD or gE are recognised by murine virus-specific cytotoxic T lymphocytes. Journal of Virology 61, 2438-2447.


SALAHUDDIN, S.Z., ABLASHI, D.U., MARKHAN, P.D., JOSEPHS,


Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child. Journal of Infectious Diseases 146, 673-682.


SPRECHER, E. AND BECKER, Y. (1986). Skin Langerhan's cell
play an essential role in the defense against herpes simplex virus type 1 infection. Archives of Virology 91, 341-349.


virus in spinal ganglia of mice. Science 173, 843-847.


TAHA, M.Y., CLEMENTS, G.B. AND BROWN, S.M. (1989a). A variant of herpes simplex virus type 2 strain HG52 with a 1.5 kb deletion in R_L between 0 to 0.02 and 0.81 to 0.83 map units is non-neurovirulent for mice. Journal of General Virology 70, 705-716.


THOMPSON, R.L., ROGER, S.K. AND ZERHUSEN, M.A. (1989). Herpes simplex virus neurovirulence and productive infection of neural cells is associated with a function which maps between 0.82 and 0.832 map units on the HSV genome. Virology 172, 435-450.


TIMBURY, M.C. (1971). Temperature-sensitive mutants of


WHITLEY, R.J., SOONG, S.J., LINNEMAN, C., JR., LIU, C.,


WILKIE, N.M. (1973). Substructure of herpesvirus DNA: The


The JH2604 deletion variant of HSV2 (HG52) fails to produce necrotising encephalitis following intracranial inoculation of mice

Mahmoud Y Taha, S Moira Brown*, Geoffrey B Clements¹ & David I Graham²

MRC Virology Unit
Institute of Virology
Church Street
GLASGOW G11 5JR

1. Regional Virus Laboratory
Ruchill Hospital
GLASGOW G20 9NB

2. Department of Neuropathology
Southern General Hospital
GLASGOW G51

Key words: HSV/deletion variant/encephalitis